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Mechanisms of resistance of Pseudomonas aeruginosa to the 4-quinolones were
investigated by examining the outer membrane proteins and DNA gyrases of resistant
clinical isolates. Minimum inhibitory concentrations (MICs) were determined for
fluoroquinolones, imipenem, p-lactams, gentamicin, kanamycin, carbenicillin and
tetracycline. Ciprofloxacin was the most active 4-quinolone, followed by ofloxacin and
norfloxacin. Resistant clinical isolates had an MIC of ciprofloxacin of 4mg/l or greater,
and resistance was shown to be stable after 20 passages on nutrient agar in all but one
of the isolates. In several isolates cross-resistance with imipenem and P-lactams was
seen. All clinical isolates were resistant to tetracycline, carbenicillin and kanamycin.
Outer membrane profiles of sensitive and resistant strains of P.aeruginosa were
examined and shown to be variable. In highly resistant strains, resistance to 4-
quinolones could not be attributed to a particular membrane alteration as the isolates
were not paired. The predominant membrane alterations observed, however, were in
proteins of 51kD, 36kD and 32kD. Low level quinolone resistance in a series of paired
isolates was linked with an increase in expression of a 46kD protein and the decrease in
expression of a 51kD protein, and ceftazidime resistance with the appearance of a 42kD
protein. These proteins were found to be non-covalently associated with peptidoglycan
suggesting that they act as porins. Experiments with EDTA also demonstrated that all of
the quinolone-resistant strains carried OMP mutations.
DNA gyrases from 23 clinical strains were isolated from a novobiocin/sepharose
column and assayed by gel electrophoresis. The level where quinolones inhibited 50%
of gyrase supercoiling activity on relaxed pBR322 (IC50), was determined for
ciprofloxacin, ofloxacin, norfloxacin and novobiocin in all strains. In general the IC50
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concentrations were equivalent to, or greater than, the MIC of each drug. All IC50
values for clinical isolates were significantly greater than those of the reference strain
PAOl, indicating that the strains possessed gyrA mutations. The clinical strains fell into
three categories; those with a relatively low IC50 of 4-20 mg/1 ciprofloxacin, those with
an intermediate value of 50-100 mg/1 ciprofloxacin and those with values greater than
150 mg/1 ciprofloxacin. Five strains exhibited raised novobiocin IC50S suggesting that
they contained gyrB mutations. No correlation between MIC and IC50 values were
observed.
GyrA mutations were analysed indirectly in 18 ciprofloxacin-resistant unpaired strains
by restricting PCR fragments with the enzyme Sstll which cleaves the fragment
between amino acids 83 and 84 in the sensitive strain PAOl. Sstll cleavage did not
occur in 8 clinical isolates indicating that they possessed a gyrA mutation within this
region. DNA gyrases were also investigated for mutations with pNJR3-2, a plasmid
which carries a wild type Escherichia coli gyrA gene and confers quinolone sensitivity.
Experiments to introduce the plasmid into P.aeruginosa by conjugation and
electroporation were unsuccessful. Attempts to sequence the gyrA genes of selected
clinical isolates were also unsuccessful, as transconjugants carrying the 300 base pair
fragment were not selected.
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Pseudomonas aeruginosa was originally observed by medical practitioners as a blue-
green stain that frequently appeared upon surgical dressings, and the nature of this
coloured substance was first investigated by Fordos (1860). Later, in 1882, Gessard
proved that the pigment was produced by a bacillus, named Bacillus pyocyaneus,
which was easily isolated in pure culture. Attempts to determine the nature of the
pigment produced by B.pyocyaneus lead to considerable confusion amongst
investigators. Thumm (1895) claimed that a single pigment was produced and that this
was identical to the blue-green pigment produced by common water bacteria, whereas
Charrin and de Nittis (1898) claimed that the same strain of B.pyocyaneus was able to
produce as many as four distinct pigments.
These findings were clarified by Jordan (1899) who separated B.pyocyaneus into four
varieties; 1) pyocyanigenic and fluorescigenic, 2) pyocyanigenic only, 3) fluorescigenic
only and 4) nonchromogenic. Jordan (1899) suggested that the chief difference
between Bacillus fluorescens liquefaciens, later termed Pseudomonas fluorescens, and
his fluorescigenic non-pyocyanin-variety of B.pyocyaneus, later termed Pseudomonas
aeruginosa, was one of temperature, and perhaps their behaviour in animals. Jordan
(1899) also mentioned that P.fluorescens might be a modified form of P.aeruginosa,
and as such they were related.
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The inability of investigators to distinguish between Pseudomonas groups persisted
until 1943 when Seleen and Stark separated 199 cultures on their ability to grow at 5°C
and 42°C, their action on milk, liquefaction of gelatin and reduction of nitrates. Sub¬
groups were also identified by pyocyanin production and the ability to utilise sucrose,
acetic acid, lactic acid or tartaric acid as the sole carbon source. More recently the family
Pseudomonadaceae has been classified by nucleic acid homologies, and Pseudomonas
has been assigned five sub-groups on the basis of ribosomal RNA/DNA homologies
(Palleroni et al 1973; Palleroni 1986).
P.aeruginosa was found to be widely distributed in nature, where it existed as a
saprophyte, occasionally giving rise to pathological lesions and generalised infection in
man (Lartigau 1898; Fraenkel 1917). P.aeruginosa was also one of the first
microorganisms known to produce substances antagonistic to other bacteria. Bouchard
(1889) observed that injecting small quantities of a culture of P.aeruginosa into rabbits
previously injected with a virulent strain of Bacillus anthracis resulted in the rabbits'
survival. Other investigators observed that old cultures and culture filtrates of
P.aeruginosa were bactericidal for many microorganisms, and termed the substance
they found pyocyanase (Emmerich and Low 1899).
P.aeruginosa is able to colonise humans, where it acts as a saprophyte, and is
frequently present in small numbers in normal intestinal flora and the skin.
P.aeruginosa is an opportunistic pathogen, presenting no problem to healthy
individuals, but causing grave problems in patients with impaired resistance (Clarke
1989). It is a dangerous hazard in hospitals as it survives in many reservoirs, such as
hospital humidifiers, weak disinfectants, brushes, mops and sinks (Lowbury 1975).
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P.aeruginosa is only pathogenic in areas devoid of normal body defences; when
mucous membranes or skin are disrupted by tissue damage, when intravenous or
urinary catheters are used, or when neutropenia is present, for example during cancer
therapy (Clarke 1989). P.aeruginosa is associated with a variety of clinical
manifestations including infections of burns and surface wounds; urinary tract, ear and
eye infections; infection of the cerebrospinal fluid in meningitis and colonisation of the
lungs in cystic fibrosis (Clarke 1989). In the last decade P.aeruginosa has become the
major cause of morbidity and mortality in patients with cystic fibrosis (Govan 1988). In
many cases P.aeruginosa causes chronic disease.
P.aeruginosa colonises patients by attaching to mucous membranes, or skin, invading
locally and then causing systemic disease (Pollack 1984). The process is promoted by
pili and the production of various enzymes, toxins and pigments: exotoxin A and exo-
enzyme S are protein synthesis inhibitors and elastase and alkaline protein are
extracellular proteases. Virulence factors are also produced by P.aeruginosa and
include haemolysin and phospholipase A, which break down lipids and lecithin (Liu
1979). Another characteristic of P.aeruginosa is that it produces pigments such as
pyocyanin, a phenazine pigment which is a secondary metabolite produced during the
biosynthetic pathway for aromatic amino acids. Pyocyanin is a strong iron chelating
compound which enables the bacteria to grow in niches with low iron content, such as
the lung environment in cystic fibrosis patients, and makes the organism highly
adaptable (Clarke 1989).
P.aeruginosa provides a major obstacle to antimicrobial chemotherapy as it is highly
resistant to many of the antimicrobial agents in use today (Nikaido and Hancock 1986).
This resistance is brought about by three mechanisms; intrinsic resistance, adaptive
resistance and the acquisition of new genetic material in the form of plasmids and
transposons.
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Intrinsic resistance is brought about by the impermeability of the cell wall of P.
aeruginosa. The major porin protein in the cell wall of Pseudoinonas, through which
antibiotics can diffuse, is protein F and in isolates of P.aeruginosa the majority of F
protein channels are either maintained in a closed state, or have very small diameters
which block the passage of many antibiotics (Nicas and Hancock 1983). This, coupled
with the fact that the lipopolysaccharide (LPS) on the pseudomonad cell wall is closely
packed, thus protecting the cell surface, renders the bacterium impermeable to many
hydrophobic and hydrophilic antibiotics (Nikaido and Hancock 1986). Another form of
intrinsic resistance is chromosomally mediated, and in the case of the older P-lactam
drugs this is brought about by an inducible chromosomally specified (^-lactamase
(Sabath and Abraham 1964). P.aeruginosa is also intrinsically resistant to kanamycin,
brought about by a chromosomally encoded aminoglycoside phosphorylating enzyme.
(CAcirto: iTrT)
Adaptive resistance occurs when selective pressures affect bacteria, a classic case being
lung colonisation of P.aeruginosa in cystic fibrosis patients. Here the lungs are
colonised by wild type P.aeruginosa, and the high salt and low nutrient conditions
there trigger P.aeruginosa into producing alginate, a highly viscous polymer which
protects the bacteria by rendering them resistant to antibiotics and phagocytosis (Berry
et al 1989). In cystic fibrosis this adaptive type of resistance is responsible for a
persistent and recurrent infection, and is unstable in the absence of the selective
pressure; in other situations adaptive resistance has been shown to be stable.
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Plasmicbmediated resistance acquired by P.aeruginosa has major effects therapeutically.
Plasmids may carry alternative genes which add to the intrinsic resistance of
P.aeruginosa. The most common plasmids in P.aeruginosa are very large, have a
narrow host range and belong to the P-2 incompatibility group (Jacoby 1986).
P.aeruginosa, however, is also a host for a wide range of plasmids, and resistance
genes carrying ^-lactamases, aminoglycoside modifying enzymes, and resistance to
tetracycline, sulphonamides and chloramphenicol, have been found to transfer into the
bacteria (Clarke 1989). Klebsiella species have also been known to transfer resistance
genes into P.aeruginosa.
The intrinsic resistance that P.aeruginosa exhibits to many antimicrobial agents was
thought to have been overcome by the advent of the synthetic quinolone antibuebaaa& as
no natural antimicrobial agents resembled them. Within three months of the introduction
of the modern fluoroquinolones, however, clinical reports of resistance in P.aeruginosa
to ciprofloxacin were documented (Crook et al 1985; Roberts et al 1985). This
highlighted the adaptability of P.aeruginosa to antimicrobial agents, and has lead to a
worrying situation therapeutically as overall antimicrobial resistance in P.aeruginosa is
on the increase.
1.2 BACTERIAL RESISTANCE TO ANTIMICROBIAL AGENTS.
Adaptive resistance derives from the bacterial chromosome and develops as a
consequence of spontaneous mutations in a locus which controls susceptibility to an
antimicrobial agent. The chromosomal mutants produced are often resistant by virtue of
a change in a structural receptor for the drug. Acquired resistance is usually introduced
by extra chromosomal genetic elements, commonly R plasmids, which often carry
several genes confering resistance to one or several antimicrobial agents and heavy
metals. This means that, in clinically important bacteria, plasmids tend to be the main
reservoir of resistance to most antimicrobial agents (Jacoby 1986).
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Many plasmid resistance genes have obvious chromosomal origins, either from
genetically-distant species, as in aminoglycoside resistance (reviewed by Foster 1983);
or from genetically-related species, as in trimethoprim resistance in Staphylococcus
aureus (Iordanescu etal 1978) or the production of the (3-lactamase BIL-1 (reviewed by
Amyes et a1 1992). A mechanism must exist, therefore, which enables the mobilsation
of resistance genes from their original location to the plasmid. The discovery of
transposons (Hedges and Jacob 1974) provided an explanation by which resistance
genes could be moved independently to new sites within a genome, or be 'picked up'
by a plasmid. Transposons are able to transpose genetic material from a donor DNA
molecule to a recipient, but are unable to replicate themselves independently.
Transposons, with a few exceptions, possess one, or several, transposase genes
whose products act on inverted repeat sequences found at the ends of the transposable
element (Berg 1989).
The modes of transfer of chromosomal and plasmid mediated resistance are
fundamentally different; resistance determinants carried on the chromosome are
normally restricted to vertical transmission, that is from mother to daughter cells during
cell division and replication. Plasmids, however, may be transferred both vertically and
horizontally, between bacteria of the same species or genera. Plasmid-mediated
resistance thus tends to spread at a significantly faster rate than chromosomally-
determined resistance.
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Resistance to all antimicrobial agents can arise via four mechanisms, reviewed by
Lewis (1989), which are:-
1) Alteration of the target site or hyperproduction of the target, thus reducing or
preventing binding of the antimicrobial agent to the target.
2) Blockage of transport of the agent into the cell, usually by permeability changes.
3) Destruction or inactivation of the antibiotic.
4) Metabolic bypass - the cell is provided with a replacement for the metabolic step
inhibited by the antimicrobial agent.
1.2.1 Alteration of the Target Site.
This type of resistance occurs as a result of the selection of rare, pre-existent mutants in
a sensitive bacterial population, in the presence of an antimicrobial agent. Streptomycin
resistance is brought about by a single amino acid mutation in the structural protein of
the 30S ribosomal subunit of bacteria (Davies 1964). This mutation subsequently
prevents drug binding and is responsible for high levels of drug resistance. Alterations
in the 50S bacterial subunit may also bring about erythromycin resistance (Teroaka and
Tanaka 1974); but generally erythromycin resistance in staphylococci and streptococci
occurs because of the presence of an inducible plasmid mediated enzyme, which causes
the methylation of the 23S ribosomal ribonucleic acid (rRNA) (Lai and Weisblum
1971). Resistance to a few penicillins and cephalosporins may be caused by mutations
which encode the loss or alteration of penicillin binding proteins (PBPs) (Spratt 1983).
Alterations in PBPs are very important resistance mechanisms in Staphylococcus
aureus, streptococci and enterococci, as they prevent the inhibition of peptidoglycan
synthesis, and the mutant bacteria are also resistant to imipenem.
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1.2.2 Interference With Drug Transportation.
This resistance usually results from permeability changes encoded by mutations in the
bacterial chromosome, which alter the size and/or the distribution of the membrane
channels, thus preventing drugs from entering the cells. This affects a wide range of
antimicrobial agents and generally results in cross resistance, where an organism
becomes resistant to several unrelated antimicrobial agents at one time (Cohen et al
1988). Permeability mutations are particularly characteristic ofGram-negative bacteria
such as P.aeruginosa (Hirai et al 1987) and Escherichia coli (Harder et al 1981).
Antibiotics affected by this type of resistance include aminoglycosides and tetracycline.
Tetracycline resistance occurs in both Gram-positive and Gram-negative bacteria and is
usually plasmid-encoded, although chromosomally-encoded tetracycline resistance has
been reported (Foster 1983). Tetracycline resistance is associated with decreased
accumulation of the drug, although the precise mechanism by which this occurs is
unknown (McMurry et al 1980). Tetracycline resistance is generally inducible, and a
new inner membrane protein is synthesised (Levy et al 1977) which is linked to the
development of an active efflux system (McMurry et al 1980). This was demonstrated
by the use of E.coli everted membrane vesicles which concentrated tetracycline by an
active influx mechanism. Tetracycline-resistant cells exhibited no alteration in
tetracycline accumulation compared to sensitive strains, demonstrating that the efflux of
tetracycline is a major resistance mechanism, whereby drug entering the cell is
simultaneously removed and never reaches an inhibitory level there (McMurry et al
1980).
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1.2.3 Destruction or Inactivation of the Antibiotic.
The major cause of resistance to penicillins and cephalosporins is the production of P-
lactamases, which catalyse the hydrolysis of the P-lactam ring to form an inactive
product. In Gram-negative bacteria P-lactamase production may be either
chromosomally-or plasmid-mediated. The P-lactamases that are chromosomally-
mediated are normally closely bound to the cell membrane and are generally species-
specific (Matthew et al 1975). Chromosomal P-lactamases also tend to be inducible,
that is various different P-lactam antibiotics are able to stimulate the production of p-
lactamases (Minami et al 1980). Chromosomally-mediated p-lactamases are found in
most species of clinical bacteria.
In the clinical environment, resistance to penicillins and cephalosporins is caused by
plasmid-mediated enzymes, of which more than 60 have been identified in Gram-
negative bacteria (Wiedemann 1989). The most prevalent of these enzymes is
designated TEM-1, and may be specified on a number of different plasmids (Roy et al
1983; Simpson et al 1986; Reid et al 1988), as the genetic information encoding it
resides on a transposon. Transposons allow the translocation of genes between
plasmids and the host chromosome, and probably explain the wide distribution of
TEM-1 in the bacterial population, including many Enterobacteriaceae, P.aeruginosa,
Haemophilus influenzae and Neisseria gonorrhoeae.
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Plasmid-mediated resistance to aminoglycosides in Gram-negative bacteria is also
brought about by drug inactivation. The plasmids encode modifying enzymes which
either catalyse adenylylation, phosphorylation or acetylation reactions (Reynolds and
Smith 1979; Shannon and Phillips, 1982). The modifying enzymes are present in the
periplasmic space between the inner and outer cell membranes, and are closely
associated with the inner cytoplasmic membrane where they are accessible to acetyl
coenzyme A and adenosine triphosphate (ATP). The presence of a few molecules of the
modified drug appear to interfere with active transport mechanisms and block further
drug transport into the cell (Dickie et al 1978).
Drug inactivation is also responsible for bacterial resistance to chloramphenicol in both
Gram-positive and Gram-negative bacteria (Shaw 1983). Resistance is plasmid
encoded and is the result of acetylation of chloramphenicol by chloramphenicol
acetyltransferases. The acetylated chloramphenicol can no longer bind to the bacterial
ribosome and therefore has no effect on protein synthesis (Shaw 1967; 1971).
1.2.4 Metabolic Bypass.
This mechanism accounts for bacterial resistance to sulphonamides and trimethoprim,
and occurs when the cell acquires a replacement for the metabolic step inhibited by the
drug. In the case of the sulphonamides and trimethoprim, resistance is brought about
by the production of target enzymes resistant to the antimicrobial agents in question.
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Sulphonamides inhibit the enzyme dihydropteroate synthetase, which links para-
aminobenzoate and pteridine to form dihydropteroate, a step in the synthesis of
tetrahydrofolic acid, which is a co-factor essential in many of the metabolic processes
of the living cell (reviewed by Foster 1983). In Gram-negative bacteria plasmids
encode a sulphonamide-resistant dihydropteroate synthetase which co-exists with the
chromosomal sulphonamide-sensitive enzyme in the cell, and thus permits the
continued functioning of the metabolic pathway, even in the presence of the drug
(Skold 1976; Swedberg and Skold 1980).
Trimethoprim acts at a later stage in the same metabolic pathway by blocking the action
of the enzyme dihydrofolate reductase, which converts dihydrofolate into an active and
reduced form, tetrahydrofolate. Trimethoprim-resistant bacteria produce a plasmid-
encoded trimethoprim-resistant dihydrofolate reductase, which also co-exists in the cell
with its chromosomally-encoded drug-sensitive counterpart (Amyes and Smith 1974;
1976). There are now over sixteen different plasmid-borne trimethoprim-resistant
dihydrofolate reductases which have been differentiated by DNA:DNA hybridisation
and biochemical characteristics (Amyes and Towner 1990).
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1.3 THE OUlNOLONfi ANTIMICROPIAU AGENTS,
1.3.1 The History and Development of the Quinolones.
Unlike most of the antimicrobial agents in use today, the quinolones were not isolated
from moulds and fungi; instead they are synthetically manufactured antimicrobials. The
first quinolone, nalidixic acid (1-ethyl-1, 4-dihydro-7-methyl-4-oxo-l, 8-
naphthyridine-3-carboxylic acid) was discovered as a by-product of antimalarial
research in 1962, during the purification of chloroquine by Lesher and colleagues.
Nalidixic acid was found to possess a narrow spectrum of activity against aerobic
Gram-negative bacteria and was used primarily in the treatment of urinary tract and
enteric infections, particularly against dysentery caused by Shigella sonnei (Moorhead
and Parry 1965). It was subsequently discovered, however, that low level nalidixic
acid-resistant organisms could be selected for easily in vitro and in vivo (Crook et al
1985), and it was assumed that nalidixic acid would run out of clinical usefulness.
During the 1970's two other quinolone compounds, oxolinic acid and cinoxacin, were
developed, based upon the same general structure (Fig1.1). These too had a limited
spectrum of activity against the Enterobacteriaceae.
1
Fig 1.1. The Basic Quinolone Skeleton.
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A breakthrough in quinolone research came with the introduction of a piperazine ring at
position ? and the addition of a fluorine to position 6 (Koga et al 1980; Rustige et al
1990). These substituents caused a thousand-fold improvement in the activity of the
quinolones: the piperazine ring increasing the spectrum of activity of the drugs against
P.aeruginosa and the nalidixic acid-resistant mutants of E.coli (Koga et al 1980). The
first of the new fluorinated quinolones to be used clinically in Germany was
norfloxacin, which had a broad spectrum of activity against Gram-negative and Gram-
positive bacteria (Wolfson and Hooper 1989). Several other quinolone antimicrobials
followed the development of norfloxacin, and these included ciprofloxacin, ofloxacin,
pefloxacin and enoxacin. Most of the new quinolones are quinoline derivatives,
whereas nalidixic acid and enoxacin with aza (nitro) substituents at position 8 of the
basic quinolone structure are strictly naphthryidines. In order to avoid confusion the
agents containing the basic quinolone skeleton were termed the 4-quinolones (Smith
1984a).
In all of the newer compounds the basic 4-quinolone nucleus with a carboxylate
substituent at position 3 has been retained, with only side group substituents being
changed (Fig 1.2). The similarity in the structures of the new 4-quinolone compounds
occur as the 4-quinolone structure has been shown to be relatively fixed. Schentag and
Domagala (1985) demonstrated that in order for quinolones to interact with their target,
bacterial DNA gyrase, the possession of a carboxylic acid at position 3 and a (3-ketone
at position 4 were essential. Also, the possession of a fluorine molecule at position 6 is
necessary for a broad antimicrobial spectrum and high activity (Koga et al 1980).
Antipseudomonal activity is further enhanced by having a nitrogen grouping at position
7 (Rustige et al 1990). Modification of position 2 by the addition of any group was










Fig 1.2. Structures of the New 4-quinoIones Compared to Nalidixic
Acid.
The more recent 4-quinolones, such as temafloxacin, have a modified position 1 which
includes a phenyl group that has increased the solubility of the compound. Modification
of the piperazine ring has also improved the lipid solubility of temafloxacin compared
with ciprofloxacin and ofloxacin (Percival 1991).
In comparison with nalidixic acid the fluorinated quinolones have an extended spectrum
ofmicrobiological activity. These quinolones are most active against E.coli, Shigella,
Salmonella, Enterobacter and Neisseria species. They are moderately active against
P.aeruginosa, H.influenzae and Legionella pneumophila and have low activities against
Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA)




The recently developed 4-quinolones, temafloxacin and WIN 57273, show a greater
antimicrobial spectrum for Gram-positive organisms such as S.aureus, Streptococcus
and Enterococcus species. This increase in apparent potency against Gram-positive
bacteria and obligate anaerobes, which were previously intrinsically resistant to the
older 4-quinolones, was brought about by the addition of a second fluorine molecule to
the basic structure.
In clinical use the fluorinated quinolones are characterised by improved absorption,
wide distribution into body tissues, and lower half lives in the body than nalidixic acid.
They are used mainly in the treatment of urinary tract infections and also as a second
line treatment for lower respiratory tract, bone and joint infections. Quinolones are also
used as a second line treatment where bacterial resistance to primary drug treatments
has developed; and have been seen to be active in vitro against multiply antibiotic
resistant Gram-negative bacilli and P-lactamase producing N.gonorrhoeae (Wolfson
and Hooper 1985).
1.3.2 Quinolone Uptake Into Bacterial Cells.
Uptake into bacterial cells is thought to be important in determining the activity and
antibacterial spectrum of the quinolones, and decreased drug uptake is thought to play a
role in quinolone resistance. The outer membrane is an effective barrier to drug
permeation in Gram-negative bac, Vi1. , and generally there are three routes by which
antimicrobial agents may enter a cell; the porin pathway, the hydrophobic pathway and
the self promoted route utilised by cationic compounds (Bryan and Bedard 1991).
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At first quinolones are rapidly taken up by bacterial cells and then uptake reaches a
steady state; in the Enterobacteriaceae and S.aureus this state is reached after 60-80
seconds, whereas P.aeruginosa and Klebsiella pneumoniae achieve a steady state
plateau at six minutes (Piddock 1991). Uptake in P.aeruginosa and E.coli has been
shown to be non-saturable (Bedard etal 1987; Bedard etal 1989; Celesk and Robillard
1989; Hooper et al 1989), which indicates that uptake probably occurs by simple
diffusion through non-specific channels and not by saturable carrier proteins.
Experiments by Hirai and colleagues (1986b) provided strong evidence that in E.coli all
quinolones enter the cell via the porin pathway.
Other factors implicating passive diffusion through water filled porin channels include
experiments by Bedard and co-workers (1987), which showed no competition between
uptake of ciprofloxacin or enoxacin in E.coli and Bacillus subtilis. Also, mutants of
E.coli and Salmonella typhimurium exhibiting decreased expression of a membrane
porin, outer membrane protein F (OMPF), show resistance to and a decreased uptake
of quinolones. (Hirai et al 1986a; Bedard et al 1987; Cohen et al 1989).
Quinolones may also penetrate the outer membrane via the phospholipid bilayer. Hirai
and colleagues (1986a) demonstrated that quinolones with low relative hydrophobicity,
like ciprofloxacin, penetrate through OMPF in E.coli and S.typhimurium, but those
with high relative hydrophobicity, such as nalidixic acid and oxolinic acid, permeate
through OMPF and the phospholipid bilayer. Nalidixic acid and oxolinic acid also
exhibited decreased uptake in S.typhimurium strains with lipopolysaccharide (LPS)
defects compared with the newer fluorinated quinolones.
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Quinolones have been shown to exhibit self-promoted uptake by acting as chelating
agents for divalent cations on the cell surface, and so facilitating the entry of other
quinolone molecules (Chapman and Georgopapadakou 1988). Fleroxacin and the
newer 4-quinolones are able to chelate magnesium ions on the cell surface LPS,
causing it to be displaced and creating hydrophobic patches of exposed lipid domains
on the outer membrane. This then enables other fleroxacin molecules to diffuse through
these exposed domains.
Chapman and Georgopapadakou's (1988) observations were supported by the work of
Smith and Lewin (1988), which showed that the presence of magnesium ions could
increase bacterial minimum inhibitory concentrations (MICs) of quinolones. Chapman
and Georgopapadakou (1988) also demonstrated that diffusion rates through the
bacterial outer membrane were influenced by the relative hydrophobicity and ionic
charge of the quinolones, and that the preferred route of penetration for enoxacin,
ciprofloxacin and norfloxacin, was through the porin channels. The porin pathway may
also be the preferred route for fleroxacin penetration (Hirai et al 1986a), but failure to
detect fleroxacin-resistant mutants with only OMPF defects indicates that the non-porin
pathway is also a major entry route for this agent (Chapman et al 1989).
Self-promoted uptake of quinolones has not been shown to occur in P.aeruginosa
(Young and Flancock 1992). Strains of P.aeruginosa overexpressing a non-porin
protein, OprH, were shown to exhibit increased quinolone uptake into the cell, in
comparison with parent strains. Overexpression of OprH is thought to neutralise the
overall negative charge on the cell surface of P.aeruginosa, as it is a basic protein, and
allows quinolones better access to the sites involved in uptake via the non-porin
pathway.
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Studies of the passage of 4-quinolones through the inner membrane of Gram-negative
bacteria have led to conflicting results. Chapman and Georgopapadakou (1988)
advocate a passive diffusion mechanism, which is therefore energy independent, and
this has been corroborated by Bedard and colleagues (1987) with their studies on
enoxacin uptake in E.coli and Bacillus subtilis. An energy-dependent active transport
mechanism, however, has also been implicated, coupled to the proton motive force, as
the uptake of ciprofloxacin, pefloxacin and amifloxacin were inhibited by 2,4-
dinitrophenol (DNP), an uncoupling agent (Diver et al 1990b).
Whatever the pathway of quinolone uptake into bacterial cells, whether by an active or
totally passive means, it is clear that the cell wall of quinolone sensitive bacteria
provides very little interference to drug accumulation in the cell. This is because 4-
quinolone uptake, bactericidal activity, and inhibition of DNA synthesis are very rapid.
It is also clear from studying resistant mutants that no single mechanism accounts for
the total quinolone uptake into the bacterial cell, although the porin pathway seems to be
the preferred route.
1.4 MODE OF ACTION OF OIJINOLONES.
The quinolones have been shown to act upon a unique bacterial enzyme, DNA gyrase
(bacterial topoisomerase II : EC number 5.999.1.3) (Gellert et al 1976). DNA gyrase
has the unique ability to introduce negative supercoils into closed circular double
stranded DNA with adenosine triphosphate (ATP) hydrolysis. DNA gyrase is essential
for bacterial function, and in the absence of ATP is able to relax negative supercoiled
DNA. DNA gyrase is also responsible for catenating and decatenating duplex DNA
circles, and resolving knotted single DNA duplexes. In the presence of ATP, DNA
gyrase relaxes positively supercoiled DNA in a reaction analogous to the introduction of
negative supercoils.
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Bacteria are faced with a major problem, as the DNA which encodes their
characteristics is a large linear molecule. In E.coli the DNA is 1,100 |J.m in length
(Cairns 1963) and must be accommodated in a cell of approximately 1 or 2 jam in
length. This begged the question of how bacteria managed to accommodate the DNA in
the cell. In 1974 Worcel found the answer when studying the E.coli chromosome. He
discovered that the E.coli chromosome is divided into about 65 separate regions, or
domains, of 20 |im in length, each domain being attached to a ribonucleic acid (RNA)
core. The size of each domain was also reduced by supertwisting against the direction
of the DNA helix, termed negative supercoiling (Wang 1974). The introduction of
negative supercoils reduces the number of helical turns required in the DNA, thus
compacting it, and also aids strand separation.
DNA also presents bacteria with another problem. In order to survive bacteria must
replicate, which involves the duplication of DNA, its division into daughter
chromosomes, the transcripton of genes to form new cell components, and the splitting
into two daughter cells without lethally entangling the DNA present. The nature of the
DNA helix is such that in E.coli the helix, comprised of 4xl06 base pairs, is
intertwined 400,000 times, and this must unwind 400,000 times in order for
semiconservative replication to occur. To bring about unwinding, the strands separate
and a 'swivel' mechanism operates in front of the replication fork as it advances (Caims
1963). The negative supercoiling of DNA also provides the bacteria with a unique
problem, as energy is required to both supercoil and uncoil the DNA.
In prokaryotes the condensing and replicating of DNA is carried out by topoisomerases
(Gellert et al 1976). Topoisomerases are present in every cell and are enzymes
responsible for altering the linking number of DNA by controlling, via the breaking and
rejoining of strands, the number of times the duplex winds around its complementary
strand. Topoisomerases are divided into two main groups:-
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1) Type I are responsible for relaxing negatively supercoiled DNA, conversion of two
closed single strands of DNA into a double stranded form, knotting and nicking single
stranded DNA and the interlocking of DNA duplexes (Rose 1988). They reduce the
linking number by one.
2) Type II topoisomerases alter the linking number by two, and are able to unknot and
catenate unnicked DNA, and may break both DNA strands. Some type II
topoisomerases are able to introduce positive or negative twists into DNA, and most
type II topoisomerases require ATP as a co-factor to catalyse reactions (Sutcliffe et al
1989).
1.5 THE STRUCTURE AND FUNCTION OF DNA GYRASE.
DNA gyrase is a type II topoisomerase and is unique to prokaryotes. It is the only
enzyme known that is able to introduce negative supercoils into covalently closed
circular DNA; a reaction which requires adenosine triphosphate (ATP). DNA gyrase
has been isolated from many bacterial species including E.coli (Swanberg and Wang
1987), Micrococcus luteus (Klevan and Wang 1980), P.aeruginosa (Robillard and
Scarpa 1988), Citrobacter freundii (Aoyama et al 1988a), B.subtilis (Lampe and Bott
1984) and Streptomyces sphaeroides (Thiara and Cundliffe 1988), and has been found
to possess a highly conserved structure. This is highlighted further by the cloning and
sequencing of the gyrA genes of E.coli (Swanberg and Wang 1987), B.subtilis
(Lampe and Bott 1984), S.aureus (Hopewell etal 1990), Klebsiella pneumoniae (Dimri
and Das 1990) and C.freundii (Aoyama et al 1988b), in which greater than 50%
homology is seen. This high degree of homology is both structural and functional as
the gyrB subunit of B.subtilis has been demonstrated to complement the gyrA of E.coli
in vitro to form an active gyrase complex (Orr and Staudenbauer 1982).
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DNA gyrase is a tetramctric molecule composed of two a and two p subunits. The
gyrase complex was demonstrated to contain equivalent amounts of a and p proteins
by mixing different ratios of the separate gyrase proteins with DNA, followed by the
separation of the DNA-protein complex from the free protein by gel filtration (Sugino et
al 1980). Sedimentation analysis of gyrase complexed with 140 base pair fragments of
DNA suggested that the gyrase had an OC2P2 composition (Klevan and Wang 1980).
This structure was further supported by small angle neutron scattering, suggesting a
mass of 353 kilodaltons (kD) for the E.coli DNA gyrase which is compatible with an
«2P2 complex (Kreuger et al 1990). In E.coli the a subunits are 97kD proteins
encoded by the gyrA gene, located at 48 minutes on the E.coli map, and the p subunits
are 90kD in mass, encoded by the gyrB gene and located at 83 minutes on the E.coli
map. In B.subtilis the gyrA and gyrB genes are contiguous and located in the region of
the replication origin.
The action of DNA gyrase has been well studied (Horowitz and Wang 1987, Morrison
and Cozzarelli 1981). The enzyme binds non-covalently to sequences of DNA; in E.coli
this DNA binding site was shown to be at the amino acid tyrosine 122 on the a subunit
(Horowitz and Wang 1987). The binding sites on the DNA, however, show no specific
sequence, although there is a general consensus (Fisher et al 1981). DNA gyrase then
requires co-factors of magnesium ions and ATP to introduce negative supercoils
(Higgins and Cozzarelli 1982). The requirement for ATP is specific, as dATP is a poor
substitute and other nucleotide triphosphates are completely inactive (Sutcliffe et al
1989).
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In 1981 Morrison and Cozzarelli proposed a model for negative supercoiling by gyrase.
Double stranded DNA is wrapped around the outside of the gyrase with a 50 base pair
central region being protected by the gyrase. The a subunit is responsible for nicking
each strand of the DNA helix at intervals of four base pairs apart, producing a staggered
cut, and then holds the strands apart (Fig 1.3). The DNA strand is then passed through
the nicks in a positive sense, introducing an extra twist, by the (3 subunit. The a
subunits then reseal the nicked strands, restoring the DNA helix. The binding of ATP
induces a conformational change in the gyrase-DNA complex, triggering strand passage
through the nick in the helix, and is then hydrolysed to 'recock' the gyrase-DNA
complex, and another cycle is initiated (Rau et al 1987).
Fig 1.3. The oc-Subunits of DNA Gyrase Introduce Nicks Into the DNA
Strands at Specific Sites 4 Base Pairs Apart (Source: Bayer, UK).
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In the bacterial cell DNA gyrase and topoisomerase I act in concert to regulate DNA
transcription and replication. The amount of each enzyme is dictated by the
superhelicity of the DNA molecule: decreasing the negatively supercoiled state of DNA
stimulates the transcription of gyrA and gyrB, and suppresses the transcription of the
topA gene. Increasing the superhelicity of DNA has the opposite effect, repressing
gyrA and gyrB transcription whilst inducing transcription of topA (Menzel and Gellert
1983).
1.6 INHIBITION OF DNA GYRASE.
The action of DNA gyrase is inhibited by two major classes of antimicrobials, the
courmarins which include novobiocin, and the quinolones.
1) Courmarins : These inhibit bacterial DNA, RNA and protein synthesis, with their
primary effect exerted on DNA synthesis (Ryan 1976). Investigations by Gellert et al
(1976) showed that novobiocin and coumermycin caused the relaxation of negative
supercoils, and, by utilising drug-resistant bacteria, demonstrated that the target of the
courmarins is the gyrase (3 subunit. The courmarins act by binding directly to the ATP
binding site on the P subunit and prevent ATP hydrolysis.
2) Quinolones : the target for the quinolones in the bacterial cell was determined to
be the a subunit of DNA gyrase, when Sugino and colleagues (1977) purified the nalA
gene and showed it to be the target for nalidixic acid. In the same year the a subunit of
DNA gyrase was proved to be the primary target of oxolinic acid and nalidixic acid
(Gellert et al 1977). Earlier investigations had indicated this when Goss (1964; 1965)
and his co-workers (Cook et al 1966; Dietz et al 1966) reported that nalidixic acid
selectively antagonised DNA synthesis, caused DNA degradation, and induced bacterial
filamentation.
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Other evidence that the a subunit was the target for 4-quinolones was that
a) Quinolones are highly specific inhibitors ofDNA gyrase.
b) Mutations leading to high level drug resistance are found predominantly in gyrA,
the structural gene for the a subunit.
c) Quinolones inhibit the supercoiling activities of DNA gyrase, the active site of
which is in the a subunit.
Despite many investigations, it has been impossible to elucidate the mechanism by
which quinolones exert their effects. Initial reports suggested that quinolones bound
directly to DNA (Shen and Pernet 1985), as tritiated norfloxacin was demonstrated to
bind preferentially to single stranded DNA and not to DNA gyrase, and on binding,
norfloxacin blocked the functions of DNA gyrase. Other reports directly opposed this
view, suggesting that DNA gyrase was the target for the quinolones, as quinolones are
able to inhibit the activity of purified DNA gyrase (Barret et al 1990). Also, 19F nuclear
resonance experiments by Le Goffic (1985) demonstrated the affinity of pefloxacin for
DNA gyrase. Further evidence for quinolone binding to DNA gyrase comes from
bacterial resistance associated with DNA gyrase mutations (Gellert et al 1977; Sato et al
1986).
Another model for the molecular basis of quinolone action was proposed by Shen et al
(1989). They suggested that a co-operative drug-DNA binding model occurred, which
inhibited gyrase. In this model DNA gyrase binds to double stranded DNA, cleaves
both DNA strands and induces a binding site for the quinolones on the relaxed DNA.
Drug binding occurs on the exposed single strand region at the enzyme's active site,
prior to the DNA strand being twisted through the DNA 'gate', and binding locks the
DNA strands in place, preventing the turnover of the gyrase molecule.
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Quinolone binding to DNA is proposed to occur by hydrogen bonds formed between
the DNA and the carbonyl and carboxyl side chains common to all quinolones. Drug
binding is thought to be co-operative with the binding of one quinolone molecule
facilitating the binding of a second, with four or more molecules binding in the DNA
'gate' and interacting with each other by ring stacking.
This proposed model is further supported by experiments performed by Willmott and
Maxwell (1993), who found by rapid gel filtration techniques that norfloxacin bound to
a gyrase-DNA complex, and not to the gyrase or DNA alone; and that the efficiency of
quinolone binding was determined primarily by the gyrA subunits. Yoshida and co¬
workers (1993) dispute this model, contending that a quinolone pocket model is
favoured, as the quinolone stacking model takes no account of mutations in gyrB
causing high level resistance, or the fact that quinolones have a wide variety of side
chains and structures that DNA is meant to bind to. The pocket model proposes that
quinolones exert their action by binding to gyrase-DNA complexes, and that the
binding affinities of the quinolones for the complex is determined by both the gyrA and
gyrB subunits. Yoshida and colleagues (1993) also demonstrated that enoxacin exhibits
two different binding affinities for the gyrase-DNA complex, depending upon the
mutant strain used, which also supports the pocket model theory. It is still unclear,
however, whether quinolones make contact with the a subunit alone, or with the (3
protein as well, as mutations in both the gyrA and gyrB genes of DNA gyrase have
been demonstrated to reduce quinolone binding.
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1.7 ACTIONS OF OUINOLONES ON INTACT BACTERIA.
As DNA gyrase inhibition prevents bacterial replication, the effect of the quinolone
antimicrobials might be assumed to be bacteriostatic. This, however, is not the case, as
exposure of susceptible bacterial cells to all quinolones results in rapid cell death (Smith
1984a; Lewin and Hastings 1990). Subjecting susceptible bacteria to quinolone
concentrations above the MIC leads to a biphasic response. In the first instance, the
lethality of the drugs increases until an optimum bacterial concentration (OBC) is
reached, and thereafter bactericidal activity declines.
One reason suggested for this biphasic response is that the 4-quinolones inhibit
bacterial RNA synthesis at concentrations above the OBC (Smith 1984a; Smith and
Lewin 1988). The inhibition ofDNA gyrase may cause the relaxation of chromosomal
DNA to such an extent that it can no longer be efficiently transcribed into RNA. Smith
and Lewin (1988) established that bacterial protein and RNA synthesis are prerequisites
for the bactericidal activity of nalidixic acid in E.coli by abolishing nalidixic acid's
bactericidal activity with the addition of rifampicin, an inhibitor of bacterial RNA
synthesis. Thus, the inhibition of RNA synthesis above the OBC would be expected to
abolish the bactericidal activity of the quinolones.
The bactericidal activity of nalidixic acid, however, does not explain the killing
mechanisms of all the 4-quinolone antimicrobials. Whilst the addition of a protein
synthesis inhibitor, chloramphenicol, or rifampicin, an inhibitor of RNA synthesis,
completely inhibits the bactericidal activity of nalidixic acid against E.coli in nutrient
broth, they only reduce the bactericidal activity of ciprofloxacin and norfloxacin under
the same conditions (Smith 1984a; Smith and Lewin 1988). A second observation was
that nalidixic acid does not exhibit a lethal effect in phosphate buffered saline, where
bacteria are unable to divide, whereas both ciprofloxacin and ofloxacin are active in this
medium (Smith 1984b).
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These results led to the proposition that the principal mechanism of action of all the 4-
quinolones was a mechanism which required protein and RNA synthesis, and cell
division for lethality, and this mechanism, mechanism A, was the only bactericidal
mechanism exhibited by nalidixic acid. Smith (1984a) also suggested that ciprofloxacin
and ofloxacin possessed a second bactericidal mechanism, termed mechanism B, which
was independent of protein and RNA synthesis and active against non-dividing
bacteria. Mechanism B occurs in the newer flouroquinolones like lomefloxacin (Lewin
etal 1989a).
Not all quinolones exhibit mechanism B. Investigations into the action of norfloxacin
demonstrated that the bactericidal activity of the drug was abolished in the absence of
protein or RNA synthesis, depending upon whether chloramphenicol or rifampicin was
added to the medium. Norfloxacin, unlike nalidixic acid, is active against non-dividing
bacterial cells, and therefore displays a third mechanism of action, termed C, in addition
to mechanism A (Ratcliffe and Smith 1985). Enoxacin also exhibits mechanism C
(Lewin et al 1989a). The possession of an extra bactericidal mechanism on top of
mechanism A may explain why the fluoroquinolones are more bactericidal at their
respective OBC's than nalidixic acid.
Inhibition of protein and RNA synthesis may reduce or abolish the ability of the
quinolones to kill bacteria, but it has no effect on their ability to prevent DNA synthesis
(Dietz et al 1966). Other conditions may also affect the bactericidal activity of
quinolones : strict anaerobiosis (Morrissey et al 1990), treatment with dinitrophenol
(DNP) (Dietz et al 1966), and starvation in buffered saline (Lewin et al 1989b) all
reduced the bactericidal activity of the quinolones studied. The quinolones may also
exhibit different bactericidal mechanisms against different species of bacteria.
Ciprofloxacin has been shown to kill E.coli by mechanism B, but during preliminary
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investigations seems to lack mechanism B against Staphylococcus albus or S.aureus
(Lewin and Smith 1987).
Against E.coli and S. aureus, ciprofloxacin and ofloxacin have been found to be
bacteriostatic under anaerobic conditions (Smith and Lewin 1988; Lewin et al 1989b,
Morrissey et al 1990). Aeration of cultures was shown to restore some bactericidal
activity and it was postulated that DNA supercoiling may account for the lack of effect.
DNA superhelicity has been implicated as a control mechanism in the expression of
several genes involved in the anaerobicity of both E.coli and Salmonella typhimurium
(Yamamoto and Droffner 1985; Dorman et al 1988). Mutants of S.typhimurium which
were obligate aerobes were found to be gyrase-deficient, implying that gyrase activity is
essential for growth under anaerobic conditions. Anaerobicity is also responsible for
influencing DNA supercoiling, and through this regulates the production of the OMPC
porin gene (Dorman et al 1988). Lewin and colleagues (1989b) postulated that altered
porin configuration might lead to a decrease in quinolone uptake, and so decrease their
bactericidal activity under anaerobic conditions.
Although the exact method of cell death caused by quinolones is still unclear, several
proposals have been put forward. Smith (1984a) proposed that quinolones cause DNA
gyrase to damage DNA by nicking, thus inducing the SOS DNA repair system. The
SOS genes code for a cascade of proteins which repair DNA, and may be induced by
the 4-quinolones (Piddock and Wise 1987). The quinolones also triggered the SOS
response with maximum intensity at a drug concentration which produced the greatest
bactericidal effect, and it was proposed that one of the SOS genes might code for a
lethal protein (Phillips et al 1987). Later work has implicated the SOS gene sfiA in the
lethality of the 4-quinolones (Walters et al 1989).
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Other investigations have indicated that mutations which lead to defective SOS
responses have an effect on, or increase, the susceptibility of bacteria to nalidixic acid
and ciprofloxacin, and that the induction of the SOS response is purely consequential
(Lewin et al 1989c; Piddock et al 1990). These results contradict the proposal that an
SOS gene encodes a lethal protein, and it was suggested that the hypersusceptibility of
some SOS deficient mutants is a result of deficient recombination repair and not SOS
repair (Lewin et al 1989c). The induction of the SOS response and its subsequent
effects fits the criteria of killing by mechanism A proposed by Smith (1984a).
Quinolones induce the production of recA , the primary protein in the SOS response,
and this induction requires active protein synthesis, as does mechanism A. The
inhibition of cell filamentation at concentrations above the OBC, and the subsequent
inhibition of cell division, also fit the criteria for mechanism A (Piddock et al 1990).
The bactericidal activity of quinolones against mutants with defective SOS responses
would then presumably be caused by mechanism B.
The use of electron microscopy techniques has demonstrated that quinolones alter the
membrane integrity of E.coli, resulting in cytoplasmic leakage and ultimately cell death
(Dougherty and Saukkonen 1985). Chapman and Georgopapadakou (1988) reported
that quinolones induced LPS release from cell surfaces and acted as chelating agents for
membrane bound divalent cations. The chelating effect lead to membrane
disorganisation, which then facilitated the entry of further quinolone molecules through
the outer membrane.
Other effects mediated by quinolones are cell filamentation and plasmid elimination.
Filamentation has been reported in both P.aeruginosa (Benbrook and Miller 1986) and
E.coli (Crumplin etal 1984) when cells were treated with norfloxacin, and is indicative
of an imbalance in normal cell metabolism. The inhibition of DNA gyrase by
norfloxacin may result in several effects : premature cell division, delayed cell division
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events, and total failure of cell division culminating in lysis of the cell (Crumplin et al
1984).
Investigations on E.coli filamentation, utilising ciprofloxacin, determined that gross
filamentation occurred at concentrations close to the MIC, but that filamentation was not
as extensive at the most bactericidal concentration (Diver and Wise 1986). This was a
result of inhibition of RNA and protein synthesis; and cell death caused by
filamentation was found to be a secondary effect as 90% of the cells were non-viable.
The secondary effect of filamentation did, however, eliminate around 10% of the cells,
which concurs with Smith's postulate (1984a) that ciprofloxacin exhibits two
mechanisms of killing in E.coli. In all cases, filamentation occurs before cell death and
may be a result of the antagonism of DNA synthesis and the induction of the SOS
response (Phillips et al 1987).
Plasmid elimination was reported in E.coli on treatment of bacterial cells with
subinhibitory concentrations of nalidixic acid and fluoroquinolones (Weisser and
Wiedemann 1985; 1986). Piatt and Black (1987) also established this phenomenon
when treating E.coli with ciprofloxacin, but found that only R plasmids were eliminated
and not small high copy number plasmids. Further studies of an E.coli mating system
suggested that some quinolones could reduce the efficiency of plasmid conjugation at
quinolone concentrations at or above the MIC (Weisser and Wiedemann 1987).
Furthermore, treatment with quinolones, particularly enoxacin, has been found to affect
plasmid function, resulting in a decrease in antibiotic resistance gene expression and in
replication related transcription (Courtright et al 1988). Whilst these observations offer
no insight into the bactericidal mechanisms of the quinolones they might help to explain
the lack of plasmid mediated resistance to these antimicrobial agents.
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1.8 BACTERIAL RESISTANCE TO THE FOtJR-OlJINOLONES.
As described previously there are several mechanisms of bacterial resistance to
antimicrobial agents, and these fall into two major categories, plasmid and
chromosomally mediated resistance. Quinolones, unlike most other antimicrobial
agents, have no substantiated reports of plasmid mediated resistance. Two reports of
plasmid mediated resistance to quinolones have occurred, however, the first by Munshi
and colleagues (1987) in Shigella dysenteriae and the second by Tanaka et al (1991) in
S.aureus.
Munshi and colleagues (1987) claimed that S.dysenteriae carried a 20 megadalton
plasmid encoding nalidixic acid resistance which could be transferred by conjugation.
Their claim was refuted after careful inspection of the data, as it was established that
nalidixic acid resistant mutants of the recipient strain had been selected for and not
studied, and not the authentic transconjugants (Courvalin 1990). Tanaka and
colleagues' report (1991) is slightly more conclusive, but the strains carrying the
alleged plasmid borne resistance also possessed gyrA mutations, and it is likely that the
methods of plasmid extraction from these strains could have caused the changes in MIC
observed and not plasmid borne resistance (Tanaka personal communication). The
absence of plasmid-mediated resistance to quinolones was confirmed by extensive
experiments conducted by Burman (1977) who attempted, unsuccessfully, to transfer
nalidixic acid resistance into Proteus mirabilis, Klebsiella, Enterobacter and
Pseudomonas species.
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Other evidence which suggests that plasmid-mediated quinolone resistance is unlikely
was submitted by Weisser and Wiedemann (1987) who established that quinolones
have a plasmid curing effect in E.coli. Plasmid conjugation is also inhibited by
quinolones (Nakamura et al 1976; Burman 1977) and expression of mutants causing
decreased outer membrane permeability is delayed when introduced into wild-type cells
(Foulds 1976). This might indicate that quinolone resistance determined by outer
membrane protein alterations may also be delayed.
A plasmid- mediated drug destruction mechanism is unlikely to occur, as quinolones are
synthetic drugs. However, bacteria have developed an efflux system for 4-quinolones
which probably evolved from an existing efflux mechanism. Therefore, a remote
possibility exists that bacteria could adapt a plasmid-mediated drug modification
mechanism to suit 4-quinolones.
A plasmid-borne, resistant DNA gyrase is also unlikely as resistant gyrases have been
shown to be recessive to the sensitive wild-type gyrase gene in genetic studies (Hane
and Wood 1969; Yoshida et al 1988; Robillard 1990). This trait was employed to
identify alterations in DNA gyrases of resistant Gram-negative bacteria by conferring
quinolone sensitivity to those strains by transforming them with plasmids carrying
quinolone-susceptible genes (Lewin et al 1990).
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1.8.1 Chromosomally Mediated Resistance to the Four-Quinolones.
Chromosomally-mediated resistance to the 4-quinolones is the only confirmed
resistance mechanism reported, and may occur in several ways: mutations may occur
that affect the permeability of the drug into the bacterial cell, whether by LPS or porin
alterations. Also, there may be alteration in the target molecule, DNA gyrase. A third
mechanism is the active efflux of the drug from the cell. In the case of the quinolones
all three mechanisms of resistance have been reported, and will be dealt with separately.
1.8.1.1 ALTERED PERMEABILITY.
Resistance to quinolones via altered drug permeability has been documented for E.coli
(Hirai et al 1986a; 1986b) K.pnemoniae (Sanders et al 1984), Enterobacteriacae and
Serratia species (Gutmann et al 1985), P.aeruginosa (Hirai et al 1987; Inoue et al
1987), Proteus vulgaris (Ishii et al 1991) and Citrobacter species (Aoyama et al 1988a).
Most reports conclude that this resistance is brought about by changes in outer
membrane proteins, or porins, although some reports have also implicated LPS
changes in reduced uptake (Hirai et al 1986b; Moniot-Ville et al 1991). The resistance
to quinolones via altered permeability mechanisms has been well documented in E.coli,
and for this reason E.coli will be concentrated upon here.
Quinolone resistance brought about by altered permeability is generally characterised by
low level resistance to the quinolones and structurally unrelated drugs. High level
resistance linked to permeability changes, however, have been documented in
Citrobacter freundii and Bacillus fragilis (Kato et al 1988). In E.coli several mutations
have been established (Table 1.1). The first report of low-level nalidixic acid resistance
was by Hane and Wood (1969) when investigating E.coli K-12, and was designated
nalB. Later in 1973, Bourguignon and colleagues identified nalB as a permeability
mutation, as EDTA abolished the resistance to nalidixic acid. Other mutations involving
low level nalidixic acid are icd, purB and ctr whose mechanisms of action are
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unknown. The mutations crp and cya occur in the cyclic adenosine monophosphate
(cAMP) genes and are responsible for pleiotropic drug resistance to quinolones and
aminoglycosides, brought about by a decreased cAMP-dependent OMPF expression.
Cohen and co-workers (1989) found that quinolone resistance could be selected with
tetracycline or chloramphenicol. This cross resistance was a result of changes in two
outer membrane proteins, OMPC and OMPF. Cohen and colleagues (1989) speculated
that drug permeability was decreased as a result of the increased expression of a narrow
channelled porin, OMPC, coupled with decreased expression of the wider channelled
porin, OMPF.
GENOTYPE MECHANISM AND LINK LOCATION
(mins)
cfxB marA energy dependent decrease in drug
accumulation
32
nfxB marA energy dependent decrease in daig
accumulation
19
nalB low level resistance 58
norB decreased expression of OMPF porin 34
noiG decreased expression of OMPF porin, defective
LPS core, hypersusceptibility to detergent
8
cya decrease in cAMP dependent OMPF expression 85
crp decrease in cAMP dependent OMPF expression 74
ctr - 52
icd, purB - 25
Table 1.1. Permeability Mutations in Escherichia coli.
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The importance of OMPF expression in quinolone resistance was established by Hirai
and colleagues (1986b), who documented that spontaneous single-step E.coli mutants
deficient in OMPF were four-fold less susceptible to quinolones than the parent strain,
and also accumulated norfloxacin at a slower rate. OMPC mutants were shown to
accumulate norfloxacin at the same rate as the parent strain, suggesting that OMPF is
the major route for influx of quinolones into E.coli (Hirai et al 1986b). These results
have been confirmed by other authors. Hooper et al (1989) isolated two mutations nfxB
and cficB, selected with norfloxacin and ciprofloxacin, respectively. Both mutations
mapped at sites distinct to the OMPF protein, which maps at 21 minutes. Both nficB,
mapping at 19 minutes, and cfxB, mapping at 34 minutes, are mutations in the
regulatory genes which control OMPF expression at the post-transcriptional level, and
cause a major decrease in OMPF expression (Lewin et al 1990).
CfxB was found to be closely linked to marA, isolated previously by selection with
tetracycline and chloramphenicol, and which also carried nalidixic acid resistance
(Cohen et al 1989). MarA resistance was linked to decreased drug permeability as a
consequence of reduced OMPF expression and altered LPS. NfxB also appears to have
a functional relationship with marA, as inactivation of marA by transposon insertion
caused the loss of the ability to recover the nfxB mutation. It is thought that the marA+
genes encode factors which negatively regulate OMPF expression and, therefore,
mutations in marA may increase the expression of this factor.
Decreases in OMPF proteins have been implicated in fleroxacin resistance (Chapman et
al 1989), norfloxacin resistance (Hirai et al 1986b) and ciprofloxacin resistance (Bedard
et al 1989) in E.coli. The norB mutation results in low level resistance to quinolones,
cefoxitin, tetracycline and chloramphenicol (Hirai et al 1986b). The norC mutation
encodes hypersusceptibility to hydrophobic quinolones, such as nalidixic acid, and
results in decreased OMPF expression coupled with LPS changes. Resistance brought
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about by outer membrane protein mutations is thought to have less effect on nalidixic
acid than modern 4-quinolones, as nalidixic acid is more hydrophobic and may,
therefore, permeate into the bacterial cell through the lipid bilayer (Hirai et al 1986a).
Other bacteria showing resistance to quinolones because of decreased expression of an
OMPF protein include Enterobacter cloacae, where a decrease in OMPF and an increase
in OMPC resulted in low level resistance to sparfloxacin, fleroxacin, temafloxacin and
ciprofloxacin.
Reports in Klebsiella and Serratia species also implicate a reduction in outer membrane
proteins in quinolone resistance (Gutmann et al 1985). In this report, however,
resistance caused by altered permeability was insufficient to account for the total
resistance. On investigating ofloxacin resistance in Proteus vulgaris low level resistance
was linked to reduced expression of a 37kD porin protein which was thought to be
analogous to OMPF in E.coli (Ishii et al 1991). Chapman et al (1989) suggested that as
fleroxacin was less affected by OMPF deficiency than ciprofloxacin, there might be
other routes of quinolone permeation into the cell. Studies on non-porin entry suggest
that drugs such as ciprofloxacin, norfloxacin and enoxacin can utilise non-porin
pathways, but that these are not the preferred routes (Bryan and Bedard 1991).
1.8.1.2 ALTERATIONS IN THE TARGET ENZYME.
The second chromosomally-mediated quinolone resistance is brought about by
alterations in the bacterial DNA gyrase, and was originally associated with high levels
of quinolone resistance, although experiments by Yoshida and co-workers (1988) have
indicated that mutations in the gyrA gene of E.coli can cause various levels of
resistance. Mutations in DNA gyrase have been reported in many bacterial species
including E.coli (Hirai et al 1986b; Cullen et al 1989), S.aureus (Tanaka et al 1991),
P.aeruginosa (Inoue et al 1987; Robillard and Scarpa 1988), K.pneumoniae (Piddock
and Zhu 1991), Providencia stuartii (Heisig and Wiedemann 1991), Enterococcus
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faecalis (Nakanishi et al 1991a), Campylobacter jejuni (Gootz and Martin 1991),
Serratia marcescens (Fujimaki et al 1989), S.epidermidis (Sreedharan et al 1991),
E.cloacae (Yamashita et al 1986), N.gonorrhoeae (Power et al 1992), C.freundii
(Aoyama et al 1988b), B.subtilis (Lampe and Bott 1984) and Proteus mirabilis (Power
et al 1992). A gyrase mutation coupled with a decrease in drug accumulation has also
been implicated in the resistance of clinical strains of Streptococcus pneumoniae to 4-
quinolones (Jin and Piddock 1993). The existence of DNA gyrase mutations in both
Gram-negative and Gram-positive bacteria implicates them as the major resistance
determining mechanism to 4-quinolones.
Alterations in the DNA gyrase have been documented in both the gyrA and gyrB genes,
although the majority of mutations are found in the gyrA gene, indicating that it has a
major part to play in quinolone resistance. The resistance genes in E.coli encoding gyrA
resistance include nalA, nfxA, norA, ofxA and cfxA (Table 1.2) (Yamagishi et al 1981;
1986). Studies of gyrA resistance were further aided by the determination of the
nucleotide sequences for two nalidixic acid-resistant and two pipemidic acid-resistant
E.coli strains (Yoshida et al 1988). In each mutation a single base pair was altered. The
four documented mutations were all located in the N-terminal sequence of gyrA, in the
hydrophilic regions of the peptide, which suggests that they are situated near the
surface of the a subunit. The mutations occur at amino acid serine 83, close to the
codon tyrosine 122, which is the site of DNA attachment to the a subunit when DNA
gyrase has cleaved the DNA in the presence of the quinolone antimicrobial agents





gyrA cfxA, nfxA 48 Resistance to
norA, Alteration in a subunit quinolones only.
ofxA, nalA
gyrB nalC 82 Alteration in (3 subunit Hypersusceptible to
(nal31) new quinolones.
nalD 89 Alteration in (3 subunit Low level resistance to
(nal24) and altered LPS. new quinolones.
Table 1.2. Mutations in the DNA Gyrase of Escherichia coli.
Yamagishi and colleagues (1981; 1986) identified two mutations in E.coli, nalC and
nalD, when selecting with nalidixic acid. The nalD mutation was found to increase
resistance to the new 4-quinolones, particularly those with piperazinyl substitutions,
whilst nalC mutations appeared to determine an increased susceptibility to new
quinolones. The mutations encoded single amino acid changes which altered protein
charge in opposite directions, suggesting that charge may be related to drug-enzyme
interaction.
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There have been several mutation sites documented for E.coli (Table 1.3). All gyrA
mutations were shown to fall between amino acids 67 and 106, and this has been
termed the 'quinolone resistance-determining region' (Yoshida et al 1990a). The high-
level resistance mutations have shown a single nucleotide change resulting in the
alteration of Ser83 to leucine or tryptophan (Cullen et al 1989). Other mutations may
occur in concert with a mutation at Ser83, or in combination with a mutation at Asp87.
Low-level resistance-determining mutations were not isolated singularly, and always
appeared in combination with another mutation. In all cases, experiments have
established an alteration in Ser83 as the most common gyrA mutation, and that a







gyrA Ala (67) to Ser low level Yoshida et al 1988
Gly (81) to Cys medium level Yoshida etal 1990a
Ser (83) to Ala low level Hallett and Maxwell 1991
Ser (83) to Leu high level Yoshida et al 1990a
Ser (83) to Trp high level Yoshida et al 1988
Ala (84) to Pro medium level Yoshida et al 1988
Asp (87) to Gly high level Heisig etal 1993
Asp (87) to Asn medium/high level Yoshida etal 1990a
Asp (87) to Val low level Oram and Fisher 1991
Gin (106) to Arg low level Hallett and Maxwell 1991
Gin (106) to His low level Yoshida etal 1990a
gyrB Asp (426) to Asn low/medium level Yamagishi etal 1986
Lys (447) to Glu low level Yamagishi etal 1986
Table 1.3. Quinolone-Resistant Mutations of Escherichia coli DNA
Gyrase.
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'Silent mutations'have been documented in E.coli (Oram and Fisher 1991), which
appear to occur outside the quinolone resistance-determining region, and many strains
with Ser83 mutations have been shown to carry the same silent mutations. Cullen and
colleagues (1989) have also found silent mutations occurring outside the quinolone
resistance-determining region which encode neutral changes of Asp678 to glutamine
and Ala828 to serine. Neither of these mutations contributed to the resistant phenotype.
Other bacteria exhibit similar resistance patterns to E.coli (Table 1.4). In S.aureus gyrA
and gyrB genes were shown to have 66% homology with their E.coli and 76%
homology with their B.subtilis counterparts (Hopewell et al 1990). Mutations in the
S.aureus gyrase have been investigated, and amino acid changes which are analogous
to those found in E.coli have been reported. Sreedharan and co-workers (1991)
discovered cytosine to thymine transitions in S.aureus which conveyed a serine to
leucine change at amino acid 84, and/or a Ser85 to proline codon change.These are
analogous to changes at amino acids 83 and 84 in E.coli. They also discovered a novel
Ser84 to Phe mutation in S.epidermidis.
These documented changes have been verified by Fasching and colleagues (1991) in
clinical isolates of MRSA with oligonucleotide probes, and by Goswitz et al (1992) by
Polymerisation Chain Reaction (PCR) and direct DNA sequencing. Goswitz and
colleagues (1992) reported serine to alanine mutations at amino acid 84 and glutamine
to lysine at amino acid 88, with all the quinolone-resistant strains possessing at least
one mutation between these amino acids.
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Recent investigations by Wang and colleagues (1993) have identified amino acid
changes in the gyrA gene of C.jejuni. The gyrA sequence of C.jejuni shows 50%
identity with the sequences of other documented gyrA sequences, with the quinolone
resistance-determining regions being virtually identical. The mutations found in
C.jejuni occurred at Thr86, Asp90 and Ala70 which are analogous to Ser83, Asp87
and Ala67 in E.coli. The mutations at Thr86 and Ala70 conferred high and medium






Staph, aureus gyrA 84 (83)* Ser to Leu High level Sreedharan et al 1990
84(83) Ser to Ala Medium level Goswitz et al 1992
85 (84) Ser to Pro Medium level Sreedharan et al 1990
88 (87) Glu to Lys Medium level Goswitz et al 199Z
Staph.epidermidis gyrA 84(83) Ser to Phe Medium level Sreedharan et al 1991
Camp, jejuni gyrA 70 (67) Ala to Thr Low level Wang et al 1993
86 (83) Thr to lie High level Wang et al 1993















tuberculosis gyrA 90(83) Ala to Val High level Takiff et al 1993
()* Equivalent amino acid position in Escherichia coli.
Table 1.4. Quinolone-Resistant Mutations of Other Bacterial DNA
Gyrases.
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Although gyrA mutations occur more frequently, gyrB mutations in E.coli may affect
quinolone resistance. GyrB mutations have been implicated in low-level quinolone
resistance (Inoue etal 1978) and their relevance to overall quinolone resistance has been
questioned. It has been suggested that the peripheral parts of the 4-quinolone molecule
may react with the P subunit of E.coli DNA gyrase, and so mutations affecting this may
confer low level resistance. An alternative suggestion is that alterations in the P subunit
may act indirectly by altering the conformation of the a subunit, and through this the
quinolone binding site (Reece and Maxwell 1991). Recent work by Yoshida and
colleagues (1993) has established that the P subunit does have a significant role to play
in determining quinolone resistance.
The nal31 mutation (Yamagishi et al 1986), also documented as the nalC mutation
(Inoue et al 1978), and the nal24 mutation (Yamagishi et al 1986) are both point
mutations which alter amino acids 436 and 427 in the P subunit respectively. This
region has been proposed to be the region involved in the binding of the P subunit to
the a subunit (Cozzarelli 1980). The nal24 mutation involves an asparagine to aspartic
acid substitution, and the nal31 one from lysine to glutamic acid. As in the gyrA
mutations, these substitutions involve an alteration in the charge of the p subunit. The
nal24 mutation decreases the negative charge of the protein at that point, and the nal31
increases the negative charge.
Investigations into novobiocin resistance in Haloferax by Holmes and Dyall-Smith
(1991) found similar gyrB mutations to those reported in E.coli. On sequencing the
novobiocin resistance gene the documented amino acid changes were Asp82 to glycine,
Serl22 to threonine, and Argl37 to histidine. On further investigation it remained
unclear which amino acid changes were responsible for the resistant phenotype and
which, if any, were silent mutations.
42
The effect of both gyrA and gyrB mutations seems to involve an alteration of the charge
or hydrophobicity in the relevant amino acid. Two hypotheses have been proposed to
explain how quinolone resistance is brought about by these alterations. The first
suggests that mutations involving amino acid changes might alter the structure of the
enzyme to interfere with quinolone activity (Goswitz et al 1992). The second, and more
widely accepted hypothesis, is that an alteration in charge either prevents or facilitates
the binding of quinolones (Yoshida et al 1991; Goswitz et al 1992). This theory is
further proved by the observations of Smith (1984b), where the nal31 mutation only
conferred resistance to acidic 4-quinolones lacking a position 7 piperazine substituent;
but at the same time rendered bacteria hypersensitive to the amphoteric quinolones
possessing a position 7 piperazine substituent, which is positively charged. This
anomaly is thought to occur as amphoteric quinolones have a positive grouping in an
ideal position to interact with the (3 subunit at the mutation site (Yoshida et al 1991).
1.8.1.3 ACTIVE EFFLUX MECHANISM.
Until recently, tetracycline was thought to be the only antibiotic which was actively
excreted from the bacterial cell (McMurry et al 1980). Examples of efflux based
resistance to hydrophilic quinolones, however, have been documented in clinical
isolates of S.aureus (Nakanishi et al 1991b; Tanaka et al 1991), P.vulgaris (Ishii et al
1991) and E.coli (Hooper et al 1989; Kotera et al 1991).
In S.aureus it has been suggested that the gene norA might be linked to quinolone
efflux from the cell. NorA encodes a hydrophobic membrane protein of approximately
43kD (Ubukata et al 1989) and is dominant over the wild-type quinolone-susceptible
phenotype of E.coli, so is unlikely to involve gyrase mutations (Kaatz et al 1991). The
membrane protein encoded by norA displays homology with other transport proteins
known to be coupled to the electrochemical proton gradient (Yoshida et al 1990c).
Another norA type gene, norA 1199, was recently isolated by Kaatz and co-workers
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(1993) and was established to be a multidrug efflux transporter, which transported
hydrophilic quinolones faster than hydrophobic ones. NorAl199 exhibits significant
homology with tetracycline efflux proteins but is chromosomally-encoded, instead of
plasmid-encoded like its tetracycline counterpart. NorA1199 was reported to show a
high degree of homology with the B.subtilis Bmr protein, which mediates the efflux of
chloramphenicol and fluoroquinolones (Neyfakh etal 1993).
Efflux systems have been reported in the inner membrane of E.coli and are energy
requiring and saturable. Efflux was identified by using everted inner membrane vesicles
in which norfloxacin accumulation reflected drug efflux in a normal intact cell (Cohen et
al 1988). Active efflux was demonstrated to be a resistance mechanism in P.vulgaris by
the use of carbonylcyanide m-chloro-phenylhydrazone (CCCP) an energy inhibitor.
Ishii et al (1991) determined that ofloxacin accumulation in P.vulgaris was forty-fold
higher in the presence of CCCP than in its absence. CCCP was also used to
demonstrate active efflux of hydrophilic quinolones in S.aureus (Nakanishi et al 1991b)
and efflux of norfloxacin in E.coli (Hooper et al 1989).
In all these reports, active drug efflux has not been implicated as the sole mechanism of
bacterial resistance to quinolones; indeed it seems to play a secondary role in quinolone
resistance compared to permeability changes and DNA gyrase mutations. When
coupled with other resistance mechanisms, however, active efflux of hydrophilic
quinolones from the bacterial cell has contributed to highly resistant organisms, which
if selected further could cause many problems clinically.
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1.9 MECHANISMS OF OUINOLONE RESISTANCE IN
PSFAJDOMONAS AERUGINOSA.
P.aeruginosa has been shown to be highly resistant to quinolones both in vivo and in
vitro, and this resistance is becoming increasingly important clinically. Quinolone
resistance in P.aeruginosa, like other bacteria, is caused by permeability and gyrase
mutations and drug efflux mechanisms, enabling the resistant bacteria to be broadly
categorised
Type 1 : Resistant to all quinolones but susceptible to unrelated antibiotics, mediated
by gyrase mutations.
Type 2 : Resistant to quinolones, carbenicillin, novobiocin and chloramphenicol,
caused by decreased drug penetration.
Type 3 : Resistant to quinolones and chloramphenicol but hypersusceptible to
gentamicin and carbenicillin, probably via decreased drug transport (Yoshida et al
1990b).
The categories were also classified by their ability to be transformed by the wild-type
E.coli gyrA gene. Type 1 isolates became quinolone-susceptible, whereas types 2 and 3
demonstrated no alteration in resistance. This classification, however, does not take
into consideration the ability of P.aeruginosa to exhibit more than one quinolone
resistance mechanism (Reece and Maxwell 1991).
1.9.1 Permeability Mutations.
The quinolone resistance mechanism in P.aeruginosa that has been most widely
documented is that produced by permeability mutations. Several porin proteins have
been implicated in the resistance to antimicrobial agents in P.aeruginosa. These include
OprE (OMPE), OprD (OMPD2), OprB (OMPDi) and OMPC (Hancock et al 1990).
Resistance to quinolones via permeability mutations in P.aeruginosa may also result in
cross resistance to unrelated antimicrobial agents, for example imipenem (Radberg et al
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1990) and (3-lactam antibiotics (Rella and Haas 1982; Fukuda et al 1990). The
documented alterations in outer membrane proteins in P.aeruginosa are similar to those
seen in E.coli in that they confer less resistance to nalidixic acid than to the fluorinated
quinolones (Lewin et al 1990). The mutations differ from those reported in E.coli,
however, in that several outer membrane proteins are implicated and not just OMPF
(Table 1.5).
GENOTYPE MECHANISM CHARACTERISTICS REFERENCE
nalB - High level quinolone resistance, low Rella and Haas
level nalidixic acid resistance 1982
cfxB Extra 51kD protein High level quinolone resistance, cross Robillard and
resistance to tet, chlor, nov and cab. Scarpa 1988
Qrl, Qr2 reduction OmpG and Cross resistance to |3-lactams, tet. and Chamberland et al
40kD protein chloramphenicol. 1989
nfxB New 54kD protein Hypersusceptibility to (3-lactams and Hirai et al 1987
aminoglycosides.
nfxC Increased expression Cross resistance to imipenem and chlor Fukuda et al 1990
50kD protein and hypersusceptibility to fS-lactams
and aminoglycosides.
tet - tetracycline, chlor - chloramphenicol, nov - novobiocin, cab - carbenicillin.
Table 1.5. Permeability Mutations in Pseudomonas aeruginosa.
Resistance to quinolones has been linked with the loss of OMPF in P.aeruginosa and
conferred ureidopenicillin cross resistance (Piddock etal 1987), but most resistance has
been associated with other membrane proteins. Resistance linked to the cfxB and nalB
mutations was shown to be unrelated to OMPF, and exhibited cross resistance to
carbenicillin. The nalB mutation, later termed cfxB, conferred high level resistance to
ciprofloxacin, ofloxacin, norfloxacin and enoxacin, on a par with gyrase mutations, but
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only low level resistance to nalidixic acid (Rella and Haas 1982; Robillard and Scarpa
1988). The cfxB mutation encoded an additional 51kD protein and exhibited cross
resistance to chloramphenicol, tetracycline and novobiocin as well as carbenicillin.
Other investigators have implicated the loss of, or reduced expression of, a 31-32kD
outer membrane protein in low-level quinolone resistance in clinical isolates of
P.aeruginosa (Daikos et al 1988; Kaatz and Seo 1988). This alteration in a 31-32kD
protein was unlike the cfxB mutation as it was unstable, reverting back to ciprofloxacin
sensitivity after serial passaging, and it conferred no cross resistance to unrelated
antimicrobial agents.
Chamberland and colleagues (1989) reported low level quinolone resistance in two
norfloxacin-resistant mutants of P.aeruginosa , termed Qrl and Qr2. The altered
permeability of these bacteria did not reside in major rearrangements of outer membrane
proteins, or a modification of OMPF. Instead it was associated with a reduction in
OMPG and an antigenically related 40kD outer membrane protein. The function of
OMPG could not be established, and the relationship between the two proteins was
unclear, but the mutant bacteria also exhibited cross resistance to some ^-lactams,
chloramphenicol and tetracycline.
Quinolone resistance in P.aeruginosa is not solely associated with decreased expression
of outer membrane proteins, but has also been reported to involve the increase of
certain proteins. Hirai and colleagues (1987) demonstrated that norfloxacin resistance in
P.aeruginosa, designated n fxB, was linked to the appearance of a 54kD protein by
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The nfxB
mutation was unlike any other, as instead of conferring cross resistance to (3-lactams
and aminoglycosides like cfxB, it conferred hypersusceptibility to these drugs.
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Furthermore, the nfxB mutation was not linked to chloramphenicol and tetracycline
susceptibility or resistance.
The presence of a 54kD protein conferring quinolone resistance was also documented
by Legakis et al (1989) when utilising ciprofloxacin selection. Resistance involved
increased expression of this protein, however, rather than the appearance of a new
protein. The mutation was established to be different from nfxB as it encoded cross
resistance to (3-lactams and aminoglycosides. Fukuda and co-workers (1990) have
implicated an increase in a 50kD protein in quinolone resistance, as mutations
designated nfxC produced large amounts of this protein on SDS-PAGE.
Overproduction of this 50kD protein was linked with resistance to imipenem and
chloramphenicol and hypersusceptibility to P-lactams and aminoglycosides. The nfxC
mutants also exhibited reduced expression of OMPG, but unlike the findings of
Chamberland and colleagues (1989), no alterations in a 40kD protein were
documented. Fukuda et al (1990) also reported that nfxC mutants were cross resistant
to imipenem and that this was linked to the decreased expression of a 46kD protein.
Quinolone and imipenem cross resistance has been reported in clinical isolates of
P.aeruginosa (Radberg et al 1990), and has been associated with reduced expression of
protein D2, a 47kD outer membrane protein (Rohner et al 1992). Resistance caused by
decreased expression of protein D2 was linked with increases in the amount of cell
surface LPS, although the LPS alterations were thought to exert a minimal effect on
resistance. Furthermore, alterations in LPS coupled with outer membrane protein
changes have been implicated clinically in ciprofloxacin-resistant P.aeruginosa strains
from cystic fibrosis patients (Diver et al 1991). Legakis and co-workers (1989) also
demonstrated that permeability mutations were linked with truncated LPS in
P.aeruginosa, and Michea-Hamzehpour and colleagues (1991) suggested that an
increase in LPS expression in ciprofloxacin- and norfloxacin-resistant P.aeruginosa
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might produce a permeability barrier which restricted the penetration of these
hydrophilic quinolones into the bacterial cell.
To summarise, permeability mutations in P.aeruginosa , unlike E.coli, are not solely
associated with the decreased expression of one protein, but instead are associated with
either alterations, reduced expression or loss of several proteins, or the increased
expression and appearance of new proteins. They are also invariably coupled with
alterations in bacterial LPS expression or with DNA gyrase mutations.
1.9.2 DNA Gyrase Mutations.
There have been reports of mutations in both the P.aeruginosa a and (3 subunits of
DNA gyrase. The main documented mutations in gyrA are nalA (Hirai et al 1987;
Inoue et al 1987), cfxA (Robillard and Scarpa 1988), and nfxA (Fukuda et al 1990),
and one in gyrB (Yoshida et al 1990b). All of the mutations were identified by the
transformation of a sensitive E.coli gyrA gene into resistant isolates of P.aeruginosa,
which revert to quinolone susceptibility if a gyrA mutation is present.
Inoue and co-workers (1987) separated the subunits of DNA gyrase and showed via
inhibition tests on reconstituted gyrases, containing combinations of a and P subunits,
that resistant strains had alterations in the a subunit. These mutations were
subsequently found to map on the nalA gene. Inoue and colleagues (1987) concluded
that the product of the nalA gene was the gyrase a subunit protein, and that mutations
in this protein were responsible for high levels of quinolone resistance in P.aeruginosa.
Later Robillard and Scarpa (1988) isolated cfxA mutations in laboratory mutants of
P.aeruginosa, selected with ciprofloxacin, and via the isolation of DNA gyrase and
inhibition studies demonstrated that the mutations conferred high level quinolone
resistance, and that they too mapped in the nalA region of the P.aeruginosa genome.
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Transformation experiments by Yoshida and colleagues (1990b) identified a
P.aeruginosa isolate as being gyrB resistant when a plasmid carrying the E.coli wild
type gyrB conferred an eight-fold susceptibility to enoxacin on the strain. Yoshida and
co-workers (1990b) also reported 12 isolates carrying gyrA mutations. Transformation
methods have also been employed by Heisig and Wiedemann (1991) and Piddock and
co-workers (1992) to show gyrA mutations in clinical isolates of P.aeruginosa. So far,
the gyrA sequence of P.aeruginosa has not been published, therefore specific gyrA
mutations in this organism have not been identified further.
1.9.3 Efflux Mechanisms.
Both Bryan and colleagues (1989) and Bedard and co-workers (1989) have reported
increases in whole cell accumulation of norfloxacin, ciprofloxacin and enoxacin in
P.aeruginosa isolates treated with CCCP. They also reported that sodium azide, sodium
fluoride, sodium arsenate and EDTA are able to increase ciprofloxacin accumulation in
P.aeruginosa mutants as well as CCCP and DNP. This would indicate the presence of
an active efflux mechanism in P.aeruginosa, although this has been established to have
a minor effect on quinolone resistance compared to gyrase mutations or alterations in
drug permeability.
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1.10 AIMS OF THIS THESIS.
This thesis investigated the mechanisms of resistance of P.aeruginosa to the 4-
quinolones. The aims of this thesis were:-
1) To investigate the nature and the frequency of outer membrane protein mutations in
clinical and laboratory isolates of P.aeruginosa, and to determine the effects of these
mutations upon quinolone resistance.
2) To determine the nature and frequency of DNA gyrase mutations in ciprofloxacin -
resistant clinical isolates of P.aeruginosa by investigating their specific activities.
3) To investigate possible mutation sites in the DNA gyrase of clinical isolates of
P.aeruginosa, and their frequency of occurrence.





All chemicals and reagents were supplied by Sigma Chemical Co. Ltd. unless otherwise
stated.
2.2 BACTERIAL STRAINS.
Forty clinical isolates were investigated in this thesis, and are listed in Tables 2.1 and
2.2. The bacterial isolates were stored at -70°C in a 10% skimmed milk solution
(Oxoid). Strains were always subcultured from the stock and not passaged. All strains
were pyocin-typed by the method of Govan et al (1983) to verify that they were the
P.aeruginosa isolates stated.
STRAIN PYOCIN TYPE SOURCE ISOLATED FROM:-
91-32 1/d (s-a)* GRI Blood culture on 21/3/91
91-33 1/d (s-a) GRI Blood culture on 28/3/91
91-40 1/d (s-a) GRI Blood culture on 6/4/91
91-41 1/d (s-a) GRI Blood culture on 5/4/91
91-42 1/d (s-a) GRI Blood culture on 8/4/91
91-44 1/d (s-a) GRI Blood culture on 9/4/91
91-46 1/d (s-a) GRI MIC plate of 91-40
91-76 10/d GRI Blood culture 11/4/91
91-28 44/m GRI Patient II Blood culture on 20/3/91
91-36 ut/m GRI Patient II Blood culture on 28/3/91
90-62 1/c (s-5) GRI Patient III Blood culture on 27/7/90
90-67 1/c (s-5) GRI Patient III Blood culture on 20/8/90
ut - untypable strains * (s- ) sensitivity shown to reagents named
Table 2.1. Origins of Paired Clinical Strains.
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STRAIN PYOCIN TYPE SOURCE
PAOl - Public Health Laboratory Service,
(PHLS) Colindale.
U423 76/ut (s-7,a,d,e)* Royal Infirmary of Edinburgh (RIE)
CI ut/v RIE
C2 10/h (s-b) RIE
C32 105/w RIE
C48 10/c (s-3,6,7) RIE
C48s 10/c (s-3,6,7) This laboratory
C49 1/a (s-4,6) RIE
3 ut/a (s-b,d) Royal Infirmary of Cardiff (RIC)
48 10/c (s-3,6,7) RIE
52 ut/k RIE
135 1/d RIE
271 10/a (s-7) RIC
273 ut/p (s-5) RIC
274 48/ut (s-l,2,5,6,7,a,d,e) RIC
4124 10/ut (s-a) Leicester, (PHLS Colindale)
4125 10/ut (s-a) Leicester, (PHLS Colindale)
4131 10/h (s-b) Shrewsbury, (PHLS Colindale)
4133 10/h (s-b) Shrewsbury, (PHLS Colindale)
4149 10/c (s-3,6,7) PHLS Colindale
4158 3/e (s-3) Glasgow Royal Infirmary (GRI)
4161 3/e (s-5) GRI
4269 1/a (s-4,6) Exeter, (PHLS Colindale)
4352 9/h France, (PHLS Colindale)
4374 9/ut France, (PHLS Colindale)
4375 10/c (s-3,6) PHLS Colindale
4495 ut/k Isle ofWight, (PHLS Colindale)
4532 5/ut PHLS Colindale
* ut - untypable strains (s- ) sensitivity shown to reagents named
Table 2.2. Origin of Unpaired Clinical Strains.
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2.3 ANTIBIOTICS.
Antimicrobial agents were supplied as sterile powders from the manufacturers. The 4-
quinolones ciprofloxacin, ofloxacin (Tarivid®, Roussel Laboratories Ltd.) and
norfloxacin (Noroxin®, Merck, Sharp and Dohme) were weighed aseptically,
dissolved in sterile 0.1M sodium hydroxide solution (NaOH) and diluted to the required
concentration with sterile distilled water. Imipenem (Primaxin®, MSD.), ceftazidime
(Fortum®, Glaxo Laboratories Ltd.), cefotaxime (Claforan®, Roussel), gentamicin,
carbenicillin (Pyogen®, SmithKline Beecham), tetracycline, ampicillin (SmithKline
Beecham) and kanamycin were dissolved in pyrogen-free water (Milli-Q, Millipore).
Trimethoprim (Wellcome Foundation Ltd.) was dissolved in lactic acid (Fisons) and
sterile distilled water. All drug solutions were prepared fresh when needed. Drugs were
stored as dry powders in darkness at 4°C.
2.4 MEDIA.
All growth media, both broth and agar, were sterilised by autoclaving at 121°C at 15
pounds/square inch for 15 minutes.
2.4.1 Complex Media.
The following complex media were used; Isosensitest Broth
agar (CM471), nutrient agar (CM3), and nutrient broth no.
Oxoid. PIA was supplied by Difco.
2.4.2 Davis-Mingioli Minimal Salts Media.
Double strength and single strength minimal salts media were prepared as described by
Davis and Mingioli (1950), the ingredients of which are shown in Table 2.3. Davis and
Mingioli (DM) agar plates were prepared with 50ml of double-strength DM media
supplemented with the appropriate amount of the required amino acid stock solutions,
to achieve the final concentrations as shown in Table 2.4. Appropriate amounts of
(1ST, CM473) and 1ST
2 (CM67) supplied by
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selecting antibiotics were then added, as was a 20% D-glucose solution to give a final
concentration of 0.28%. The volume was then made up to 60ml with sterile distilled
water. This solution was added to 40ml of sterile molten Bacteriological Agar No. 1 (lg
agar / 40ml distilled water, Oxoid) and the plates poured immediately.






Table 2.3. Ingredients of Double Strength DM Media.




L-Elistidine (BDH) 5g/l 50mg/1
L-Methionine (BDH) 5g/l 50mg/1
L-Proline (BDH) 5g/l 50mg/1
L-Tryptophan (BDH) 2g/l 50mg/1
Table 2.4. Concentrations of Amino Acid Supplements.




The constituents of one litre of SOC broth were as follows:-
20g Bacto tryptone (Difco); 5g Bacto yeast extract (Difco); lOmM NaCl; 2.5mM KC1;
lOmM MgCh; lOmM MgS04; and 20mM glucose. The pH was adjusted to 7.0 with
NaOH.
2.4.4 Hepes/Glycerol (HGEB) Broth.
The constituents of one litre of HGEB broth were ImM Hepes solution (pH 7.0) and
10% w/v glycerol.
2.4.5 Luria-Bertani (LB) Broth
The constituents of one litre of L broth were, lOg Bacto peptone (Difco); 5g Bacto yeast
extract (Difco) and 5g Sodium Chloride.
2.4.6 Pseudomonas (P) Broth.
The constituents for a litre of P broth are shown in Table 2.5. The broth was prepared
by autoclaving the magnesium sulphate and the glucose separately, and then adding
them to the remaining constituents, just prior to the inoculation of the starter cultures.
CONSTITUENT AMOUNT g/1
Bacto peptone (Difco) 10






Table 2.5. The Constituents of P Broth.
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2.5 DETERMINATION OF MINIMUM INHIBITORY
CONCENTRATIONS IMICs)
MICs were determined for 34 quinolone-resistant and 7 quinolone-sensitive clinical
isolates of Pseudomonas aeruginosa, and one reference strain, PAOl. Strains with
MICs greater than the breakpoints determined by the Working Party of the British
Society of Antimicrobial Chemotherapy (BSAC 1991) were deemed resistant to the
antimicrobial concerned. The break points were as follows cefotaxime, lmg/ 1;
ceftazidime 2mg/ 1; imipenem 4mg/ 1; ciprofloxacin 4mg/ 1; ofloxacin 8mg/ 1;
norfloxacin 4mg/ 1; tetracycline lmg/ 1; chloramphenicol, 8mg/ .1; trimethoprim
0.5mg/ 1; ampicillin, 8mg/ 1; gentamicin lmg/ 1 and carbenicillin 32mg/ 1.
MICs were determined by an agar dilution technique on both 1ST agar and PIA by
following a doubling dilution schedule unless otherwise stated. The antibiotic plates
were inoculated with a multipoint inoculator (Denley) delivering approximately 105
colony forming units (cfu) per spot, and were incubated aerobically at 37°C unless
otherwise stated. The MIC was defined as the lowest concentration of antibiotic at
which no visible growth of bacteria was observed. The technique was validated by
type strains of Pseudomonas (NCTC 10662), Escherichia coli (NCTC 10418) and
Staphylococcus aureus (NCTC 6571), and consistency of results was ensured by
including PAOl as a standard on every plate.
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2.6 MECHANISMS OF OIJINOLONE RESISTANCE.
2.6.1 Stability of Quinolone Resistance in Clinical Isolates of
Pseudomonas aeruginosa.
MICs of ciprofloxacin were determined on 1ST agar for 20 ciprofloxacin-resistant
clinical isolates. Strains were streaked out for single colonies on drug-free PIA and
incubated aerobically overnight at 37°C. A single colony was then passaged onto new
PIA plates and treated as before. Strains were passaged daily for 15 days, and their
MICs determined initially before passaging, and subsequently every five days.
2.6.2 Production of 4-Quinolone Resistant Mutant Isolates.
To produce spontaneous mutant bacteria, universals containing 10ml of drug-free
nutrient broth were inoculated with a single colony of P.aeruginosa and incubated
aerobically overnight at 37°C. The resulting cultures were harvested by centrifugation at
3000 rpm (Sorvall RT 6000D, DuPont) for 20 minutes and the resultant pellet
resuspended in 1ml fresh nutrient broth, to give cell concentrations in excess of 1010
cfu per ml. Aliquots (0.1ml) of undiluted, 10"2, 10"4 and 10~6 dilutions were spread
onto 1ST agar plates containing either ciprofloxacin or ofloxacin at 2, 5 and 10 times the
respective MICs. The plates were incubated at 37°C for 24 or 48 hours. Resistant
colonies were subcultured onto PIA plates containing antibiotic at the same
concentration to verify resistance, and colonies pyocin typed to link them to the parent
strain.
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2.7 ALTERATIONS IN OUTER MEMBRANE PROTEINS (OMPs).
2.7.1 Preparation of OMPs.
All 22 quinolone-resistant isolates, 5 sensitive clinical isolates, 14 paired isolates and
PAOl were investigated for OMP alterations. The quinolone-resistant mutants obtained
from the mutation experiments were also examined for OMP alterations. OMPs were
prepared from two 250ml nutrient broth cultures grown shaking, aerobically, overnight
at 37°C. Cells were harvested by centrifugation at 6000rpm (GS3 rotor, Sorvall RC-
5B, DuPont) for 15 minutes and lysed by sonication at 8|im for four 30 second bursts,
separated by 30 second cooling periods, with an ultrasonic disruptor (MSE Soniprep
150, MSE Instruments).
The lysate was then centrifuged three times at 12,000rpm (SA600 rotor, Sorvall RC-5B
DuPont) for 15 minutes to remove whole cells, and the inner membranes solubilised by
the addition of lauryl sarcosinate (sarcosyl) to a concentration of 0.7%. The outer
membranes were isolated by ultracentrifugation at 100,000g (TFT 70.38 rotor, Sorvall
OTD65-B, DuPont) for 1 hour at 4°C. The membranes were washed with 5ml
pyrogen-free water (Milli-Q, Millipore) and harvested by centrifugation at 100,000g for
1 hour at 4°C. The precipitated membranes were finally resuspended in 1ml Milli-Q
water and stored at -20°C.
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2.7.2 Analysis of Outer Membrane Proteins by Sodium Dodecyl
Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE).
OMPs were diluted in Milli-Q to a concentration of lmg/ml. Protein concentration
estimates in the OMP preparations were determined by the method ofWaddell (1956).
The samples were diluted in sterile distilled water and their absorbance was measured at
wavelengths of 215 and 225nm on a Perkin-Elmer UV/Vis Lambda II
Spectrophotometer. The protein concentration was determined by reference to a
previously prepared standard curve.
The proteins were resolubilised prior to electrophoresis by boiling in a SDS sample
buffer for 5 minutes. The OMPs were analysed either on a gel gradient of 10-15%
polyacrylamide (Pharmacia LKB.) on the PhastSystem® (Pharmacia), or on a gel
gradient of 12% polyacrylamide (BioRad) on the BioRad Mini Protean System®. A
coomassie brilliant blue R staining technique was employed to examine the separated
protein bands.
2.7.3 Examination of OMPs For Non-Covalent Association With
Peptidoglycan.
The method of Darveau et al (1983) was employed to investigate whether the OMPs
were non-covalently associated with peptidoglycan. Briefly, cell envelopes, isolated by
the outer membrane protein technique, were solubilised in a buffer containing 2% (w/v)
SDS, 10% (w/v) glycerol and lOmM Tris-HCl (pH 7.4) at 30°C for 30 minutes.
Envelopes were isolated by centrifugation at 100,000g for 1 hour and resuspended in
the same buffer containing 0.1M sodium chloride. The resulting extract was analysed
by SDS-PAGE on the Mini Protean® system as described above.
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2.8 ANALYSIS OF DNA GYRASE.
2.8.1 Preparation of the Novobiocin/Sepharose Column.
A novobiocin/sepharose column was prepared according to the method of Staudenbauer
and Orr (1981), with modifications. Epoxy-activated Sepharose 6B (5g, Pharmacia)
was swelled overnight at room temperature in 400ml Milli-Q. The water was removed
by a vacuum pump, and the beads washed with 150ml of 0.2M sodium carbonate
buffer (pH 9.5). The beads were then resuspended in 100ml 0.2M sodium carbonate
buffer (pH 9.5) and transferred to a shaking water bath at 37°C. After an hour, 700mg
of novobiocin in 0.2M sodium carbonate buffer was added, and the mixture incubated,
shaking, overnight at 37°C.
Next, 100ml of 0.1M Tris-HCl buffer (pH 7.5) was added to the flask, and the mixture
incubated for a further 4 hours, shaking at 37°C. The beads were washed with 200ml
of 0.5M sodium chloride in 0.2M sodium carbonate buffer (pH 9.5) with a vacuum
pump, and washed again with Milli-Q water. The beads were then washed with 200ml
of 0.5M sodium chloride in 0.2M sodium acetate buffer (pH 4.5) and again with 200ml
ofMilli-Q. In the final step the beads were washed with 200ml TED buffer containing
lOmM Tris-HCl (pH 7.5), ImM ethylene diamine tetraacetic acid (EDTA) (pH 8.0) and
ImM dithiothreitol (DTT). The beads were resuspended in 50ml TED buffer and the
column poured. The column was washed with 100ml TED buffer containing 5M urea,
and then washed with TED buffer for 20-30 minutes, until the eluate was clear.
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2.8.2 Preparation and Isolation of DNA Gyrase.
DNA gyrase was prepared according to the method of Inoue and colleagues (1987),
with modifications. In brief, 10ml of starter culture was grown, shaking, at 37°C
overnight and added to a litre of P broth. For each strain 4-6 litres of culture were
grown shaking at 37°C for 4-6 hours in P broth. Cells were harvested by centrifugation
at 6,500rpm for 20 minutes, washed in TED buffer, and resuspended in 100ml TED
buffer. Cells were lysed chemically with 1.4ml of 200mM DTT, 5.5ml of 0.5M EDTA
(pH 8.0) and 13.8ml of 1M potassium chloride (KC1). The solution was mixed gently
and 5.5ml of 20mg/ml lysozyme and 10% (w/v) polyoxyethylene 20 cetyl ether (Brij
58) added. The mixture was then incubated, stirring, at 4°C for 2 hours, or until
complete lysis of the cells had occurred.
The cell extract was isolated by centrifugation at 100,000g at 4°C for 1 hour, and the
DNA precipitated by the addition of 2% (w/v) streptomycin sulphate. The mixture was
centrifuged at 10,000rpm for 15 minutes and unwanted proteins were removed from the
supernatant by 20% (w/v) ammonium sulphate precipitation at 4°C; with the floating
precipitate being removed after centrifugation at 10,000g for 15 minutes. The crude
enzyme was then isolated by 40% (w/v) ammonium sulphate precipitation, with the
precipitated pellet being resuspended in 10ml TED. The crude enzyme was then
dialysed overnight in TED buffer at 4°C.
Sterile dialysis tubing was prepared by boiling the tubing (visking size 8/32" Medicell
International Ltd.) in one litre of distilled water containing 2ml of 0.5M EDTA and 20g
of sodium bicarbonate. The tubing was boiled for 10 minutes in a water bath and
washed four times in sterile distilled water. The dialysis tubing was then sterilised by
autoclaving prior to use.
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DNA gyrase was isolated on a novobiocin/sepharose column at 4°C. The column was
equilibrated with TED buffer before the addition of the crude enzyme preparation, and
then eluted with 0.1M KC1 in TED buffer to remove any unwanted proteins and
DNAses. The DNA gyrase was eluted with 5M urea in TED buffer and the resulting
fractions dialysed in 1ml aliquots, twice against TED buffer at 4°C for two hours, and
then against TED buffer with 50% (v/v) glycerol (Molecular Biology Reagent Grade,
Sigma, TGED) overnight. The purified enzyme was stored in TGED buffer at -70°C
for up to a month.
2.8.3 Relaxation of pBR322.
The relaxation of pBR322 (Northumbria Biologicals Ltd.) was carried out by mixing
the reagents in Table 2.6. The reagents were mixed and incubated at 37°C for 2 hours.
The same volume of 80% phenol, equilibrated in TED buffer, was added and the
mixture vortexed and centrifuged at 13,000rpm in an MSE Micro Centaur for a minute.
The lower phenol layer was discarded, and an equal volume of 1:1 phenol: chloroform
added to the aqueous layer. The mixture was again vortexed and centrifuged, and the
lower layer discarded. An equal volume of chloroform was added, vortexed and
centrifuged, and the upper layer added to an equal volume of ether, previously
equilibrated in TED buffer. The ether layer was then removed, and any remaining ether
evaporated off in a 60°C water bath. The relaxed state of the pBR322 was confirmed
by gel electrophoresis on 0.8% agarose (refer to Materials and Methods section 2.8.4).
The relaxed pBR322 was stored at 4°C.
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REAGENT AMOUNT ADDED
1M Tris-HCl buffer (pH 7.5) 45(0.1
1MKC1 45(0.1
200mM magnesium chloride 45(0.1
50mM DTT 45(0.1
lmg/ml bovine serum albumin 45(0.1
2mM EDTA (pH 8.0) 120(0.1
330 mg/ml pBR322 (NBL) 534(0.1
Topoisomerase I (10 units/fil, Gibco-BRL) 21(0.1
Table 2.6. The Constituents of the pBR322 Relaxation Mixture.
2.8.4 Analysis of DNA Gyrase.
DNA gyrase activity was assayed by gel electrophoresis in a Horizon 20.25 horizontal
gel tank (Gibco-BRL). Aliquots obtained from the novobiocin/sepharose column were
assayed for their ability to supercoil relaxed pBR322.
To assay DNA gyrase activity, 8|il of the enzyme was added to 8(il of assay mix,
containing relaxed pBR322 (Table 2.7) and 4(il Milli-Q. The reagents were incubated
statically at 37°C for 1 hour, and then run on an 0.8% agarose gel in single strength
TEAS buffer (pH 8.0). The constituents of 20x TEAS buffer were:- 121.lg Trizma
base; 14.9g EDTA; 54.43g sodium acetate and 21.4g NaCl per litre.
64
INGREDIENTS VOLUME (|il)










Table 2.7. Constituents of the DNA Gyrase Assay Mix.
Agarose gels were prepared from TEAS buffer and were loaded with either the 20(il
samples or a marker dye consisting of:- 2ml of 10 times TEAS buffer, lmg of
bromophenol blue, 12mg of sucrose, 0.8ml of 0.5M EDTA and Milli-Q to 20ml. The
gel was run for fifteen minutes at 120mA, until the marker dye had left the wells. The
gel was then submerged in buffer and run at 30mA overnight.
Gels were stained with 0.75mg/l ethidium bromide for 1-2 hours and visualised over a
long wave ultraviolet light source (Ultra-violet Products Inc.). Aliquots producing
supercoiling were stored at -70°C for up to a month.
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2.8.5 Determination of IC50 Values.
Active DNA gyrase, as determined above, was assayed against ciprofloxacin,
ofloxacin, norfloxacin and novobiocin by gel electrophoresis on 0.8% agarose, as
described in section 2.8.4. Doubling dilutions of each drug were prepared in Milli-Q
from 256mg/l to 0.06 mg/1 for ciprofloxacin, ofloxacin and norfloxacin, and from
8mg/l to 0.06mg/l for novobiocin. The assay mixture consisted of 8p.l active gyrase,
8(ll relaxed pBR322 assay mix (Table 2.7, with no Milli-Q water and 180(ll of relaxed
pBR322) and 4|il of the relevant antibiotic concentration.
The reagents were incubated statically for 90 minutes at 37°C. Gels were run and
stained as described previously and photographed under an ultraviolet light source. The
concentration of antibiotic which inhibited 50% of the supercoiling of the relaxed
pBR322 (IC50) was calculated on a Chromoscan 3 densitometer (Joyce Loebl) with the
Chromoscan 3 External Data Analysis VS. 1 software (Joyce Loebl).
2.9 ISOLATION AND PURIFICATION OF TOTAL GENOMIC DNA.
Total genomic DNA was prepared by the method of Zyskind and Bernstein (1989).
Bacterial strains were grown in 4.5ml of nutrient broth overnight at 37°C and 1.2ml
broth was spun down in a MSE Micro Centaur centrifuge at 13,000 rpm and
resuspended in HTE buffer (50mM Tris-Cl pH 8.0; 20mM EDTA ). Cells were lysed
by 2% sarcosyl in HTE buffer and RNA removed by the addition of RNAse. The
mixture was incubated for 15 minutes at 37°C, and lysis completed by the addition of
pronase and incubating for one hour at 50°C. DNA was isolated by phenol/chloroform
and ether extraction, and precipitated by the addition of 3M sodium acetate and
isopropanol at -70°C for 30 minutes. The mixture was centrifuged at 13,000rpm for 10
minutes and the DNA pellet washed three times in 70% ethanol, dried and resuspended
in TE buffer (lOmM Tris-HCl (pH 8.0); O.lmM EDTA).
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2.9.1 Analysis of Genomic DNA.
Genomic DNA was analysed by the Polymerase Chain Reaction (PCR) technique. PCR
was carried out based on the method of Disney and Dove (1991). The PCR was carried
out with two specific primers taken from the quinolone resistance determining region of
the P.aeruginosa gyrA gene. The sequence of the P.aeruginosa gyrA gene was kindly
given by Dr L.E. Bryan and the primers supplied by the University of Edinburgh
Department of Chemistry, King's Buildings. The sequences of the two primers were:-
5' GGA TCC CAT GCG CAC TTC GGT GTA 3' antisense
5' GGA TCC GTG CTT TAT GCC ATG AGC GAG 3'sense
Both primers incorporated a BamHl restriction site.
The PCR was carried out in a total reaction volume of lOOpl (refer to Table 2.8) in
0.5ml polypropylene microcentrifuge tubes (Alpha Laboratories), with a Techne PHC-2
Dri-Block® Cycler (Cambridge Bioscience). The reaction mixtures were overlaid with
two drops of mineral oil and subjected to the denaturation, annealing and extension
cycles described in Table 2.9. After the PCR reaction was completed, samples were
'quenched' on ice to prevent any further reaction. The subsequent double-stranded
DNA was extracted by ethanol precipitation and checked for purity by gel
electrophoresis on 1.5% agarose as before.
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INGREDIENTS VOLUME SUPPLIER
lOx Taq reaction buffer (Mg2+ free) lOptl Promega
25mM MgCl2 10(J,1 Promega
4mM dNTP stock solution* Boehringer Mannheim UK
P.aeruginosa gyrA sense primer 10 pmoles -
P.aeruginosa gyrA antisense primer 10 pmoles -
Genomic DNA preparation 2jil -
Taq DNA polymerase 1 unit Promega
Milli-Q water to 100|il Millipore
* 4mM dNTP stock solution: linM dTTP; ImM dGTP; ImM dCTP; ImM dATP in lOmM Tris-Cl
(pH 7.5).
Table 2.8 PCR Reaction Components.
SEGMENT TEMP. TIME RAMP RATE NUMBER OF
CYCLES
FUNCTION
1 96°C 30 sees 48°C / min 1 DNA denaturation
50°C 60 sees 10°C / min Primer annealing
70°C 90 sees 30°C / min Primer extension
2 96°C 15 sees 48°C / min 24 DNA denaturation
50°C 30 sees 10°C / min Primer annealing
70°C 90 sees 30°C / min Primer extension
3 70°C 5 min - 1 Final extension
Table 2.9 The PCR Heating Cycle Protocol.
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2.10 DIRECT ANALYSIS OF DNA GYRASE GYRA MUTATIONS.
2.10.1 Restriction and Transformation Technique.
P.aeruginosa DNA was obtained by PCR techniques, as described in section 2.9.1.
The PCR sequence was digested with a BamHl restriction enzyme (Gibco-BRL), as
recommmended by the manufacturer, in a 'REact' buffer system supplied with the
enzyme. The restricted DNA was then ligated into pUC18. Ligations were carried out in
a 20|il reaction volume containing ligation mix (Gibco-BRL), digested vector, pUC18,
and the restricted target DNA to which was added 0.1 unit of T4 DNA ligase (Gibco-
BRL). The ligation mixture was then incubated at 16°C overnight, after which the
sample was transferred into the host cell.
MAX Efficiency DH5a™ Competent cells (Gibco-BRL) were stored at -70°C and
thawed on ice. DNA, from the ligation mix, was added to 50|il aliquots of DH5oc cells
and gently mixed before incubation on ice for 30 minutes. The cells were subjected to a
heat pulse for one minute, returned to the ice, and 800(tl of SOC broth added. The cells
were allowed to recover by incubation for one hour at 37°C, and then were plated onto
1ST agar plates containing 25(1 g/ml of 5-bromo-4-chloro-3-indolyl (3-D-
galactopyranoside (X-gal), 50|ig/ml of isopropyl (3-D-thiogalactopyranoside (IPTG)
and lOOfll/ml ampicillin. To determine the transformation efficiency, a known
concentration of pUC18 DNA was transformed, and the number of transformants
calculated from the 1ST agar plates.
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2.10.2 Direct Sequencing From PCR Products.
Single-and double-stranded DNA sequencing was carried out with the USB
Sequenase® Version 2.0 DNA sequencing kit (Cambridge Bioscience), based on the
chain-termination method of Sanger et al (1977). Reaction products were radiolabeled
with [35S] a-dATP label (Amersham International pic.) and separated by
electrophoresis.
Electrophoresis was performed with the Sequi-Gen® Nucleic Acid Sequencing Cell
(BioRad), in a denaturing polyacrylamide gel (8%T 5%C acrylamide /bA-acrylamide,
7M urea) under an electrolytic gradient. The Sequi-Gen Cell was cleaned and assembled
according to the manufacturer's recommendations. The sequencing method employed
was that ofWinship (1989).
The denaturing polyacrylamide gel consisted of a plug solution containing 20ml 8%T
5%C acrylamide //u'sacrylamide, 7M urea stock solution (Table 2.10), 140|il of 25%
w/v ammonium persulphate and 50(ll TEMED. The gel solution contained 55ml 8%T
5%C acrylamide /Z?/Tacrylamide, 7M urea stock solution, 220(il 25% w/v ammonium








Table 2.10. The Ingredients of the Denaturing Acrylamide//>t,s acrylamide
Stock Solution.
70
The plug solution was allowed to polymerise for 10-15 minutes, and the electrophoresis
gel allowed to polymerise for one hour. The inner plate chamber of the Sequi-Gen Cell
was then filled with half strength TBE buffer (lOx TBE stock solution contains: 0.89M
Tris-borate (pH 8.3); 20mM EDTA), and the lower chamber was filled with 400ml of
single strength TBE buffer. The gel was pre-run for 30-40 minutes at constant power
(60W, 3000V and 50mA) to bring the apparatus to a running temperature of 50-55°C.
Samples were loaded and the gel run for one hour. After this, 200ml of 3M sodium
acetate (pH 5.5) was then added to the lower buffer chamber and electrophoresis
continued at 60W for 2-3 hours.
The gel was removed from the apparatus and washed in a solution of 10% v/v methanol
and 10% v/v acetic acid for forty five minutes and dried at 80°C for two hours under
vacuum in a flat-bed gel drier. Autoradiography was carried out with an Amersham
autoradiography cassette and Amersham Hyperfilm MP with 24 hour exposure at room
temperature. The film was kindly developed by the X-ray department at the Royal
Infirmary of Edinburgh.
2.11 INDIRECT ANALYSIS OF GYRA MUTATIONS.
2.11.1 Restriction of PCR Fragments.
Genome fragments of 17 ciprofloxacin-resistant strains, and PAOl, were amplified by
PCR methods (as described in Section 2.9.1). The fragments were ethanol-precipitated
and resuspended in 17(il TE buffer. For each restriction digest, 2|il of the appropriate
'REact' buffer (Gibco-BRL) and lpl of Sstll restriction enzyme (Gibco-BRL) were
added to the PCR fragment, and the mixture incubated at 37°C for three hours. The
restricted fragments were then ethanol-precipitated and resuspended in lOfil TE buffer.
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2.11.2 Analysis of Restricted DNA.
The restricted fragments were analysed on 1.5% agarose gels by horizontal gel
electrophoresis as described in Section 2.8.4 with TAE buffer [lOx stock solution per
500ml104g Trizma base; 5.7ml of glacial acetic acid; 10ml of 0.5M Na2EDTA (pH
8)]. Before analysis of each sample, loading buffer was added to each preparation to
create a ratio of loading buffer to sample of 1:6 respectively. The constituents of the
loading buffer were 0.25% bromophenol blue; 0.25% xylene cyanol; 30% glycerol in
sterile distilled water.
Electrophoresis was performed with gels submerged in TAE buffer for 45 minutes at
120 Volts. The gels were stained and visualised as described previously. Restricted
fragments were run against controls which contained either a non-restricted PCR
fragment, or a PCR fragment incubated in the presence of 'REact' buffer for three
hours at 37°C.
2.11.3 Probing for GyrA Mutations.
Genetic studies have shown that the quinolone-resistant gyrA gene is recessive to the
sensitive allele, and a cosmid vector pNJR3-2 (Robillard 1990) has been made to screen
bacteria for gyrA mediated quinolone resistance. The pNJR3-2 was obtained from
Bayer, UK. with the kind permission of N. Robillard, and contains the E.coli
quinolone-sensitive gyrA gene. The pNJR3-2 was used to probe 4 high level
quinolone-resistant isolates of P.aeruginosa. A high copy number plasmid, pUC19,
was used as a negative control to ensure that the act of conjugation itself did not affect
quinolone resistance. Minipreparations of plasmid DNA were obtained by the alkaline
lysis method of Takahashi and Nagano (1984), from 4.5ml of cells grown overnight in
nutrient broth at 37°C with vigorous shaking.
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The conjugations were carried out by the method of Robillard (1990). In brief, the
E.coli donor strain containing pNJR3-2, and the P.aeruginosa recipient strains were
grown in ML broth (per litre:- lOg Bacto tryptone (Difco), 5g Bacto yeast extract
(Difco), 5g NaCl and 2g K2HPO4.) overnight, with aeration at 37°C. The donor strain
was grown in the presence of 5|ig/ml tetracycline. Five hundred microlitres of donor
culture was added to 0.5ml recipient culture and centrifuged for half a minute at
13,000rpm in a microcentrifuge. The mating mixture was resuspended in 50|il of
0.15M NaCl and plated onto ML agar [ML broth containing 1.5% Bacteriological Agar
No. 1 (Difco)].
Mating was allowed to occur during a five hour incubation period at 37°C, and the
mating mixture was harvested in 3ml of 0.15M NaCl. The mixture was then plated onto
ML agar containing 400, 500 or 600(ig of tetracycline per ml, and plates were incubated
for 24 or 48 hours at 37°C. Conjugants were purified on selection media. Control
reactions containing pUC19 were plated onto ML agar containing 100|lg of ampicillin
per ml.
Conjugation experiments were also carried out as described by Amyes and Gould
(1984). In these experiments donor and recipient strains were grown statically
overnight at 37°C. Then, either 0.1ml of donor culture was mixed with 1ml of recipient
culture in 4.5ml nutrient broth, or 1ml of the donor strain was mixed with 1ml of the
recipient culture in 4.5ml nutrient broth. The mixtures were then incubated at 37°C for
six hours. Mating mixtures containing E.coli with pNJR3-2 and P.aeruginosa strains
were plated onto 1ST agar containing 400 and 600(ig/ml tetracycline; whereas mating
mixtures containing E.coli with pNJR3-2 and the E.coli strain J62-2 were plated onto
DM agar plates containing rifampicin at 25(lg/ml.
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2.11.4 Transformation of P.aeruginosa by Electroporation.
Three ciprofloxacin-resistant clinical isolates of P.aeruginosa, 4124, 4125 and 3, and
the sensitive strain PAOl were electroporated with either pNJR3-2 or pUC18, which
was used as a negative control. Plasmid DNA was prepared by the method of
Takahashi and Nagano (1984). Electroporation was performed with an Electrocell
Manipulator 6000 (BTX.) according to the method of Diver et al (1990a). Strains were
grown overnight in 500ml of LB broth and immediately placed on ice. Cells were
harvested by centrifugation at 5,500rpm for 15 minutes and the pellet washed three
times in ImM Hepes buffer. The final pellet was resuspended in 7ml of HGEB. All cell
washing procedures were carried out on ice.
Aliquots of 50|il of the mixture were placed into 1.5ml microcentrifuge tubes and 5|ll of
either pUC18 or pNJR3-2 added. The same volume of buffer was added to a control
tube. Tubes were placed on ice for one minute and transferred to prechilled cuvettes
with a 0.1cm electrode gap. The electrical settings of the Electrocell Manipulator were
as follows:- set voltage 1.4kV; discharge capacitor 25pF; and pulse controller parallel
resistor 246Q (giving a theoretical time constant of between 5 and 10 milliseconds).
The capacitor was discharged through the sample, and immediately after discharge
950(il of ice cold SOC broth was added. Samples were incubated on ice for 30 minutes,
transferred back to their tubes and incubated at 37°C for 90 minutes. Aliquots of 50(il
andlOOp.1 of the samples were plated onto 1ST agar containing 150|ig/ml tetracycline
and incubated at 37°C for 48 hours. Samples containing the plasmid pUC18 were
selected on 1ST agar plates containing 50|ig/ml ampicillin. Transformants were purified
by selection on the appropriate media.
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RESULTS.
3.1 MINIMUM INHIBITORY CONCENTRATIONS.
Minimum inhibitory concentrations (MICs) measure the amounts of various
antimicrobial agents required to inhibit completely the growth of the target organism,
and thus allow comparisons between bacterial strains. MICs may be determined by agar
dilution or broth dilution techniques. In the case of the 4-quinolones, MICs must be
determined by agar dilution as filamentation of bacteria, caused by quinolones, can lead
to erroneus MIC values in broth dilution techniques (Smith 1984b).



















Table 3.1. Minimum Inhibitory Concentrations of Quinolones on PIA.
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MICs of ciprofloxacin, ofloxacin and norfloxacin were determined by employing a
doubling dilution method against 14 ciprofloxacin-resistant and 2 ciprofloxacin-
sensitive strains on Pseudomonas Isolation Agar (PIA), and against 25 ciprofloxacin-






PAOl 0.5 1 2
U423 0.25 1 -
CI 16 64 >128
C2 32 32 64
C32 8 32 64
C48 32 64 >128
C49 8 8 32
3 64 128 >128
48 2 16 -
52 4 8 32
135 2 8 -
271 8 64 128
273 8 64 64
274 4 8 32
4124 64 128 >128
4125 64 >128 >128
4131 16 64 >128
4133 64 128 >128
4149 8 32 128
4158 16 32 64
4161 16 64 128
4269 16 128 128
4352 16 32 128
4374 16 64 128
4375 8 64 128
4495 16 64 128
4532 8 64 >128
5762 0.25 - -
6397 0.25 - -
- not done
Table 3.2. Minimum Inhibitory Concentrations of Quinolones on 1ST
Agar.
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Strains were classified as quinolone-resistant if they exhibited an MIC to quinolones of
4mg/l or greater, and quinolone-sensitive if they demonstrated an MIC of less than
2mg/l. In all strains, resistance to ciprofloxacin resulted in resistance to all other
quinolones tested. Ciprofloxacin was the most active quinolone, being at least twice as
active as ofloxacin and four to eight times as active as norfloxacin in terms of MIC





RATIO OF DRUG RESISTANCE TO
CIPROFLOXACIN RESISTANCE
Ofloxacin Norfloxacin
U423 0.25 1 4
PAOl 0.5 1 2 2 4
48 2 16 - 8 -
135 2 8 - 4 -
52 4 8 32 2 8
274 4 8 32 2 8
C32 8 32 64 4 8
C49 8 8 32 1 4
271 8 64 128 8 16
273 8 64 64 8 8
4149 8 32 128 4 16
4375 8 64 128 8 16
4532 8 64 >128 8 >16
CI 16 64 >128 4 >8
4131 16 64 >128 4 >8
4158 16 32 64 2 4
4161 16 64 128 4 8
4269 16 128 128 8 8
4352 16 32 128 2 8
4374 16 64 128 4 8
4495 16 64 128 4 8
C2 32 32 64 1 2
C48 32 64 >128 2 >4
3 64 128 >128 2 >2
4124 64 128 >128 2 >2
4125 64 >128 >128 >2 >2
4133 64 128 >128 2 >2






U423 0.5 4 8
PAOl 2 4 2
48 16 64 4
274 16 64 4
4149 16 64 4
C32 32 128 4
C49 32 32 1
273 32 >128 >4
CI 64 128 2
C2 64 >128 >2
4161 64 >128 >2
4269 64 >128 >2
C48 128 >128 >1
3 >128 >128 "
Table 3.4. Relationship of Ciprofloxacin MIC to Ofloxacin MIC on PIA.
The ciprofloxacin/ofloxacin and the ciprofloxacin/norfloxacin ratios, however, were not
constant within the groups studied, which indicates that several different quinolone
resistance mechanisms might be occurring within these strains. There was no
significant difference seen in the ciprofloxacin ratios for strains investigated on both
PIA and 1ST agar. Resistant strain 4158 exhibited the same ciprofloxacin/ofloxacin and
ciprofloxacin/norfloxacin ratios as the sensitive strain PAOl (Table 3.3), whereas most
other strains had considerably higher ratios (Tables 3.3 and 3.4).
Strains C49 and C2 exhibited lower ciprofloxacin/ofloxacin and
ciprofloxacin/norfloxacin ratios than the sensitive strains (Tables 3.3 and 3.4); and both
showed no alteration in MIC between ciprofloxacin and ofloxacin, which all other
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strains exhibited, although when MICs were carried out on PIA, C2 exhibited an
increase in the ciprofloxacin/ofloxacin drug ratio which was not reflected in the 1ST
agar results. This may be caused by the detergent present in the PIA interfering with the
results. Several strains demonstrated similar ratios despite having different initial MIC
values; 52, 274 and 4352 being in one group (Table 3.3), and C32, 4374 and 4495
being in another (Table 3.3). This suggests that these strains may be exhibiting the
same quinolone resistance mechanisms.
All quinolone MICs were less active in terms of MIC on 1ST agar compared with PIA
(Tables 3.3 and 3.4). This may have been caused by the detergent in the PIA interfering
with the quinolone antibacterials. Many of the clinical isolates exhibited mucoidy on
PIA and not 1ST agar, termed PIA dependent mucoidy (Govan et al 1983), and this
may have contributed to the greater MIC values on this media.
3.1.2 Determination of MICs of Other Antimicrobial Agents Against
P.aeruginosa.
Quinolone resistance in P.aeruginosa has been linked to cross resistance with
imipenem, carbenicillin, novobiocin and chloramphenicol and hypersusceptibility to
gentamicin and (3-lactam antibiotics. This documented cross resistance to other
antimicrobial agents is brought about by permeability mutations, generally altering the
pore size of porin molecules, or by causing decreased expression of certain porin
molecules upon the cell surface. As the mechanism of entry of many antimicrobial
agents into the bacterial cell is passive, involving diffusion of the agent through porin
channels, any alteration in porin channels is likely to bring about resistance to several
antimicrobial agents in one step. Therefore MICs of imipenem, cefotaxime,
ceftazidime, gentamicin, carbenicillin, tetracycline and kanamycin were determined by a





GN CAB TET KM
PAOl 2 8 2 2 64 64 8
U423 0.5 16 2 2 64 - -
CI 0.5 64 8 4 >128 128 32
C2 4 64 4 8 >128 64 128
C32 0.5 64 8 4 >128 256 8
C48 0.25 8 1 0.5 4 >256 8
C49 1 16 2 2 32 128 32
3 1 64 4 2 128 128 64
48 2 8 2 0.5 32 - 8
52 1 32 4 1 128 128 2
135 8 4 4 1 32 - -
271 1 16 2 4 32 64 16
273 4 64 8 2 >128 128 64
274 2 16 4 4 64 64 32
4124 1 32 2 4 64 128 32
4125 1 32 2 4 64 128 32
4131 1 32 8 16 >128 128 128
4133 4 32 4 64 >128 128 >128
4149 4 64 8 128 >128 128 64
4158 0.5 16 2 2 32 128 64
4161 0.5 8 1 2 32 128 16
4269 0.5 128 4 2 >128 128 64
4352 4 4 2 4 4 256 128
4374 4 16 2 32 16 256 >128
4375 8 64 8 128 >128 128 64
4495 4 128 8 2 32 64 32
4532 2 8 1 1 16 128 16
IM- imipenem, CTX- cefotaxime, CAX- ceftazidime, GN- gentamicin, CAB- carbenicillin, TET- tetracycline,
KM - kanamycin.
Table 3.5. Minimum Inhibitory Concentrations of P.aeruginosa to Other
Antimicrobial Agents.
According to the break point standards recommended by the Working Party of the
British Society for Antimicrobial Chemotherapy (1991), all strains were found to be
tetracycline-and kanamycin-resistant, with the exception of strain 52 which exhibited
kanamycin sensitivity. The sensitive strains PAOl and U423 exhibited high resistances
to cefotaxime, carbenicillin, tetracycline, and in PAOl, kanamycin, indicating that all
strains of P.aeruginosa are likely to be intrinsically resistant to these antimicrobial
agents. Most strains exhibited a higher resistance to cefotaxime than the sensitive
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strains, although two strains, 4352 and 135, had only a moderate resistance of 4mg/l.
Strains C48, 48, 4161 and 4532 exhibited identical levels of cefotaxime resistance to
the sensitive strains. Similar results were observed for ceftazidime, gentamicin,
carbenicillin and imipenem.
Most strains were also resistant to carbenicillin with MICs of greater than 32mg/l,
although strains 4352 and C48 exhibited MIC values of 4mg/l and strains 4374 and
4532 were observed to have MICs of 16mg/l. Seven other strains were observed to
have carbenicillin MICs lower than the sensitive strains PAOl and U423.
MICs of imipenem, ceftazidime and gentamicin were variable, with 29% strains
exhibiting imipenem resistance of greater than 2mg/l; 46% had ceftazidime resistance of
greater than 2mg/l and 46% had gentamicin resistance of greater than 2mg/l. Only four
strains, 4375, 4149, 4133 and C2, however, showed resistance to all three drugs, with
most of the other resistant strains exhibiting resistance to combinations of two of the
antimicrobial agents. Strains 3, 52 and 4269 exhibited moderate resistance to
ceftazidime only, and strains 271, 4124 and 4125 exhibited moderate resistance to
gentamicin only.
In all cases, resistance to ceftazidime was linked to high levels of resistance to
cefotaxime, although strains with the same ceftazidime MIC had varying cefotaxime
MICs. Strains 4124 and 4125 had a ceftazidime MIC of 2mg/l, on the break point for
resistance, but exhibited high level resistance to cefotaxime. It might be the case that
these strains were slightly ceftazidime-resistant, but that the experimental technique was
not suitable to reflect this.
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Of the 13 gentamicin-resistant strains, three strains, 4375, 4149 and 4133, were highly
resistant to the drug with MICs greater than 64mg/l. These three strains also exhibited
high MIC levels to all antimicrobial agents tested, suggesting that resistance was
probably caused by a major membrane protein alteration. Strains 4375 and 4149
showed moderate quinolone resistance, whereas 4133 exhibited high level quinolone
resistance.
Six strains, CI, C32, C48, 4158, 4161 and 4269 exhibited imipenem sensitivity
comparable to the sensitive strain U423. Strains 4269 and CI exhibited no sensitivity to
any other antimicrobial agent; strains 4158 and 4161 both exhibited lower carbenicillin
MICs than the sensitive strains and, in addition, 4161 was also ceftazidime-sensitive.
Strains C32 and C48 were observed to have identical kanamycin sensitivities to PAOl,
and C48 was also sensitive to all other antimicrobial agents tested, with the exception of
tetracycline and cefotaxime.
To summarise, the ciprofloxacin-resistant strains exhibited varying antimicrobial
sensitivity patterns, suggesting that the strains possessed differing quinolone resistance
mechanisms. These results also suggest that the strains with resistance to ceftazidime,
gentamicin and imipenem exhibit varying resistance mechanisms, as not all strains
possess resistance to all three antimicrobial agents. Resistance to carbenicillin,
tetracycline, cefotaxime and kanamycin is unlikely to be related to quinolone resistance,
as the quinolone-sensitive strains were also resistant to these drugs.
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3.1.3 Antimicrobial Sensitivity of Paired Clinical Isolates of
P.aeruginosa.
MICs of ciprofloxacin, ofloxacin, norfloxacin, gentamicin, imipenem, cefotaxime,
ceftazidime and carbenicillin were determined for a series of paired clinical isolates
(Table 3.6). These isolates had developed ciprofloxacin resistance during therapy at
Glasgow Royal Infirmary, and were from three separate patients (refer to Materials and
Methods Section 2.2). The relationship of resistance between the various 4-quinolones




CAZ IM CTX CAB
91-32 0.25 1 1 2 2 8 32
91-33 1 4 2 2 2 8 32
91-41 1 4 1 8 2 128 64
91-40 1 8 1 8 2 128 64
91-42 1 8 2 32 4 >128 64
91-44 1 8 2 64 4 >128 128
91-46 2 8 4 64 4 >128 128
91-76 2 8 2 8 4 128 64
91-28 0.5 4 2 2 4 16 64
91-36 2 2 2 2 4 16 64
90-62 1 4 2 2 2 16 32
90-67 4 8 2 32 2 >128 64
CIP- ciprofloxacin, OFX- ofloxacin, GN- gentamicin, CAZ- ceftazidime, IM- imipenem, CTX- cefotaxime,
CAB- carbenicillin.
Table 3.6. Minimum Inhibitory Concentrations in Paired Clinical
Isolates of P.aeruginosa.
As seen with the quinolone-resistant strains previously, ciprofloxacin resistance in the
three groups of paired isolates resulted in resistance to the other 4-quinolones,
norfloxacin and ofloxacin (Tables 3.6 and 3.7). Ciprofloxacin was observed to be the
most active 4-quinolone as it was four times more active than ofloxacin or norfloxacin.
Strains 91-36 and 90-67, however, exhibited a two-fold decrease in ofloxacin activity
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compared to ciprofloxacin. In all cases, resistance to ofloxacin and ciprofloxacin was
similar (Table 3.7), which conflicts with the results obtained when investigating the
unpaired clinical isolates previously (Table 3.3), and suggests that a single mechanism
was probably responsible for the development of low level quinolone resistance in the
paired isolates.
STRAIN MIC mg/1 Ratio of drug resistance
to ciprofloxacin resistance
Ciprofloxacin Ofloxacin Norfloxacin Ofloxacin Norfloxacin
91-32 0.25 1 1 4 4
91-33 1 4 4 4 4
91-41 1 4 8 4 8
91-40 1 8 4 8 4
91-42 1 8 8 8 8
91-44 1 8 4 8 4
91-46 2 8 8 4 4
91-76 2 8 8 4 4
91-28 0.5 4 4 8 8
91-36 2 8 16 4 8
90-62 1 4 4 4 4
90-67 4 8 16 2 4
Table 3.7. Ratios of Quinolones to Ciprofloxacin on PIA, in Paired
Clinical Isolates.
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As observed with the unpaired quinolone-resistant isolates, all of the paired strains
exhibited cefotaxime and carbenicillin resistance, again suggesting that P. aeruginosa is
intrinsically resistant to these antimicrobial agents (Table 3.6). All of the paired isolates
exhibited stable gentamicin and imipenem resistance, which was also comparable
between groups. In the case of the paired strains 90-62 and 90-67, acquisition of
resistance to quinolones was accompanied by resistance to the (3-lactam drug
ceftazidime, although whether this resistance developed independently of quinolone
resistance was unclear. Resistance to ceftazidime was also accompanied by an increased
resistance to another ^-lactam antibiotic, cefotaxime.
In the series 91-32 to 91-76, from Patient I, initial quinolone resistance was not
accompanied by cross resistance to any other antimicrobial agent. Later isolates, from
91-41 to 91-76, subsequently developed resistance to ceftazidime, which increased
throughout the series from four- to 32-fold. Again, increases in ceftazidime resistance
brought about increased resistance to cefotaxime. The strain 91-76 exhibited lower
ceftazidime resistance than previous isolates.
The paired isolates 91-28 and 91-36 demonstrated an increase in quinolone resistance
which was not linked to cross resistance to any other antimicrobial agents. These
results confirm previous suggestions that at least two quinolone resistance mechanisms
are present in the strains investigated; those that produce resistance solely to 4-
quinolones, and those which cause quinolone resistance accompanied by cross
resistance to other antimicrobial agents, particularly p-lactam antibiotics.
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3.2 STABILITY OF OIJINOLONE RESISTANCE.
It has been reported that quinolone resistance in E.coli and P.aeruginosa is reduced
after repeated passage on drug-free media (Daikos et al 1988). Conflicting reports
(Radberg et al 1990) have established litde or no alteration in ciprofloxacin resistance in
P.aeruginosa after serial passage in Mueller-Hinton broth. To investigate ciprofloxacin
stability in clinical isolates, 20 ciprofloxacin-resistant strains were passaged daily onto
drug-free PIA, with a single colony isolated for each passage. Ciprofloxacin MICs of
the 20 strains were investigated before the initial passage, and subsequently after every
five passages. After 15 successive passages of the strains on drug-free PIA, there was
little or no decrease in the MIC of ciprofloxacin on 1ST agar (Table 3.8).
STRAIN MIC of ciprofloxacin mg/1 after passage number:-
0 5 10 15
PAOl 0.5 0.5 0.5 0.5
U423 0.25 0.25 0.25 0.25
CI 16 4 4 8
C2 32 8 8 8
C32 8 8 4 8
C48 32 0.25 0.25 0.25
C49 8 8 4 4
3 64 64 64 128
48 2 4 4 4
271 8 4 4 8
273 8 8 16 16
274 4 4 4 4
4124 64 64 64 64
4125 64 64 64 64
4131 16 16 32 32
4133 64 64 32 64
4269 16 16 16 16
4352 16 8 8 8
4374 16 8 8 8
4495 16 8 8 16
Table 3.8. Stability of Clinical Isolates to Ciprofloxacin After Passage
on Drug-Free PIA.
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After 5 passages, some strains exhibited a slight decrease in ciprofloxacin MIC.
Strains CI and C2 exhibited a four-fold decrease in ciprofloxacin MIC, which after 15
passages in strain C1 resulted in a final two-fold decrease in overall resistance. Strain
C2 maintained a four-fold decrease in ciprofloxacin resistance throughout the
experiment. Strains 271, 4352, 4374 and 4495 demonstrated a two-fold decrease in
ciprofloxacin resistance, which was recovered in strains 4495 and 271 after 15
passages. In one strain, 48, an increase in ciprofloxacin resistance was observed after 5
passages, which remained stable throughout the remainder of the experiment and
suggested that the initial ciprofloxacin MIC might have been too low.
After 10 passages on drug-free media, C32, C49 and 4133 exhibited a two-fold
decrease in ciprofloxacin MIC, whilst 4131 exhibited a two-fold increase in MIC,
which was maintained until the end of the experiment. The significance of the
ciprofloxacin MIC alterations observed must be questioned, as the MICs of the relevant
strains are still classified as resistant by the break-point criteria of the Working Party of
the British Society for Antimicrobial Chemotherapy (1991), and in most cases the initial
ciprofloxacin resistance was retained.
Resistance was found to be stable in all strains, with one exception. In strain C48,
resistance after 5 passages decreased over one hundred-fold, indicating that
ciprofloxacin resistance in this strain was unstable in the absence of the drug. The
subsequent strain, C48s, was shown to have the same pyocin type as its parent strain,
and remained sensitive throughout the experiment. On repeating the same experiment
with C48, no reversion to sensitivity was observed. This result suggests that the same
strain may exhibit two different mutations, one of which is stable in the absence of
ciprofloxacin, and one which is unstable in the absence of the selective agent.
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3.3 ALTERATIONS IN OUTER MEMBRANE PROTEINS.
Previous investigations have shown that quinolone resistance in P.aeruginosa may be
associated with alterations in outer membrane proteins (OMPs) (Rella and Haas 1982;
Hirai et al 1987; Legakis et al 1989). These changes involve alterations in proteins of
32kD, 50kD, 51kD and 54kD, and may also involve cross resistance to imipenem and
other antimicrobial agents (Radberg et al 1990; Fukuda et al 1990). From the MIC
results of the quinolone-resistant unpaired clinical isolates, it seems likely that most
strains would show OMP alterations. Strains exhibiting imipenem resistance, C2, 135,
273, 4133, 4149, 4374, 4375 and 4495 would be expected to carry OMP alterations,
as would those strains with high P-lactam resistance; CI, C32, 3, 52, 4131 and 4269.
Other strains demonstrating gentamicin resistance or carbenicillin hypersusceptibility
might also harbour OMP alterations. As P-lactam resistance and imipenem resistance
are not linked in the majority of cases, strains exhibiting resistance to both antimicrobial
agents might be expected to harbour more than one OMP alteration.
The results from the paired strains indicate that 91-33, and subsequent strains in that
series, 91-36 and 90-67 should have altered OMP profiles compared to their parent
strains, as low level quinolone resistance has been linked with OMP alterations. Strain
91-41 and subsequent strains might also be expected to display another OMP alteration
from the parent strain, 91-32, and the quinolone-resistant strain 91-33, as they have
developed P-lactam resistance. Strain 90-67 might also be expected to display a similar
OMP alteration to 91-41, as it has also developed P-lactam resistance.
In order to investigate these assumptions, the OMPs of both paired and unpaired
isolates of P.aeruginosa were examined. OMPs were prepared, analysed by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and visualised by
Coomassie brilliant blue R staining. The OMPs were run, initially, on the
PhastSystem® with a 10-15% polyacrylamide gel, but band differentiation was poor in
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the lower protein molecular mass areas, as the gels were so small. The samples were
also run on the BioRad Mini Protean® system on larger gels, with a fixed
polyacrylamide gel gradient, and as this system showed improved band differentiation
it was retained for the remainder of the samples. Proteins were run against molecular
mass standards, the sizes of which are given in Table 3.9.
Molecular Mass Standards (Daltons)
Phosphorylase B 94,000
Bovine Serum Albumin 67,000
Ovalbumin 43,000
Carbonic Anhydrase 30,000
Soybean Trypsin Inhibitor 20,100
oc-Lactalbumin 14,400
Table 3.9. Molecular Masses of Standards Run on SDS-PAGE.
The OMPs of quinolone sensitive isolates were investigated to provide a comparison
for the resistant strains. The OMPs of 8 quinolone-sensitive isolates of P.aeruginosa
were separated by SDS-PAGE, using the Mini Protean® system, and visualised by
Coomassie brilliant blue R staining. The results are shown in Figure 3.1. The sensitive
strains were observed to have varied OMP profiles, although all strains possessed a
protein at 46kD. Strains C48s (lane B), PAOl (lane G) and 135 (lane J) exhibited
similar profiles with two proteins at 46kD and 26kD.
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Fig 3.1. OMP Profile of Sensitive Strains of Pseudomonas aeruginosa.
Tracks are Lane A, molecular mass standards: Lane B, C48s: Lane C, 5762: Lane D,
6397: Lane E, U423: Lane F, 91-32: Lane G, the reference strain PAOl: Lane H, 91-
28: Lane I, 8252: Lane J, 135.
A BCD EFGH I J
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Five strains exhibited another basic profile, with varying amounts of the proteins
expressed, although this is likely to be a reflection of the varying concentrations of the
preparations used. Strains 5762, 6397, U423 (lanes C-E), 91-28 (lane H) and 8252
(lane I) were observed to have similar profiles, with 91-28 possessing a very weak
51kD protein and 8252 lacking a protein at 22kD. Strain 91-32 (lane F) displayed a
profile which lacked a 36kD protein and had an extra protein at 24kD. As the OMP
profile of U423 was displayed by a majority of sensitive strains it was used as the main
comparison for the resistant isolates.
To improve the comparison of OMPs with resistant isolates, mutant bacteria were
selected from strain U423. U423 was seeded onto PIA containing ciprofloxacin at 5
times the MIC and incubated overnight. The mutational frequency was observed to be
6.1 in 105. Six mutant strains were selected from the ciprofloxacin containing plate,
and the MICs of a range of antibiotics for each of the mutant strains were determined
and compared to those of the parent strain in Table 3.10. All the mutant isolates
exhibited an eight-fold increase in ciprofloxacin resistance, compared to the parent
strain, and were also pigmented; strains U423A and C being yellow and strains
U423B, D, E and F being green.
Pyocin typing indicated that the mutant strains were related to the parent strain (refer to
Appendix i). As the mutant strains produced pigments not present in the parent strain,
it was likely that the pigment production interfered with the pyocin-typing procedure, so
the mutants did not exhibit identical pyocin profiles to the parent strain. In all cases
pigment production remained stable in the absence of the selective pressure.
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STRAIN MIC mg/1
CIP OFX GN CAZ IM CTX CAB
U423 0.25 1 1 2 2 8 32
U423A 2 8 1 1 2 8 32
U423B 2 8 0.25 1 0.25 8 8
U423C 2 8 1 1 2 8 32
U423D 2 8 1 2 0.5 8 32
U423E 2 8 0.5 2 0.5 8 32
U423F 2 8 2 2 0.25 8 16
CIP- ciprofloxacin, OFX- ofloxacin, GN- gentamicin, CAZ- ceftazidime, IM- imipenem, CTX-
cefotaxime, CAB- carbenicillin.
Table 3.10. Minimum Inhibitory Concentrations of Laboratory Mutants
of U423.
The mutant strains exhibited similar P-lactam resistance to the parent strain U423. The
two yellow-pigmented strains, U423A and U423C, exhibited identical antibiograms
and also possessed identical pyocin types. The green-pigmented strains all exhibited
imipenem sensitivity, which has been previously linked to quinolone resistance
(Radberg et al 1990). The mutants U423B and E also demonstrated gentamicin
sensitivity, and U423B displayed a lower carbenicillin MIC than the quinolone-
sensitive parent strain, U423.
As the mutants U423A and U423C exhibit antibiograms that are virtually identical to
the parent strain U423, except for the quinolone MICs, they might be expected to
exhibit quinolone resistance mechanisms other than permeability alterations, and so
would demonstrate identical OMP profiles to U423. The other mutant strains U423B,
D, E and F have acquired quinolone resistance linked to imipenem sensitivity, and other
drug sensitivities, and may exhibit OMP alterations.
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In order to investigate this further, the OMP profiles of the mutant strains were
compared to that of U423 by SDS-PAGE (Fig 3.2). All isolates exhibited identical
OMP profiles, but the resistant isolates appeared to have a slight increase in a protein of
approximately 36kD and two strains, U423E (lane C) and U423D (lane E) exhibited a
decrease in a protein of approximately 51kD.
The OMPs of eight clinical ciprofloxacin-resistant isolates were investigated by SDS-
PAGE on the Mini Protean® system. Strains were selected as they exhibited high
ciprofloxacin resistance and also had varying antibiograms (refer to Tables 3.3 and
3.5). Strains 4124 and 4125 demonstrated ciprofloxacin resistance of 64mg/l and
slightly raised cefotaxime resistance of 32mg/l. Strains 4158 and 4161 had
ciprofloxacin MIC values of 16mg/l, coupled with imipenem hypersusceptibility, whilst
strain 4269 exhibited a similar antibiogram with increased (3-lactam resistance. Strains
4352 and 4374 had a ciprofloxacin MIC of 16mg/l with raised imipenem MICs of
4mg/l, and strain 4374 also exhibited a raised gentamicin MIC. Strain 4131 was
selected as it exhibited ciprofloxacin resistance of 16mg/l coupled with ceftazidime and
gentamicin resistance.
The selected strains demonstrated slight variations in OMP profiles, with a band at
36kD being strongly expressed by them all (Fig 3.3). Strains 4161, 4158, 4124 and
4125 were observed to have a decrease in a 51kD protein, whilst 4352 (lane E) showed
a significant increase in the production of an identical protein. In strains 4374, 4352,
4125 and 4124 a double band at 38kD and 36kD was observed. Strains 4124 and 4125
also exhibited extra protein bands at 32kD and 28kD. A band at 17kD was strongly
expressed in 4161, 4158 and 4133, and was also present in most of the remaining
strains, with the exception of 4374 and 4352.
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Figure 3.2. OMP Profile of U423 and its Mutant Strains.
Tracks include Lane A, the parent strain U423: Lane B, U423F: Lane C, U423E:
Lane D, U423: Lane E, U423D: Lane F, U423C: Lane G, U423: Lane H, U423B:
Lane I, U423A: Lane J, Molecular mass standards.
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Figure 3.3. OMP Profiles of Highly Resistant Clinical Isolates.
Tracks include Lane A, 4269: Lane B, 4161: Lane C, 4158: Lane D, 4374: Lane E,




The strongly-expressed 36kD protein is also expressed in sensitive strains, but to a
lesser extent. It is also the identical protein to the protein which was found to express
itself to a greater extent in the ciprofloxacin-resistant laboratory mutants of U423. These
results suggest that the 36kD protein might be linked to quinolone resistance.
Growing bacteria in the presence of ciprofloxacin has been observed to highlight OMP
alterations, when compared to the identical strain grown in the absence of the drug
(C.S. Lewin personal communication). Four ciprofloxacin-resistant strains were grown
in nutrient broth in the presence of 1/4 MIC ciprofloxacin and their OMP profiles
compared to those of strains grown in drug-free medium by SDS-PAGE (Fig 3.4). In
all cases no visible differences in OMP profiles between the relevant pairs were
observed, which suggests that growth in ciprofloxacin-containing media may only
enhance OMP alterations in some strains.
Analysis of the OMPs of all of the ciprofloxacin-resistant strains demonstrated several
alterations compared to the sensitive strains screened, and these are listed in Table 3.11.
Many of the resistant isolates exhibited alterations in similar OMPs, with decreases in
the expression of, or total loss of, a 51kD protein predominating. This alteration was
linked, in many cases, to alterations in other OMPs; a common link being a decrease in
the expression of the 51kD protein coupled with the production of a new 28kD protein.
Several strains produced an extra 38kD protein in conjunction with alterations in the
51kD protein, although strains C48, 4269 and 4352 produced the new protein without
visible alterations in any other OMPs. Another frequent OMP alteration seen, when
compared to the sensitive isolates, was the loss of a 43kD protein. Proteins which were
altered in a minority of strains include those at 46kD, 32kD and 30kD.
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Figure 3.4. OMPs of Strains Grown in the Presence and Absence of
Ciprofloxacin.
Tracks include:- Lane A, strain 3 grown in the presence of ciprofloxacin: Lane B, strain
3 grown in the absence of ciprofloxacin: Lane C, strain CI grown with ciprofloxacin:
Lane D, strain CI: Lane E, C32 grown with ciprofloxacin: Lane F, C32: Lane G, C2
grown with ciprofloxacin: Lane H, C2: Lane I, molecular mass standards.
A BCDEFGHI
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STRAIN ALTERATION IN OMPS COMPARED TO SENSITIVE
STRAINS
C48 Extra 38kD protein.
3 Loss 51kD protein, extra 28kD protein.
52 Decreased expression of 43kD protein.
273 Decreased expression of 51kD protein, increased expression of
43kD protein, loss of 36kD protein.
274 Loss of 46kD and 32kD proteins, extra 42kD and 38kD
proteins.
4124 Loss of 51kD protein, extra 38kD, 32kD and 28kD proteins.
4125 Loss of 51kD protein, extra 38kD, 32kD and 28kD proteins.
4131 Loss of 43kD protein, extra 30kD protein.
4133 Loss of 43kD protein, extra 30kD protein.
4158 Loss of 51kD protein.
4161 Decreased expression of 51kD protein.
4269 Extra 3()kD protein.
4352 Extra 38kD protein.
4374 Decreased expression of 51kD protein, extra 38kD protein.
4495 Loss of 51kD protein, extra 32kD protein.
4532 Decreased expression of 43kD protein, extra 38kD and 28kD
proteins.
Table 3.11. Outer Membrane Protein Alterations Exhibited by Quinolone
Resistant Clinical Isolates Compared to Sensitive Isolates.
Strains 4124 and 4125, and 4131 and 4133, showed identical OMP changes, and the
pairs 4124 and 4125, and 4131 and 4133, also demonstrated identical pyocin types.
These strains were isolated from patients in the same hospitals and are therefore likely
to be related.
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The major entry route for quinolones into the bacterial cell is through porin pathways
(Hirai et al 1986b). To investigate whether the alterations in OMPs seen were
alterations in porin proteins, several resistant isolates were examined to determine
which proteins were non-covalently associated with peptidoglycan, and thus porins.
The proteins of 43kD, 46kD and 51kD appeared to be non-covalently associated with
peptidoglycan, as they remained with the peptidoglycan fraction after solubilisation
with 2% SDS at 37°C (Fig 3.5). These proteins were also released from peptidoglycan
by heating in 2% SDS at 100°C for 5 minutes, which suggests that they may function
as porins. As the strains investigated were unpaired, however, the changes observed
may not be associated with quinolone resistance, but instead may be caused by species
variation. To investigate the role of alterations in the 36kD protein further, several
paired isolates were examined.
3.3.1 Alterations in OMPs of Paired Isolates.
The OMPs of three sets of paired clinical isolates, a series of eight paired isolates which
had developed ciprofloxacin resistance during therapy, and a set of isolates comprised
of a clinical strain which reverted to ciprofloxacin sensitivity during stability testing
experiments, were examined by SDS-PAGE (Fig 3.6). The OMPs were also
investigated for non-covalent association with peptidoglycan to establish whether or not
they were porin proteins. The paired isolates 91-28 and 91-36 (lanes B and C, Fig 3.6)
exhibited identical OMP profiles, as did strains 8252 and 3221 (lanes F and G), which
suggests that quinolone resistance was brought about by other resistance mechanisms.
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Ciprofloxacin and P-lactam resistance in the paired isolates 90-62 and 90-67 appeared
to be linked to a decrease in the expression of a 46kD protein and increased expression
of 26kD and 22kD proteins. The isolates C48, and C48 grown in the presence of
ciprofloxacin (lanes H and I), had a completely different profile to the C48 sensitive
revertant C48s (lane J), which lacked both a 51kD and a 36kD band. C48s was
observed to exhibit decreased expression of a 46kD band and increased expression of a
26kD band.
The OMP profile of C48s bore a strong resemblance to that of another quinolone-
sensitive strain, PAOl (refer to Fig 3.1). The alterations exhibited in these paired
isolates mimicked the alterations reported previously in the unpaired resistant clinical
strains. As before, the 46kD, 51kD and 36kD proteins appeared to be non-covalently
associated with peptidoglycan.
On examining the OMPs of the 91-32 series of paired isolates, ciprofloxacin resistance
could be linked to an increase in a 46kD protein and an apparent decrease in a 51kD
protein (Fig 3.7), when the ciprofloxacin-resistant strain 91-33 (lane B) was compared
to its sensitive parent strain 91-32 (lane A). Ceftazidime resistance in a later isolate, 91-
42 (lane E), could also be linked to the appearance of a 42kD protein. Isolates 91-44
and 91-76 appeared to express an extra 36kD protein, which could not be linked to
resistance to any of the antimicrobial agents studied.
On further examination, the proteins of 36kD, 42kD, 46kD and 51kD appeared to be
associated with peptidoglycan, as they remained with the peptidoglycan fraction after
solubilisation with SDS. The association was then shown to be non-covalent, as the
proteins were released from the insoluble peptidoglycan fraction by boiling for five
minutes. These results suggest that the proteins are probably porins (Fig 3.8).
100
Figure 3.5. OMP Profiles of Porin Preparations of P.aeruginosa
Isolates.
Tracks are as follows:- Lane A, strain 274: Lane B, strain 273: Lane C, a sensitive
strain U423: Lane D, strain 4495: Lane E, strain 3: Lane F, the reference strain PAOl:




Fig 3.6. OMP Profiles of Paired Clinical Isolates of P.aeruginosa.
Tracks are as follows:- Lane A, molecular mass standards: Lane B, parent strain 91-28:
Lane C, resistant isolate of 91-28, 91-36: Lane D, 90-62: Lane E, resistant isolate of
90-62, 90-67: Lane F, 8252: Lane G, resistant isolate of 8252, 3221: Lane H, C48:
Lane I, C48 grown in the presence of ciprofloxacin: Lane J, strain C48s which reverted
to sensitivity during passage experiments.
ABCDEFG HI J
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Fig 3.7. OMP Profiles of the 91-32 Series of Paired Clinical Isolates.
Tracks are as follows:- Lane A, the sensitive parent strain 91-32: Lane B, the
ciprofloxacin-resistant isolate 91-33: Lane C, 91-41: Lane D, 91-40: Lane E, the
ceftazidime-resistant isolate 91-42: Lane F, 91-44: Lane G, 91-46: Lane H, 91-76:




Fig 3.8. OMP Profiles of Porin Preparations of the 91-32 Series of
Paired Clinical Isolates.
Tracks are as follows:- Lane A, the parent strain 91-32: Lane B, 91-33: Lane C, 91-41:




To confirm that the 36kD protein was responsible for ciprofloxacin resistance, the
parent strain 91-32 was plated onto media containing twice the MIC of ciprofloxacin
and mutants selected. The mutational frequency was 2.1 in 106, and the MICs of
quinolones, (3-lactams, gentamicin, imipenem and carbenicillin were determined for the
resulting mutants (Table 3.12). In all cases ofloxacin resistance increased with
ciprofloxacin resistance, but not to the same extent, as isolates 91-32-8, 91-32-9 and
91-32-11 showed a two to four-fold increase in ofloxacin resistance compared to the
rest of the mutant isolates. Also, (3-lactam resistance in the mutant strains remained
stable, unlike the results observed in their clinical counterparts.
Strains 91-32-1, 91-32-3, 91-32-4, 91-32-6, 91-32-7 and 91-32-10 developed
gentamicin resistance, which was not linked to resistance to any other non-quinolone
antibiotic. Four strains, 91-32-5, 91-32-8, 91-32-9 and 91-32-11 exhibited
hypersusceptibility to gentamicin, coupled with hypersusceptibility to imipenem. These
strains, and strain 911-32-3, which was only imipenem hypersusceptible, were the
strains observed to have the highest ofloxacin MICs, suggesting that imipenem
hypersusceptibility and high levels of ofloxacin resistance might be linked. Strain 91-
32-2 was the only imipenem-resistant strain, and strains 91-32-9, 91-32-11 and 91-32-





CAZ 1M CTX CAB
91-32 0.25 1 1 2 2 8 32
91-32-1 2 4 8 2 1 16 64
91-32-2 2 8 1 1 4 8 32
91-32-3 2 8 4 2 0.5 8 32
91-32-4 2 4 4 2 2 8 64
91-32-5 4 8 0.25 1 0.5 16 16
91-32-6 2 4 8 1 1 16 64
91-32-7 2 4 10 2 1 >8 >8
91-32-8 4 16 0.25 2 0.25 8 >8
91-32-9 2 16 0.25 1 0.5 8 8
91-32-10 2 4 10 2 1 >8 >8
91-32-11 2 16 0.25 2 0.25 8 8
CIP-ciprofloxacin, OFX-ofloxacin, GN-gentamicin, CAZ-ceftazidime, IM-imipenem, CTX-cefotaxime,
CAB-carbenicillin.
Table 3.12. MICs of 91-32 Mutant Strains.
The OMP profiles of six selected 91-32 mutants were examined by SDS-PAGE (Fig
3.9) and found to be similar to mutations seen in the series of paired clinical isolates
(refer to Fig 3.7). Strains in lanes A, C and H possessed identical profiles to 91-44 and
91-76. Strain 91-32-5 (lane G) also had a similar profile to 91-44, but exhibited an
extra 22kD protein and a marked increase in expression of a 51kD protein. Strains 91-
32-2 (lane B) and 91-32-4 (lane F) exhibited similar profiles to 91-41 and 91-40.
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Fig 3.9. OMP Profiles of Ciprofloxacin-Resistant Laboratory Mutants of
91-32.
Tracks are as follows:- Lane A, mutant strain 91-32-1: Lane B, 91-32-2: Lane C, 91-
32-3: Lane D, parent strain 91-32: Lane E, ciprofloxacin-resistant clinical isolate 91-33:




The idea that high level ofloxacin resistance and imipenem hypersusceptibility could be
linked to the production of a 36kD protein was investigated further. Mutants were
selected from the ciprofloxacin-resistant strain 91-33 with ofloxacin concentrations of
four times the MIC at a frequency of 5.4 in 106. Ten strains were then investigated for
resistance to ofloxacin, ciprofloxacin and imipenem (Table 3.13), and the OMP profiles
of 4 of these strains studied (Fig 3.10).
STRAIN MIC mg/1
Ciprofloxacin Ofloxacin Imipenem
91-33-1 4 32 1
91-33-2 4 32 1
91-33-3 4 16 2
91-33-4 1 16 2
91-33-7 2 8 2
91-33-12 1 8 2
91-33-14 4 16 2
91-33-17 2 16 2
91-33-21 1 8 2
91-33-22 1 8 2
Table 3.13. MICs of Mutants of 91-33.
In four strains, 91-33-4, 91-33-12, 91-33-21 and 91-33-22 a two-fold alteration in
ofloxacin MIC did not affect the ciprofloxacin MIC (Table 3.13). In the remaining
strains, increases in ofloxacin resistance brought about increases in ciprofloxacin
resistance. Imipenem resistance, however, remained stable. Similar results were
obtained on repeating the experiment, suggesting that the imipenem susceptibility
observed in previous experiments was not linked to high ofloxacin resistance. Also, as
quinolone resistance and the increased production of the 36kD outer membrane protein
appear to be linked, alterations in imipenem MICs are probably not associated with
altered expression of the 36kD membrane protein.
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Fig 3.10. OMP Profiles of Ofloxacin Resistant Laboratory Mutants of
91-33.
Tracks are as follows:- Lane A, molecular mass standards: Lane B, the parent strain of
the series of paired isolates, 91-32: Lane C, the ciprofloxacin-resistant laboratory
mutant of 91-32, 91-32R: Lane D, strain 91-33: Lane E, ofloxacin-resistant laboratory
mutant of 91-33, 91-33-1: Lane F, 91-33-2: Lane G, 91-33: Lane H, 91-33-12: Lane I,
91-33-14.
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The OMPs of the 91-33 mutant strains appear to have altered, when compared to the
sensitive parent strain, 91-33 (lanes D and G, Fig 3.10). The two resistant strains 91-
33-1 (lane E) and 91-33-2 (lane F) have identical OMPs which lack a 51kD protein and
have gained a 36kD protein, when compared to the parent strain 91-33 (lanes D and G).
The ofloxacin-resistant mutants display a similar profile to the ciprofloxacin-resistant
mutant 91-32R (lane C). The strain 91-32R is a ciprofloxacin-resistant laboratory strain
produced from the original parent strain of the series of paired isolates, 91-32. These
results suggest that the proteins at 51kD and 36kD are responsible for quinolone
resistance. The strains 91-33-12 and 91-33-14, in lanes H and I respectively, have
identical OMP profiles which exhibit extra protein bands at 50kD, 36kD and 32kD, in
comparison with their parent strain 91-33.
It was attempted to confirm that the production of the 36kD protein was linked to
quinolone resistance by reverting to sensitivity the ciprofloxacin-resistant strain 91-33.
Strain 91-33 was grown on media containing 1/2 MIC values of ciprofloxacin and
replica-plated onto drug-free PIA. Strain 91-33 was also seeded onto drug-free PIA and
passaged daily, as described in Methods 2.6.1 previously, for 15 days. In all
experiments no reversion to sensitivity occurred, suggesting that resistance was stable
and, not surprisingly, no alterations in OMPs were identified.
3.3.2 Indirect Analysis of OMP Mutations With EDTA.
Ethylene diamine tetraacetic acid (EDTA) is a chelating agent which is responsible for
disrupting bacterial cell outer membranes. Isolates with OMP permeability mutations
may be detected by performing MICs in the presence and absence of EDTA (Sato et al
1986; Amyes and Smith 1977). In order to determine the most effective concentration at
which EDTA should be used, MICs to EDTA were carried out on a selection of 14





0.5 1 2.5 5 10 25 50 100
PAOl + + + + + + + - - - -
U423 + + + + + + - - - - -
C32 + + + + + + + +/- - - -
C49 + + + + + + + +/- - - -
3 + + + + + + + +/- - - -
271 + + + + + + - - - - -
4125 + + + + + + + +/- - - -
4133 + + + + + + + - - -
4158 + + + + + + - - - - -
4161 + + + + + + - - - - -
4269 + + + + + + + +/- - - -
4352 + + + + + + + +/- - - -
4374 + + + + + + + - - - -
4495 + + + + + + - - - - -
+ indicates growth, - indicates no growth, +/- indicates barely visible growth.
Table 3.14. MICs of EDTA for Clinical Isolates of P.aeruginosa.
The table demonstrates that EDTA has different effects on P.aeruginosa strains. All
strains were unaffected by EDTA concentrations below 2.5mM. Growth of resistant
strains 271, 4158, 4161 and 4495 was inhibited at an EDTA concentration of 5mM, as
was growth of a sensitive strain U423. Growth of another sensitive strain, PAOl, was
inhibited at lOmM EDTA, as was growth of the resistant strains 4133 and 4374.
Strains C32, C49, 3, 4125, 4269 and 4352 demonstrated barely visible growth at
EDTA concentrations of lOmM. The table also demonstrates that EDTA is most
effective in a range between 2.5mM and lOmM, and that it completely inhibits bacterial
growth at concentrations over lOmM.
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The effects of EDTA on ciprofloxacin resistance were investigated for six sensitive
isolates and 25 resistant isolates by a geometrical progression chequerboard technique
on 1ST agar. (Table 3.15). The EDTA concentration range chosen was between 1 and
lOmM, as this had previously been shown to damage bacterial cell membranes without
preventing cell growth (refer to Table 3.14).
STRAIN MIC (mg/1) to ciprofloxacin at EDTA concentration of
QmM ImM 2mM 4mM 8mM
PAOl 0.25 0.25 0.125 0.125
U423 0.125 0.125 0.125 0.125 -
CI 16 8 4 2 -
C2 4 2 2 0.5 0.125
C32 4 2 1 1 -
C48 8 8 4 0.25 -
C48s 0.125 0.125 0.125 0.125 -
C49 2 1 0.25 0.125 -
3 >32 32 16 0.5 -
52 1 0.5 0.5 0.25 -
271 4 2 2 1 -
273 8 4 2 1 -
274 4 4 1 1 -
4124 32 16 4 4 0.25
4125 32 16 8 4 0.25
4131 16 8 4 4 0.25
4133 32 16 16 8 0.25
4149 8 4 1 1 0.125
4158 8 2 1 0.5 0.125
4161 8 8 4 1 -
4269 16 8 4 2 0.125
4352 8 4 1 0.125 -
4374 8 4 1 0.125 -
4375 4 2 1 1 -
4495 8 4 4 1 -
4532 8 4 2 0.5 -
5762 0.25 0.125 0.125 0.125 0.125
6397 0.25 0.125 0.125 0.125 0.125
90-62 2 1 0.5 0.5 0.25
91-32 0.25 0.125 0.125 0.125 -
91-33 1 0.5 0.25 0.25 -
Table 3.15. MICs for Clinical Isolates of P.aeruginosa to Ciprofloxacin
in the Presence of EDTA.
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On studying the results, the growth of 64.5% of the strains was inhibited at an EDTA
concentration of 8mM, and of the remaining strains only 4124, 4125, 4131, 4133 and
90-62 grew on plates above the lowest ciprofloxacin concentration of 0.125mg/l. This
indicated that the EDTA was interfering with bacterial growth; and so the 8mM EDTA
results were ignored for the purpose of interpreting the data.
The presence of EDTA in the medium appeared to exert little or no effect upon the
MICs of the quinolone-sensitive isolates PAOl, U423, C48s, 5762, 6397 and 91-32.
On considering the resistant isolates, most strains, with the exception of C48, 274, and
4161, exhibited a two-fold decrease in the ciprofloxacin MIC. Strain 4158, however,
exhibited a four-fold decrease in ciprofloxacin MIC, suggesting that it might possess a
membrane alteration which contributed to quinolone resistance.
At a concentration of 2mM EDTA many strains exhibited a significant decrease in
ciprofloxacin MICs, with the previously resistant strains C48 and 4161 showing a two¬
fold decrease in MIC, and 274 a four-fold decrease. Strains C32, C49, 274, 4149,
4158, 4352, 4374 and 4375 had become ciprofloxacin-sensitive. These strains had
initially demonstrated low to moderate quinolone resistance. Strains C2, 271 and 4495
were unaffected by an increase in EDTA concentration.
Most strains were observed to have become ciprofloxacin-sensitive in the presence of
4mM EDTA concentrations. Strains CI and 4269 exhibited an MIC of 2mg/l which is
the break point for resistance to ciprofloxacin. Strains 4124, 4125, 4131 and 4133
were still moderately ciprofloxacin-resistant. Of these, 4133 was affected the least,
indicating that it was likely to possess other quinolone resistance mechanisms coupled
with permeability mutations. The strain 3 showed a large decrease in ciprofloxacin MIC
between the 2mM and 4mM EDTA concentrations. All strains were observed to be
ciprofloxacin-sensitive in the presence of 8mM EDTA.
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These results suggest that all of the ciprofloxacin-resistant clinical isolates possess
permeability mutations, as disrupting the outer membrane with a chelating agent has
decreased their respective MICs of ciprofloxacin. As the strains are affected to varying
degrees, however, it is likely that several different permeability mutations exist. The
strains exhibiting similar alterations in ciprofloxacin MICs are also likely to possess
similar OMP alterations.
To investigate whether disrupting the cell membrane has the same effect on all
quinolones, the MICs of 23 strains to ofloxacin and norfloxacin were examined in the
presence of 4mM EDTA (Table 3.16). As with ciprofloxacin, the presence of 4mM
EDTA lowered the quinolone MIC in all strains except the sensitive strains PAOl and
U423. Again, strains were affected to varying degrees (refer to Table 3.15), although
four distinct patterns seemed to emerge. Similar quinolone ratios were exhibited in 48%
of the isolates and the sensitive strain U423.
Several strains, CI, 271, 274 and 4149 demonstrated a greater alteration in norfloxacin
ratios than in the ratios of the other quinolones, ciprofloxacin and ofloxacin (Table
3.16); which exhibited similar falls in MIC. The ofloxacin ratios in strains C32, 273,
4124, 4352 and 4374 seemed to be less affected by the presence of 4mM EDTA than
the other two quinolones, being on average four-fold different.
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STRAIN Initial MIC (mg/1)
CPX OFX NFX
MIC mg/1 at 4mM EDTA
CPX OFX NFX
Ratio of initial MIC to MIC
at 4mM EDTA
CPX OFX NFX
PAOl 0.5 1 2 0.125 1 1 4 1 2
U423 0.25 1 - 0.125 0.5 0.5 2 2 -
CI 16 64 >128 2 8 8 8 8 >32
C2 32 32 64 0.5 8 4 64 4 16
C32 8 32 64 1 8 4 8 4 16
C48 32 64 >128 0.25 16 16 128 4 >4
C49 8 8 32 0.125 1 2 64 8 16
271 8 64 128 1 8 4 8 8 32
273 8 64 64 1 16 4 8 4 16
274 4 8 32 1 2 2 4 4 16
4124 64 128 >128 4 32 32 16 4 >4
4125 64 >128 >128 4 16 32 16 >8 >4
4131 16 64 >128 4 32 64 4 2 >2
4133 64 128 >128 8 32 32 8 4 >4
4149 8 32 128 1 4 4 8 8 32
4158 16 32 64 0.5 2 2 32 16 32
4161 16 64 128 1 8 8 16 8 16
4269 16 128 128 1 8 8 8 16 16
4352 16 32 128 0.125 2 2 128 16 64
4374 16 64 128 0.125 2 2 128 32 64
4375 8 64 128 1 4 8 8 16 16
4495 16 64 128 1 8 8 16 8 16
4532 8 64 >128 0.5 8 16 16 8 >8
CPX - ciprofloxacin, OFX - ofloxacin, NFX - norfloxacin.
Table 3.16. Alterations in Quinolone MICs in the Presence of EDTA.
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The fourth pattern was demonstrated by strains C48 and C49, where ciprofloxacin was
the quinolone most affected by the presence of 4mM EDTA. One strain, C2, exhibited
different ratios for all of the quinolones tested. These results suggest that there might be
four different permeability mutations exhibited in these strains; the alteration in
quinolone ratio being indicative of a particular permeability change. The results also
suggest that the different quinolones may be affected by varying degrees when
permeability changes occur.
3.4 INVESTIGATION INTO DNA GYRASE MUTATIONS.
Previous work has demonstrated that P.aeruginosa strains with high quinolone
resistance exhibit mutations in the a subunit of DNA gyrase (Inoue et al 1987, Hirai et
a I 1987). This was investigated both directly and indirectly by a four-fold approach.
The direct approaches involved 1) isolating the DNA gyrase enzyme and determining its
ability to supercoil relaxed pBR322 in the presence of various antimicrobial agents, and
2) amplifying the DNA gyrA gene by Polymerisation Chain Reaction (PCR), and
sequencing the product by either transformation or direct sequencing methods.
The indirect approaches involved 3) amplifying the DNA gyrase gyrA gene by PCR
and cleaving the sequence around one of the sites involved in quinolone resistance with
the Sstll restriction enzyme. The final indirect approach 4) involved probing for gyrA
mutants with a plasmid containing the sensitive E.coli wild type gyrA gene.
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3.4.1 Determination of IC50.
To determine the IC50 of DNA gyrase, the enzyme was isolated on a
novobiocin/sepharose column and purified by dialysis. DNA gyrase is responsible for
supercoiling DNA, and in order to assess its activity, its ability to supercoil relaxed
pBR322 was investigated. DNA gyrase was assayed by gel electrophoresis in the
presence of doubling dilutions of ciprofloxacin, ofloxacin, norfloxacin and novobiocin.
Alterations in the a subunit of DNA gyrase would be reflected by high IC50 values for
the quinolone antimicrobial agents, and alterations in the P subunit by high IC50 values
for novobiocin.
The activity of DNA gyrase was established by determining the IC50 values of each
antimicrobial agent from the agarose gel. Gels were stained with ethidium bromide,
visualised under an ultra-violet light source and photographed. The IC50 value was
calculated from the negative, at the point where the action of the antimicrobial agent
inhibited 50% of the supercoiling of the pBR322, by a densitometer (Figs 3.11, 3.12,
3.13). The IC50S of 23 ciprofloxacin-resistant strains and one sensitive, reference
strain PAOl were calculated, and compared, by agarose gel electrophoresis (Table
3.17) (data shown in Appendix ii).
Figure 3.11 demonstrates the IC50 of a highly resistant DNA gyrase from strain C32.
Figure 3.12 shows the inhibition of pBR322 supercoiling in the presence of a
moderately resistant DNA gyrase, from the strain 4161. Figure 3.13 demonstrates the
supercoiling ability of a DNA gyrase which is only slightly resistant to 4-quinolones,
and was isolated from strain 4532.
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Fig 3.11. IC50 of Strain C32.
Tracks are as follows:-
Block A, the first track contains no drug and subsequent tracks contain sequential
increases in ciprofloxacin dilutions from 2 to 256mg/l: Block B, the first track contains
no drug and subsequent tracks contain sequential increases in ofloxacin dilutions from
2 to 256mg/l: Block C, the first track contains no drug and subsequent tracks contain




Fig 3.12. IC50 of Strain 4161.
Tracks are as follows:- Block A, the first track contains no drug and subsequent tracks
contain sequential increases in ciprofloxacin dilutions from 4 to 256mg/l: Block B, the
first track contains no drug and subsequent tracks contain sequential increases in
ofloxacin dilutions from 4 to 256mg/l: Block C, the first track contains no drug and
subsequent tracks contain sequential increases in norfloxacin dilutions from 4 to
256mg/l: Block D, the first track contains no drug and subsequent tracks contain




Fig 3.13. IC50 of Strain 4532.
Tracks are as follows:- Block A, the first 8 tracks contain sequential ciprofloxacin
dilutions from 256 to 2mg/l, and the last track contains no drug: Block B, the first 8
tracks contain sequential ofloxacin dilutions from 256 to 2mg/l, and the last track
contains no drug: Block C, the first 8 tracks contain sequential norfloxacin dilutions
from 256 to 2mg/l, and the last track contains no drug: Block D, the first 6 tracks









Ratio Drug / Cip
OFX NFX
PAOl 0.38 0.85 0.64 0.55 2.24 1.68
C2 10.7 14.1 44.2 0.83 1.32 4.14
C48 19.0 27.3 63.2 0.24 1.44 3.33
273 11.0 17.1 24.9 0.82 1.55 2.26
274 7.7 10.9 20.0 0.25 1.41 2.60
271 16.9 15.2 24.3 0.46 0.9 1.44
4131 5.7 10.6 13.6 - 1.86 2.39
4495 16.1 6.7 15.9 0.35 0.42 0.99
4149 9.9 10.0 23.0 1.27 1.01 2.32
4532 18.1 20.1 56.5 0.8 1.12 3.11
4125 29.0 77.8 67.2 0.51 2.68 2.32
4269 23.9 46.7 25.8 0.14 1.95 1.08
4352 27.2 31.7 53.3 1.12 1.17 1.96
4124 36.32 44.6 108.5 0.25 1.23 2.99
4133 44.3 24.0 43.23 0.47 0.54 0.98
4375 88.3 171.7 185.7 2.0 1.94 2.10
4158 77.9 56.8 172.4 0.89 0.73 2.21
4161 52.2 27.8 200.7 0.71 0.53 3.84
90-62 55.96 90.40 85.52 - 1.62 1.53
CI 178.0 90.1 223.3 0.49 0.51 1.25
C32 >256 >256 >256 3.59 - -
C49 248.9 219.1 >256 - 0.88 -
3 180.6 171.3 368.8 3.50 0.95 2.04
4374 219.4 87.4 334.7 1.27 0.40 1.53
CIP - ciprofloxacin, OFX - ofloxacin, NFX - norfloxacin, NOV - novobiocin.
TABLE 3.17. ICso Values of Clinical Isolates of Pseudomonas
aeruginosa.
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All IC50 values for clinical isolates were significantly greater than those of the reference
strain PAOl, suggesting that all of the strains possessed gyrA mutations. Strains C32
and 3 also demonstrated significantly higher novobiocin IC50 values than the sensitive
strain, or any other strains, indicating that a gyrB mutation could be present. Strains
were compared on their ability to supercoil relaxed pBR322 in the presence of
ciprofloxacin. The clinical strains fell into three main categories; those with relatively
low IC50 values of 4-20 mg/1 ciprofloxacin, those with an intermediate value of 50-100
mg/1 ciprofloxacin and those with values greater than 150 mg/1 ciprofloxacin.
The majority of clinical strains fell into the group with ciprofloxacin IC50 values
between 4-20 mg/1. In this group ciprofloxacin was the most active quinolone,
followed by ofloxacin and norfloxacin, although the ratios of the IC50S of ofloxacin
and norfloxacin to ciprofloxacin were variable. Strain 4495 exhibited an ofloxacin IC50
which was considerably lower than that of ciprofloxacin, and strains 271 and 4149 had
comparable ofloxacin IC50S to those of ciprofloxacin. Strains 4495 and 4269 also had
comparable norfloxacin IC50S to those of ciprofloxacin.
In the group with high ciprofloxacin IC50 values of greater than 150 mg/1, all of the
strains demonstrated much lower or comparable ofloxacin IC50S to those of
ciprofloxacin. Strains CI and 4374 had similar quinolone ratios, although their
novobiocin IC50 values were different. IC50 ratios in the middle group were variable,
with several strains, 4133, 4158 and 4161 possessing low ofloxacin IC50 values.
Strain 4133 also possessed a low norfloxacin IC50 value and exhibited similar
quinolone ratios to strain 4495, which was present in the low ciprofloxacin IC50 group.
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The differences in the quinolone IC50 ratios may indicate that different gyrase mutations
affect various quinolones differently, and that strains exhibiting similar ratios may
possess the same gyrase mutations. An alternative suggestion is that strains in the same
IC50 groups exhibit similar gyrase mutations.
The relationship of ciprofloxacin MICs to ciprofloxacin IC50 values in the clinical
isolates was also investigated (Fig 3.14). In general, IC50 values for each strain were
found to be greater than or equal to the corresponding MIC. No correlation was
observed between MIC and IC50 values in these strains. The relationship between
MICs and IC50 values for the other quinolones, ofloxacin and norfloxacin, was also
investigated (Figs 3.15, 3.16). Again, no correlation was observed between MIC or
IC50 values. The three graphs also showed three distinct patterns, indicating that
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Figure 3.16. Relationship of Norfloxacin MIC to IC50
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Direct comparison between the IC50 values of each strain is impossible, as each isolate
may produce varying amounts of DNA gyrase, which is then used in the assay. To
investigate the effect on the IC50 of decreasing gyrase levels, the gyrase from a strain
with a high ciprofloxacin IC50 value, C32, and the gyrase from a strain with moderate
ciprofloxacin IC50 levels, 90-62, were diluted sequentially. The diluted gyrases were
assayed for resistance to ciprofloxacin and the resulting IC50S calculated. In both cases
a geometric progression was noticed, by halving the gyrase concentration the IC50
value was halved (Fig 3.17, Table 3.18). The dilution of C32 DNA gyrase and its
subsequent reduction in IC50 levels, however, was insufficient to explain the 100-fold
differences between activities of DNA gyrases within the group with low gyrase IC50
levels and those with very high gyrase IC50 levels.
STRAIN Ciprofloxacin IC50 value (mg/1) at dilutions of :-
0 50% 75%
C32 112.13 48.83 28.18
90-62 55.96 27.70 -
Table 3.18. Values of Sequential Dilutions of Two DNA Gyrases.
The differences in IC50 values within the clinical isolates, the different quinolone ratios,
and the differences between MIC and IC50 values suggest that there are at least two
quinolone resistance mechanisms exhibited by Pseudomonas aeruginosa. To investigate
the existence of these mechanisms further, a strain in the low IC50 group, 4149, and a
high IC50 group strain, C32, were challenged by plating onto 1ST agar plates
containing ciprofloxacin at twice the MIC of the strains. The two strains were selected
as they exhibited the same ciprofloxacin MIC, but were in different IC50 groups.
125
Fig 3.17. IC50 of Sequentially Diluted C32
Tracks are as follows:- Block A, sequential gyrase dilutions from 0% to 87.5%: Block
B contains undiluted DNA gyrase; the first 5 tracks contain sequential dilutions of
ciprofloxacin from 512 to 32mg/l, and the last track contains no drug: Block C contains
50% diluted DNA gyrase; the first 5 tracks contain sequential dilutions of ciprofloxacin
from 512 to 32mg/l, and the last track contains no drug: Block D contains 75% diluted
DNA gyrase; the first 5 tracks contain sequential dilutions of ciprofloxacin from 512 to
32mg/l, and the last track contains no drug: Block E contains a positive control,
pBR322, and a negative control of relaxed pBR322.
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The resulting mutants were identified, purified, and then grown in nutrient broth in the
presence of quarter MIC values of ciprofloxacin, to maintain the selective pressure. 1ST
agar plates containing ciprofloxacin at twice the new MIC level were then seeded, and
mutants isolated and purified as before. The procedure was repeated until mutants of
both C32 and 4149 had MICs of ciprofloxacin of 32mg/l. A single mutant colony from
each strain was then selected, and their OMPs isolated and examined as described in
Methods section 2.7, in order to determine whether membrane protein alterations were
responsible for the increase in MIC (Fig 3.18). The DNA gyrases from the mutant
strains were also isolated and purified, and their IC50 values determined by gel
electrophoresis (Table 3.19).
STRAIN MIC mg/1 IC50 mg/1
CIP OFX NFX CIP OFX NFX NOV
C32 8 32 64 >256 >256 >256 3.59
C32R 32 128 >128 393.47 398.70 392.49 1.72
4149 8 32 128 9.9 10.0 23.0 1.27
4149r 32 128 >128 30.0 39.63 62.61 0.49
CIP - ciprofloxacin, OFX - ofloxacin, NFX - norfloxacin, NOV - novobiocin.
Table 3.19. The MIC and IC50 Values of Mutants of C32 and 4149.
The OMP profiles of C32 and its resistant mutant C32R appeared to be identical,
indicating that the increased resistance was not caused by membrane permeability
mutations. The OMP profiles of 4149 and 4149R were different, with 4149R exhibiting
an extra 38kD protein. This indicates that the increase in quinolone resistance might
have been brought about by an alteration in drug permeability.
127
Fig 3.18. OMP Profiles of Mutants of C32 and 4149.
Tracks are as follows:- Lane A, C48: Lane B, ciprofloxacin-resistant laboratory mutant
of the strain C48s, C48sR: Lane C, the sensitive isolate of C48, C48s, obtained from
the passage experiments: Lane D, C32: Lane E, ciprofloxacin-resistant laboratory
mutant of C32, C32R: Lane F, 4149: Lane G, ciprofloxacin-resistant laboratory mutant
of 4149, 4149r: Lane H, molecular mass standards.
AB CDEFGH
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4149r also exhibited increased IC50 values compared to its parent strain, which
indicated that a gyrase mutation had also occurred. The IC50 values of 4149R for each
drug investigated appeared to increase uniformly with an increase in MIC, when
compared to 4149; the new IC50 for each drug was three-fold greater than that of the
parent strain. The novobiocin IC50 was observed to decrease three-fold. The IC50
values of ciprofloxacin, ofloxacin and norfloxacin in strain C32R could not be
compared to those of the parent strain, C32, but a two-fold decrease in the novobiocin
IC50 was seen.
3.4.2 Direct Analysis of GyrA Mutations.
The DNA gyrase sequence of the gyrA gene of Pseudomonas aeruginosa was obtained
from Dr. L.E. Bryan (personal communication), and oligonucleotide primers
incorporating a BamHl restriction site were used to synthesise a DNA sequence of
approximately 300 base pairs, by the Polymerase Chain Reaction (PCR) technique
(Disney and Dove, 1991). Multiple copies of the fragment were obtained by PCR for
five selected strains, PAOl, C32, C49, 4149 and 4158.
PAOl was selected to confirm the nucleotide sequence of the sensitive gyrase gene.
The strains C32, C49 and 4149 were chosen because they possessed the same
ciprofloxacin MIC, but C32 and C49 were in the high IC50 group and 4149 was in the
low one. The strain 4158 was selected as it was present in the moderate IC50 group.
The PCR fragments were then either sequenced directly, or restricted with BamHl,
transformed into competent cells and sequenced by gel electrophoresis. The results are
shown in Fig 3.19.
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Fig 3.19. Sequencing Gel of C32.
Tracks are as follows:- Block A, C32 with a labelling step of five minutes, the lanes
were loaded in the order G, A, T, C: Block B, C32 with a labelling step of two
minutes, the lanes were loaded in the order G, A, T, C.
A B
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Fig 3.19 shows the nucleotide sequence of C32. Clear nucleotide sequences could not
be deduced as bands appeared in every lane, and the alterations in labelling times
appeared to have no effect. The multiplication of bands is caused by the re-annealing of
primers to the DNA strand and has been observed to be a major flaw in this technique
(S.K. DuBois personal communication).
3.4.3 Indirect Analysis of GyrA Mutations.
GyrA mutations were analysed indirectly by restricting PCR fragments from 18
ciprofloxacin-resistant clinical isolates with the enzyme Sstll. Sstll cleaves the 300 base
pair PCR fragment between amino acids 83 and 84 in the sensitive strain PAOl (Fig
3.20). This site has been reported to be an important active site for quinolone resistance
in E.coli, and is responsible for high level quinolone resistance. PCR sequences from
the clinical isolates which contain a gyrA mutation in the codon of either amino acid 83
or 84 will not be cleaved by the enzyme (Table 3.20). Analysis of the PCR fragments
in this way will give some indication of the prevalence of mutations at this site. The
restricted fragments were then analysed by gel electrophoresis and photographed as
described previously (Fig 3.21).
STRAINS CLEAVED BY Sstll RESTRICTION STRAINS UNCLEAVED BYSstllRESTRICTION
PAOl, 4374, 4532, 4149, 4375,
C32, C48, 273, 4133, 4131.
4124, 4125, CI, C2, 271, 274,
4161, 4269
Table 3.20. The Effect of Sstll Restriction on the Unpaired
Ciprofloxacin-Resistant Clinical Isolates.
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Table 3.20 indicates that most strains are cleaved by the Sstll restriction enzyme. These
strains do not harbour nucleotide alterations in either amino acids 83 or 84. The strains
unaffected by the Sstll restriction enzyme, however, do contain a mutation in either
amino acid 83 or amino acid 84. These results indicate that eight clinical isolates contain
at least one mutation in the DNA gyrase gene, which contributes to their overall
quinolone resistance.
Fig 3.20. The Cleavage Site of Sstll.
Thr 83 Ala 84 Val 85
accIgc g gtc
tgg cg c cag
Letters outlined denote the nucleotide sequence recognised by the enzyme.
3.4.4 Probing for GyrA Mutations.
To confirm the presence of gyrA mutations, the resistant clinical isolates were probed
with pNJR3-2, which contained the wild-type Escherichia coli gyrA gene. The wild-
type gene is quinolone-sensitive and has been shown to be dominant over the
quinolone-resistant DNA gyrase. On introducing the plasmid into the quinolone-
resistant clinical isolates, the isolates would be expected to revert to quinolone
sensitivity, or to become more quinolone-sensitive if they harboured other quinolone
resistance mechanisms.
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Fig 3.21 Gel of Sstll Cleaved PCR Fragments.
Tracks are as follows:- Lane A, PAOl PCR fragment: Lane B, Sstll restricted PAOl
fragment: Lane D, C32 PCR fragment: Lane E, Sstll restricted C32 fragment: Lane F,
SstH restricted C32 fragment: Lane G, Sstll restricted 4124 fragment: Lane H, 4124
PCR fragment.
A B D E F G H
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The conjugation method of Robillard (1990) was used to introduce the probe into
P.aeruginosa, but in spite of numerous attempts the plasmid did not appear to have
transferred. A major obstacle to the selection of transconjugants was the high intrinsic
resistance of P.aeruginosa to the selective agents used. pNJR3-2 contained antibiotic
resistance markers for both tetracycline and kanamycin; but the recipient P.aeruginosa
strains also exhibited resistance to these markers, making it impossible to distinguish
between recipient strains and transconjugants. An attempt was made to select the
transconjugants by replica plating the suspected transconjugant colonies onto PIA plates
containing ciprofloxacin at 1/8, 1/4, 1/2 and the MIC value of the relevant strain, but no
transconjugant strains were identified.
Alternative conjugation methods were attempted to introduce the plasmid into the
P.aeruginosa strains. The first was the method of Amyes and Gould (1984) which
involved the donor and recipient strains being grown statically in 10ml nutrient broth,
overnight at 37°C. Either 1ml of the donor strain was added to 1ml of the recipient
strain in 10ml fresh broth, or 0.1ml of the donor strain was added to 1ml of the
recipient strain, and the broth incubated statically overnight at 37°C. The resulting
bacteria were then seeded onto plates containing the selective agent, as described in
Materials and Methods section 2.11.3. Again, no transconjugants were isolated.
To investigate whether the lack of success in transferring the plasmid was caused by the
inability of the plasmid to mobilise, it was attempted to introduce pNJR3-2 into the
E.coli strain J62-2, again following the method of Amyes and Gould (1984). The
transconjugants were selected on proline, histidine and tryptophan (PHT) plates
containing rifampicin and tetracycline, and a plasmid preparation carried out on them.
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The plasmid preparations were analysed by gel electrophoresis, and provided J62-2
isolates containing the probe (Fig 3.22). This indicated that pNJR3-2 was able to
mobilise, and that the transfer problem was probably caused by strain differences
between P.aeruginosa and E.coli.
A triple mating was then carried out in order to introduce the plasmid into a
P.aeruginosa strain. The E.coli strain containing pNJR3-2 was mated with J62-2 as
described above, and the J62-2 containing the plasmid was subsequently mated with
PA02, a serine requiring P.aeruginosa auxotroph. It was decided to use PA02 as it
was a quinolone-sensitive strain, and its serine requirement enabled recipients to be
selected out from donor and transconjugant strains. As before, no transconjugant
strains were isolated.
To compensate for the intrinsic resistance to tetracycline exhibited by the P.aeruginosa
strains, the MICs of the quinolone-resistant strains to tetracycline were determined in
the presence of 4mM EDTA (Table 3.21). EDTA was used to disrupt the cell membrane
in recipient strains, thus rendering them susceptible to tetracycline and overcoming the
intrinsic resistance inherent in the P.aeruginosa strains. As the transconjugants would
be carrying plasmid-encoded tetracycline resistance, they would be expected to grow at
high tetracycline concentrations inthe presence of 4mM EDTA.
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Figure 3.22. Plasmid Preparation of J62-2 Demonstrating the Presence
of pNJR3-2.
Tracks are as follows:- Lane A, molecular mass standards: Lane B, pNJR3-2: Lanes C
- K, transconjugants isolated.
ABCDEFGH I J K
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TABLE 3.21. MICs of Tetracycline in the Presence and Absence of
EDTA.
The EDTA concentration of 4mM was selected as it had previously been shown to
overcome membrane permeability resistance without inhibiting cell growth (refer to
Results section 3.3.2). The results demonstrated that most strains retained their
tetracycline resistance in the presence of 4mM EDTA, thus indicating that tetracycline
resistance in P.aeruginosa is likely to be plasmid borne. Strains 4532, 4374, 4352,
4161, 4158, 4131 and C49 did exhibit slight reductions in tetracycline MICs, but even
with these strains no transconjugants were obtained.
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A final attempt was made to introduce pNJR3-2 into P.aeruginosa by electroporation,
employing the method of Diver and colleagues (1990a). The plasmid was isolated as
described previously (refer to Methods and Materials section 2.11.4) and its purity
checked by gel electrophoresis. The plasmid was then introduced into strains PAOl,
4124, 4125 and 3; a control plasmid, pUC18, was also introduced into the four strains.
Initial arcing of the electroporation mixture was overcome by diluting both the plasmid
and the recipient strain by ten-fold. The solution was then seeded, as before, onto 1ST
agar plates containing tetracycline, but no transconjugants were obtained. Also, pUC18
was not present in any of the resistant transconjugants recovered. The method of Diver
and colleagues (1990a) was then modified by increasing the resistivity of the Electrocell
Manipulator to 492 ohms, but this produced excessive arcing which could not be
overcome by diluting either preparation.
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DISCUSSION
The aim of this thesis was to investigate the mechanisms of resistance of Pseudomonas
aeruginosa to the 4-quinolones by studying the pleiotropic nature of both the outer
membrane protein and DNA gyrase mutations. Previous reports had indicated that
P.aeruginosa exhibits alterations in several OMPs (Hirai et al 1987; Robillard and
Scarpa 1988; Chamberland et al 1989), and reports of DNA gyrase mutations in other
bacteria, such as E.coli, S.aureus and B.subtilis (Hirai et al 1986b; Tanaka et al 1991;
Lampe and Bott 1984) indicated that P.aeruginosa might also exhibit several gyrase
mutations. No reports, however, had investigated the relationship between MIC and
DNA gyrase mutations or DNA gyrase mutations and OMP mutations. It was also
unclear whether gyrase mutations developed before or after OMP mutations in
quinolone-resistant bacteria. It was hoped, during the course of this study, to address
some of these questions.
4.1 MINIMUM INHIBITORY CONCENTRATIONS.
4.1.1 MICs of the Quinolones.
In terms of MICs of the 4-quinolones it was found that the resistant clinical isolates fell
into a range of 4-64 mg/1 ciprofloxacin, 8-128 mg/1 ofloxacin and 32-> 128 mg/1
norfloxacin. These results are similar to MICs reported by many other workers;
Robillard and Scarpa (1988) reported quinolone resistances of 4-16 mg/1 ciprofloxacin,
8-32 mg/1 ofloxacin and 4-32 mg/1 norfloxacin and Thomson and colleagues (1991)
reported resistances of 4-64 mg/1 ciprofloxacin and 4-16 mg/1 ofloxacin.
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The MICs demonstrated that ciprofloxacin was the most active 4-quinolone, followed
by ofloxacin and norfloxacin. Robillard and Scarpa (1988) reported that ciprofloxacin
was the most active 4-quinolone, and that ofloxacin and norfloxacin possessed similar
activities. Legakis and co-workers (1989) reported that the activity of ciprofloxacin was
two- to four-fold higher than that of norfloxacin. More recent reports, however, have
indicated that ofloxacin has comparable MICs to ciprofloxacin (Thomson et al 1991).
The MICs of the quinolone-resistant clinical isolates exhibited different ratios of
ofloxacin and norfloxacin resistance when compared to ciprofloxacin. The sensitive
strains PAOl and U423 demonstrated similar ratios of drug resistance, with ofloxacin
2-4 times less active than ciprofloxacin, and norfloxacin 4-8 times less active than
ciprofloxacin. If all of the ciprofloxacin-resistant clinical isolates exhibited identical
mutations then the ratios of quinolone MICs to MICs of ciprofloxacin would be
expected to be similar, but this was not observed.
The resistant clinical isolates did, however, fall into several similar categories;
1) two strains exhibited lower ciprofloxacin/ofloxacin resistance ratios and
ciprofloxacin/norfloxacin resistance ratios than the sensitive strains.
2) four strains exhibited a two-fold increase in ciprofloxacin/ofloxacin resistance ratios
and a four-fold increase in ciprofloxacin/norfloxacin resistance ratios, a pattern similar
to the sensitive strains.
3) five strains exhibited a four-fold increase in ofloxacin resistance and an eight-fold
increase in norfloxacin resistance ratios compared with ciprofloxacin.
4) six strains exhibited a four- to eight-fold increase in ofloxacin resistance ratios and
an eight- to sixteen-fold increase in norfloxacin resistance ratios.
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The variability in the ratios suggests that the bacteria are responding differently to the
selective pressures of the quinolones and also indicates that the isolates are exhibiting
several different quinolone mutations. Another conclusion drawn from these results is
that different resistance mutations affect various 4-quinolones in different ways. For
example, the mutation exhibited by strains 273 and 4269 has the same effect on
ofloxacin resistance as norfloxacin resistance, but has less effect on ciprofloxacin
resistance, as the ciprofloxacin MIC is eight-fold lower. Other strains show that
norfloxacin is affected to a greater extent than ofloxacin. Bazile and colleagues (1992)
reported that in Gram-negative organisms, high molecular weight quinolones
accumulate in the bacterial cell at a slower rate than those of a low molecular weight,
and thus the MICs of norfloxacin and ofloxacin would be expected to be greater than
those of ciprofloxacin.
The fluctuations in quinolone resistance in the paired clinical isolates, however, did not
reflect the findings in the unpaired strains. The ratios of ciprofloxacin resistance to both
ofloxacin and norfloxacin resistance either remained the same, or the
norfloxacin/ciprofloxacin ratio was two-fold greater than the ofloxacin/ciprofloxacin
ratio. These ratios were identical to those of the sensitive parent strains, and
demonstrate that a similar resistance mechanism has occurred in all of the resistant
isolates. The resistance of the paired clinical isolates was low, being 8mg/l or less to all
of the quinolones investigated, suggesting that it was caused by permeability alterations
(Hirai et al 1986a). The results indicated that resistance in the isolates 273 and 4269,
which exhibit similar quinolone ratios to the paired isolates, was also by permeability
mechanisms, and that the other unpaired resistant isolates had a second mutation, which
acted in concert with the permeability mutations.
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4.1.2 MICs of Other Antimicrobial Agents.
The observation that OMP alterations are partly responsible for quinolone resistance in
P.aeruginosa was confirmed by the MIC experiments with other unrelated antimicrobial
agents. P.aeruginosa was found to be intrinsically resistant to tetracycline, kanamycin,
cefotaxime and carbenicillin. The levels of resistance to these drugs were different,
however, ranging from 4-128 mg/1 cefotaxime, 4-128 mg/1 carbenicillin, 64->256 mg/1
tetracycline and 2->128 mg/1 kanamycin, which implied that at least two mechanisms of
resistance to these drugs were present in the isolates studied. These mechanisms were
probably permeability mutations coupled with plasmid-mediated resistance.
A study of the MICs of gentamicin, imipenem and ceftazidime in the clinical isolates
demonstrated that quinolone resistance was linked with several different patterns of
unrelated antimicrobial agent resistance. Three strains exhibited high-level quinolone
resistance in conjunction with high-level gentamicin, imipenem and ceftazidime
resistance, which indicated that drug resistance in these strains was caused by a
membrane protein alteration. Strain C2 also exhibited high-levels of gentamicin,
imipenem and ceftazidime resistance, but it was coupled with moderate quinolone
resistance, and was thought to demonstrate the same resistance mechanism.
Several strains displayed quinolone resistance with resistance to two out of the three
drugs, gentamicin, imipenem and ceftazidime; although in all cases resistance levels
were variable. These strains exhibited quinolone resistances between 8 and 32 mg/1
ciprofloxacin. Three strains were quinolone and ceftazidime resistant and one strain, 3,
had high level quinolone resistance. Three strains also exhibited moderate gentamicin
resistance, two of which had a ciprofloxacin MIC of 64mg/l. These results confirm that
more than one resistance mechanism was present in these clinical isolates.
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Quinolone and imipenera cross resistance has previously been reported by Radberg and
co-workers (1990) and Thomson and colleagues (1991) in quinolone-resistant clinical
isolates of P.aeruginosa. Radberg and co-workers, however, did not study resistance
to gentamicin or ceftazidime and so could not link them to imipenem or quinolone
resistance. In this study no strains were isolated which were solely quinolone-and
imipenem-resistant. This suggests that the strains investigated by Radberg and
colleagues (1990) were also either gentamicin-or ceftazidime-resistant. Thomson and
colleagues (1991) linked quinolone resistance in ciprofloxacin-resistant isolates of
P.aeruginosa with imipenem, gentamicin and ceftazidime resistance, although
resistance to these agents did not develop during the course of the study. Masuda and
Ohya (1992) linked quinolone and imipenem resistance in laboratory mutants of
P.aeruginosa and reported that most strains carried gentamicin and ceftazidime
resistance. The imipenem/quinolone cross resistance in the report of Masuda and Ohya
(1992) was linked to a permeability alteration in a 49kD protein (OprM).
Quinolone cross resistance with P-lactam antibiotics has also been reported (Rella and
Haas 1982; Fukuda et al 1990) and was linked with alterations in drug permeability.
Fukuda and colleagues (1990) discovered that P-lactam/quinolone cross resistance was
initiated by a decreased expression of a 46kD protein and an increased expression of a
5()kD protein. Fukuda and co-workers (1990) described similar alterations in MIC
values to those observed in this study.
Quinolone resistance has been linked to hypersusceptibility to unrelated antimicrobial
agents such as gentamicin, carbenicillin and p-lactam antibiotics, (reviewed by Yoshida
et al 1990c). These reported hypersusceptibilities have been linked to decreases in
expression of a 46kD protein and increases in expression of a 50kD protein (Fukuda et
al 1990). Similar results were obtained in this study, with five moderately quinolone-
resistant strains showing gentamicin sensitivities which were lower than those of the
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drug-sensitive strains PA01 and U423. Three strains also exhibited moderate quinolone
resistance linked to ceftazidime sensitivity and two strains exhibited carbenicillin
hypersusceptibility. One strain, C48, exhibited hypersusceptibility to all of the
antimicrobial agents investigated, but was resistant to ciprofloxacin with an MIC of
32mg/l.
In the paired isolates from patients I and III, initial quinolone resistance was not linked
with resistance to any unrelated antimicrobial agents. Only in later isolates of the 91-32
series from patient I did P-lactam resistance increase, and gentamicin and imipenem
resistance increase by two-fold. This suggests that quinolone resistance can develop
independently of resistance to unrelated antimicrobial agents, a finding which was
reported by Hirai and colleagues (1986b) and was linked to DNA gyrase mutations.
Quinolone resistance did not increase with the rise in P-lactam, gentamicin and
imipenem resistance, which suggested that the resistance mechanism of these agents
was separate to that of the quinolones. Mutations affecting resistance to these other
agents were probably via pathways which did not involve quinolone uptake, or where
quinolone uptake was minimal. In the paired isolates 90-62 and 90-67 quinolone
resistance was linked to resistance to P-lactam antibiotics, although it was unclear
whether these resistances developed independently of each other. As these two strains
were isolated a month apart, it is possible that quinolone and p-lactam resistance could
have developed independently and that this had not been observed. The P-lactam
resistance probably developed in response to treatment with P-lactam antibiotics, and
not with quinolone antibiotics, but the case histories of the patients were unavailable to
confirm this.
The choice of media affected quinolone resistance, and this has been previously
reported (Govan et al 1983; Bedard et al 1989). Govan and colleagues (1983) found
that MICs were four-fold greater on PIA than on 1ST agar, and this was attributed to
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the presence of the detergent, irgasan, in the media. This study obtained similar results.
Bedard and co-workers (1989) reported that an increase in the magnesium ions in the
media also contributes to higher MICs. The presence of excess Mg2+ is thought to
prevent quinolones from chelating LPS-associated magnesium and so limits their entry
into the bacterial cell (Chapman and Georgopapadakou 1988). PIA contains a much
higher magnesium content than 1ST agar, which explained the discrepancies in MIC
values.
The growth of P.aeruginosa strains on PIA also affected the colonial morphology of the
clinical isolates. In 1983 Govan and colleagues reported that several strains of
P.aeruginosa exhibited a mucoid colonial morphology on PIA but not upon any other
media, which they determined PIA-dependent mucoidy. Several of the clinical isolates
in this study exhibited mucoidy on PIA, which contributed to the higher quinolone
MICs on this media compared to 1ST agar, as the viscous polymer, alginate,
synthesised by the mucoid P.aeruginosa provides a very effective barrier to drug
permeation into the bacterial cell. The conversion to mucoid colonies explained why the
ciprofloxacin/ofloxacin resistance ratio in strain C2 increased on PIA and not on 1ST
agar, and it also explained why the ciprofloxacin/ofloxacin resistance ratios between
1ST agar and PIA differ slightly in some strains.
Resistance to one 4-quinolone antib™Awi leads to resistance to all 4-quinolone
antibacterials, and this has been demonstrated by many authors (reviewed by Wolfson
and Hooper 1989). Moniot-Ville and colleagues (1991) demonstrated, however, that
resistance to the 4-quinolones was linked, but that 4-quinolone-resistant bacteria also
exhibited susceptibility to nalidixic acid. This study did not investigate nalidixic acid
resistance but the MIC results for the quinolones investigated do suggest that
quinolones are affected in a variety of ways by different mutational changes.
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4.2 THE STABILITY OF OIJINOLONE RESISTANCE.
Investigations into the stability of quinolone resistance have generated conflicting
reports. Daikos and colleagues (1988) reported that quinolone resistance in
P.aeruginosa was abolished after repeated passage in drug-free medium. This finding
was confirmed by Kaatz and Seo (1988) who reported that low level quinolone
resistance linked to alterations in an OMP of 31-32kD was unstable. Radberg and
colleagues (1990) published a conflicting report which claimed that ciprofloxacin
resistance in clinical isolates of P.aeruginosa from cystic fibrosis patients demonstrated
little or no alteration in ciprofloxacin resistance after serial passage in Mueller-Hinton
broth.
On initial observation, the results from thesis suggested that the findings of Radberg
and colleagues (1990) were correct, as in all strains ciprofloxacin resistance remained
stable, or altered by two-fold after serial passage on drug-free PIA. This study did,
however, isolate one strain, C48, which on one occasion reverted to ciprofloxacin
sensitivity within five days of the start of the passage experiment. The sensitive
revertant strain, C48s, exhibited an identical pyocin type to its parent strain. The strain
C48 had demonstrated a high ciprofloxacin MIC of 32mg/l. Repetition of the
experiment on two subsequent occasions revealed no reversion to sensitivity, indicating
that ciprofloxacin resistance was stable in this strain. These results indicated, however,
that on rare occasions the same strain may exhibit two different mutations to the 4-
quinolones, one of which is stable in the absence of the selective agent, and one of
which is unstable.
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The isolation of these two different mutations might have been influenced by alterations
in temperature, or the method used to investigate the stability of resistance. This study
passaged a single colony from solid media onto a fresh plate, so it is possible that both
ciprofloxacin-resistant and ciprofloxacin-sensitive colonies existed during the initial
passage, but that only one phenotype was expressed on subsequent passages. This
explained why reversion to ciprofloxacin sensitivity was only isolated on one occasion
in the C48 strain. Radberg and colleagues (1990) passaged their strains in Mueller-
Hinton broth where a mixture of ciprofloxacin-resistant and ciprofloxacin-sensitive
colonies would be inoculated into each fresh culture and MIC broth. The MIC broth
would therefore always contain some ciprofloxacin-resistant strains, which would
result in stable ciprofloxacin resistance being observed. Both Daikos and co-workers
(1988) and Kaatz and Seo (1988) employed agar passage experiments which increased
their ability to select ciprofloxacin-sensitive colonies. This theory could be investigated
by performing viable counts on both ciprofloxacin-containing and drug-free agar plates.
4.3 ALTERATIONS IN OUTER MEMBRANE PROTEINS.
Alterations in OMPs which have been reported to be linked to quinolone resistance
include proteins of 51kD (Robillard and Scarpa 1988), 31-32kD (Daikos et al 1988),
40kD (Chamberland et al 1989), 54kD (Hirai et al 1987), 50kD (Fukuda et al 1990),
47kD (Rohner et al 1992) and OMPG (Chamberland et al 1989). The MIC results in
this study, indicated that strains cross-resistant to unrelated antimicrobial agents would
probably contain membrane protein alterations. Strains exhibiting quinolone and
imipenem resistance would be expected to express different OMP alterations from those
exhibiting quinolone and gentamicin resistance, or quinolone and [1-lactam resistance. It
was expected that strains harbouring resistance to quinolones and the other three drugs
would exhibit alterations in several OMPs.
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4.3.1 OMP Alterations in the Unpaired Clinical Isolates.
This study found that it was difficult to identify OMP mutations as a majority of the
clinical isolates were unpaired. It was attempted to overcome this by investigating the
OMPs of several quinolone-sensitive isolates, and a reference strain PAOl, to decide
whether a specific P.aeruginosa OMP profile predominated. It was unfortunate that the
sensitive isolates exhibited different OMP profiles. One profile, however, did seem to
dominate as it was observed in five of the sensitive strains; it contained OMPs at 51,
46, 43, 36, 26 and 22kD. This profile was then used as a standard with which to
compare the rest of the clinical isolates.
The molecular masses of the OMPs of all the clinical isolates were calculated from
PhastSystem gels. The BioRad Mini Protean® gels were chosen to be presented in this
study because band differentiation, especially at the lower molecular masses, was
clearer than that of the PhastSystem and because the gels were much larger in size. The
proteins greater than 30kD, however, appeared to be cramped on the BioRad gels when
compared to the PhastSystem gels, and so the molecular masses of the OMP bands
were calculated from these gels.
In the unpaired isolates alterations in several OMPs were found; those of 51, 46, 43,
42, 38, 36, 32, 30 and 28kD proteins. The predominant alteration was a decrease in
expression or total loss, of a 51kD protein. The production of an additional 51kD
protein was found to be linked to quinolone resistance (Rella and Haas 1982; Robillard
and Scarpa 1988), and isolates exhibited cross-resistance to chloramphenicol,
tetracycline and carbenicillin. In this study the eight strains with a loss or decreased
expression, of this protein were tetracycline-resistant, but four of the strains were
carbenicillin-sensitive. Two strains, 4158 and 4161, exhibited low carbenicillin MICs
linked with imipenem hypersusceptibility. The results therefore suggest that the 51kD
protein may not be associated with quinolone/carbenicillin cross-resistance which
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contradicts the report of Robillard and Scarpa (1988); however these workers
investigated laboratory mutants of only one strain, PA02.
Other investigators have implicated the presence of a 54kD protein in quinolone
resistance (Hirai et al 1987; Legakis et al 1989). On observing the OMP profiles of the
P.aeruginosa isolates investigated by Legakis and colleagues (1989), the protein at
54kD appears to be the identical protein to the protein in this study found to migrate to
51kD. Legakis and co-workers (1989) found that the increased production of this 54kD
protein was linked to [5-lactam and aminoglycoside cross resistance. This result
contradicts the findings of this study, as although alterations to the 51kD protein were
associated with increases in MIC of both aminoglycoside and (5-lactam antibiotics, the
51kD protein expression was seen to decrease and not to increase. This might suggest
that these two proteins were indeed different, although the OMP profiles seem to
indicate otherwise.
Hashmi and Smith (1991) reported increased expression of a 52kD protein, which
conferred high-level quinolone resistance, but no cross resistance to unrelated
antimicrobial agents. Again, on studying the OMP profiles of Hashmi and Smith's
isolates (1991), the 52kD protein appears to be identical to the 51kD protein in this
thesis. Two strains, 4158 and 4161, were solely quinolone-resistant but displayed a
decreased expression or loss, of a 51kD protein, which contradicted the report of
Hashmi and Smith (1991) where the expression of the 52kD protein increased.
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Decreased expression or the loss, of the 51kD protein was coupled with the production
of a new 28kD protein and was linked with p-lactam resistance in four strains,
suggesting that P-lactam resistance is caused by the synthesis of a new membrane-
bound protein. The production of a new 28kD protein linked to quinolone resistance
has been reported by Daikos and colleagues (1988) but their isolates were only
quinolone-resistant and not resistant to any other antimicrobial agents. This indicated
that the P-lactam resistance was caused by other mechanisms.
Alterations in a 51kD protein were also linked with the production of a new 38kD
protein, although three other strains were observed to produce the new 38kD protein
without visible alterations in the 51kD OMP. The production of a 38kD protein could
not be linked with resistance to any other antimicrobial agent, and strains producing this
extra protein showed different antibiograms. This suggests that the 38kD protein might
be linked to quinolone resistance, but no other reports of increases in this protein have
been documented.
Another frequent OMP alteration observed was the loss or decreased expression, of a
43kD protein. The loss of this protein and the production of a new 30kD protein was
linked in two strains to an increase in gentamicin resistance. This correlates with the
results observed by Daikos and colleagues (1988) who reported that quinolone
resistance was caused by alterations in the expression of a 43kD and a 31-32kD
protein.
Other protein alterations observed were those at 46 and 32kD. Decreased expression of
protein D2, a 47kD protein, has been linked to quinolone/imipenem cross resistance in
P.aeruginosa (Michea-Hamzehpour et al 1991). In this study, however, the loss of a
46kD protein was not linked to any alterations in imipenem resistance. The production
of a new 32kD protein in three strains was linked with quinolone and p-lactam
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resistance but two of the strains also had alterations in a 51kD protein and produced
two other new proteins at 38 and 28kD. Reports by Daikos and colleagues (1988) and
Kaatz and Seo (1988) have implicated the loss or decreased expression of a 32kD
protein in low level quinolone resistance, which again seems to contradict the findings
of this study. It is clear, however, from considering the alterations in the unpaired
clinical isolates in this study, and the reports of other investigators, that P.aeruginosa
may exhibit several OMP alterations in conjunction with quinolone resistance.
It was also observed that all of the quinolone-resistant isolates contained a protein at
36kD. In isolates with ciprofloxacin resistance above 8mg/l the expression of this
protein was significantly increased compared to its expression in sensitive strains. This
suggested that this 36kD protein was involved in quinolone resistance.
4.3.2 OMP Alterations in Paired Clinical Isolates.
The paired isolates from patient II displayed no alterations in OMP profiles, which
suggested that quinolone resistance was brought about by either a DNA gyrase
mutation, usually associated with high level quinolone resistance, or the presence of an
active efflux system. Neither of these suggestions were investigated further.
The paired isolates from patients I and III exhibited similar alterations in OMP profiles,
and isolates from both patients acquired (3-lactam resistance in conjunction with
quinolone resistance. The resistant strains 90-67 and 91-33 displayed alterations in the
production of a 46kD protein. The quinolone-resistant strain from patient III exhibited a
decreased production of a 46kD protein, coupled with an increased expression of two
proteins at 26kD and 22kD. In patient I, quinolone resistance was linked to the
increased expression of a 46kD protein and the decrease of a 51kD protein.
Development of ceftazidime resistance in patient I was linked to the production of a new
42kD protein. This protein was present in the membranes of both patient Ill's strains
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and so ^-lactam resistance in this strain probably developed independently of quinolone
resistance.
4.3.3 OMP Alterations in Laboratory Mutants.
Results from both the unpaired and paired strains implicated three major proteins in
quinolone resistance, those at 36kD, 46kD and 51kD. The results obtained from mutant
strains confirmed these observations. The mutant strains from U423 exhibited an
increased expression of a 36kD protein linked to an eight-fold increase in quinolone
MIC. Two mutants also exhibited alterations in the expression of a 51kD protein,
which might be linked to imipenem hypersusceptibility. Two other strains which
demonstrated imipenem hypersusceptibility, however, did not display any visible
alterations in the expression of the 51kD protein. The strains with imipenem
hypersusceptibility were all green pigmented, and demonstrated similar pyocin types,
so imipenem sensitivity might be linked to pyocin production and not to quinolone
resistance.
Mutant isolates were also obtained from 91-32 and 91-33; the mutational frequencies
observed of 2.1 in 106 and 5.4 in 106 were within the range reported by Wolfson and
Hooper (1989) for P.aeruginosa isolates, although they were more frequent than the
values quoted by Robillard and Scarpa (1988) of 1.5 in 107. Mutant bacteria from the
strain 91-32 displayed variable quinolone resistances, unlike the mutant strains from
U423, suggesting that more than one mutational step had occurred in strain 91-32 to
produce these isolates.
The mutant laboratory strains from 91-32 exhibited similar OMP profiles to the
ciprofloxacin-resistant clinical isolates obtained from this strain. The mutant isolates 91-
32-1, 91-32-3 and 91-32-6 exhibited identical profiles to the clinical isolates 91-44 and
91-76. Their MICs , however, were very different. The three mutant strains exhibited
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gentamicin resistance, whereas the clinical isolates were slightly gentamicin-resistant,
and none of the laboratory mutant strains had the high levels of ceftazidime resistance
demonstrated by their clinical counterparts. The mutant strains were also more sensitive
to cefotaxime than the clinical isolates. These results were reflected by strains 91-32-2
and 91-32-4 which displayed identical OMPs to the clinical isolates 91-40 and 91-41.
The mutant strains, however, possessed lower cefotaxime resistances and were
ceftazidime-sensitive, unlike their clinical counterparts. This again suggested that the p-
lactam resistance observed was linked to the patient's drug therapy and not to quinolone
resistance.
MIC evaluations on the laboratory mutants of 91-32 showed that strains exhibiting high
ofloxacin and ciprofloxacin MICs were imipenem-sensitive and, in some cases,
gentamicin hypersusceptible. Several other strains with similar ofloxacin MICs
exhibited gentamicin resistance and so sensitivity to gentamicin was disregarded.
Hypersusceptibility to imipenem, however, had also been observed in the
ciprofloxacin-resistant U423 laboratory mutants. This imipenem hypersusceptibility
and quinolone cross resistance appeared to be linked to the production of a 36kD
protein.
In order to investigate whether imipenem hypersusceptibility was linked to the
increased production of a 36kD protein and if it was co-linked with quinolone
resistance, the ciprofloxacin-resistant clinical isolate, 91-33, was selected further for
mutants exhibiting high ofloxacin resistance. If imipenem hypersusceptibility was
linked to quinolone resistance then the imipenem resistance of the mutant strains should
alter. Ten mutant isolates, exhibiting various quinolone MICs, were studied and no
alterations in imipenem resistances were observed. These results indicate that imipenem
and ciprofloxacin resistance are not linked and, as ciprofloxacin resistance seems to be
linked to alterations in 36kD and 51kD proteins, imipenem hypersusceptibility can not
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be linked to alterations in either of these proteins. Unlike Radberg and colleagues
(1990), alterations in imipenem resistance could not be linked to either quinolone
resistance or alterations in OMPs. It is possible that the imipenem resistance reported by
Radberg and colleagues (1990) could have resulted from the patients' treatment rather
than in concert with quinolone resistance.
Experiments to confirm that either the 36kD or the 51kD proteins were responsible for
quinolone resistance in the clinical strains, by reverting the resistant clinical strains to
sensitivity, were unsuccessful. The experiments demonstrated that quinolone resistance
was stable in these strains, and not surprisingly, no alterations in OMPs were found.
These results from the clinical strains confirm the results previously observed in the
unpaired isolates and demonstrate that, for the purpose of quinolone resistance,
alterations in OMPs appear to be permanent. The reversion of C48 to sensitivity
suggests that two types of OMP mutations may occur, but that detection of the sensitive
strains is difficult.
4.3.4 OMP Alterations in the Presence of EDTA.
To clarify which of the quinolone-resistant strains carried OMP alterations, the MICs of
quinolones for several strains were monitored in the presence of increasing
concentrations of EDTA. Previous work with trimethoprim (Amyes and Smith 1977)
and quinolones (Sato et al 1986) has demonstrated that permeability mutations may be
detected by performing MICs in the presence and absence of EDTA. Disruption of the
bacterial outer membrane with EDTA has been reported to facilitate quinolone uptake by
opening the hydrophobic pathway to them (Chapman and Georgopapadakou 1988). It
would therefore be expected that strains harbouring OMP mutations would be affected
by the presence of EDTA and that in these cases the quinolone MIC would be seen to
decrease.
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EDTA concentrations above 8mM were found to inhibit bacterial growth, which is not
surprising, as disruption of the cell membrane would allow osmotic changes to occur,
and the chelation of divalent cations in the bacterial cell by excessive EDTA molecules
would prevent many essential cell processes from taking place. EDTA had no effect
upon the sensitive bacteria, until the 8mM EDTA concentration was reached. The
resistant strains, however, exhibited varying reactions at different EDTA
concentrations. All of the strains demonstrated significant decreases in quinolone MIC
when subjected to concentrations of 8mM EDTA; although 11 out of the 24 resistant
isolates investigated managed to grow at these concentrations. These results suggest
that all of the strains possessed OMP alterations, but that several strains also possessed
other resistance mechanisms.
Most strains displayed gradual decreases in quinolone MIC with increasing EDTA
concentrations, suggesting that in these strains OMP mutations were the primary
resistance mechanism. The quinolone-resistant mutant of the paired strain 91-32, 91-
33, exhibited a four-fold decrease in quinolone MIC at 2mM EDTA concentrations,
which was linked to the decreased expression of a 51kD protein and increased
expression of a 46kD protein. Four strains also exhibited similar alterations in
quinolone MIC, which were also linked to the altered expression of a 51kD protein.
Strains 3, 4124, 4161 and 4495 showed different alterations in quinolone resistance in
the presence of EDTA, suggesting that they exhibited other quinolone resistance
mechanisms, and possibly different OMP alterations.
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At concentrations of 4mM EDTA more than 50% of the resistant isolates exKaAt^d
quinolone sensitivity. The remaining isolates exhibited MICs of 4mg/l ciprofloxacin or
greater, indicating that they possessed quinolone resistance mutations other than
permeability mutations. These mutations were thought to be gyrase mutations, and not
efflux mutations, as the disruption of the outer membrane would affect the mechanism
of action of an efflux system.
The EDTA results confirmed that all of the resistant strains possessed OMP mutations.
Alterations in quinolone MICs within the resistant bacteria were not linked to alterations
in specific membrane proteins, although strains exhibiting the loss or decreased
expression of a 51kD protein did show similar falls in quinolone MICs. The alterations
in quinolone MICs in the presence of EDTA were similar to those reported by Sato and
co-workers (1986). The fact that specific OMPs could not be linked to changes in
EDTA concentrations seems to confirm that in P.aeruginosa several OMP mutations,
acting separately or in conjunction with each other, are responsible for quinolone
resistance. The presence of other resistance mechanisms in these strains, such as gyrase
mutations, also contributed to the variable quinolone MICs in the presence of different
amounts of EDTA. Strains carrying mutant DNA gyrases would be expected to exhibit
higher initial quinolone MICs in the presence of EDTA, as there would be insufficient
EDTA in the medium to affect the inner cell contents. As EDTA concentrations
increase, Mg2+ ions in the cell would be chelated, and gyrase-mediated quinolone
resistance would be inhibited. This caused the sudden decrease in quinolone resistance
seen in eight strains.
The study of MIC alterations in the presence of EDTA implicated four different
alterations in membrane proteins, as four patterns of quinolone resistance emerged; an
alteration in ciprofloxacin/ofloxacin resistance or ciprofloxacin/norfloxacin resistance
ratios being indicative of a specific permeability change. The comparison of quinolone
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ratios with permeability changes showed no correlation. The results suggested that
different quinolones may be affected to varying extents by permeability alterations; the
extent of the effect on quinolone permeation into the cell depending upon the
permeation route of the quinolone investigated. Reports by Hirai and colleagues
(1986a) suggest that the more hydrophobic quinolones, for example nalidixic acid and
oxolinic acid, would be less affected by permeability changes than the hydrophilic
quinolones, ciprofloxacin and norfloxacin, as they are able to diffuse directly through
the outer membrane.
Permeability alterations also affect quinolone accumulation in the cell, and through this
the MIC, as they enable efflux mechanisms to play a significant role; as less quinolone
molecules penetrate the cell, an efflux mechanism would exert more effect and
quinolone MICs would be expected to become higher. The disruption of the cell
membrane with EDTA influences the actions of any efflux mechanism, allowing
quinolones to diffuse in and out of the bacterial cell. This explains why the norfloxacin
MICs dropped considerably in the presence of EDTA, as norfloxacin has been shown
to be excreted from E.coli cells (Cohen et al 1988) and it is likely that a similar
mechanism may exist in P.aeruginosa.
The proteins of 51kD, 46kD, 43kD, 36kD, 32kD and 28kD were observed to be non-
covalently associated with peptidoglycan, as they remained with the peptidoglycan
fraction after solubilisation with SDS. They were also released from the peptidoglycan
fraction after heating in SDS which suggested that they might function as porins. Hirai
and colleagues (1986b) reported that the major entry route for quinolones into the
bacterial cell was through porin pathways, and that alterations in porin proteins
increased quinolone MICs. The results of this study confirm this report, as alterations
in suspected porin proteins brought about increases in quinolone MICs.
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4.4 ALTERATIONS IN DNA GYRASE.
Previous work in both E.coli (Hirai et al 1986b) and P.aeruginosa (Hirai et al 1987;
Inoue et al 1987) has demonstrated that mutations in DNA gyrase cause high-level
quinolone resistance. These studies on P.aeruginosa only investigated the presence of
gyrase mutations in two ways, either a) by separating the a and (3 subunits of DNA
gyrase and recombining them with wild-type, sensitive, a and (3 subunits or b) by
using plasmid probes expressing wild-type, and thus quinolone-sensitive, gyrase
genes.
The first method of separating gyrase subunits, employed by Robillard and Scarpa
(1988) and Inoue and colleagues (1987), although demonstrating the presence of DNA
gyrase mutations, is very inaccurate. On separating and reconstituting DNA gyrase,
investigators pick a ratio of a to (3 subunit which supercoils the largest amount of
pBR322, and this is not necessarily the ratio of a to p subunits present in the bacterial
cell. It is also difficult to ensure that all of the gyrase subunits have reconstituted to
form a single enzyme, and so the results, although valid are inaccurate and can not be
compared with other bacteria (Dr K. Sato personal communication).
The second technique used plasmid or cosmid vectors carrying sensitive gyrase genes,
which caused bacteria to revert to quinolone sensitivity. This technique has recently
been questioned by Soussy and co-workers (1993) whose experiments indicated that
this method is unreliable, produces false negative results, and overestimates the level of
gyrA resistance in many cases.
This study investigated gyrA mutations in P.aeruginosa directly, by isolating the whole
DNA gyrase enzyme and determining its ability to supercoil relaxed pBR322 in the
presence of several antimicrobial agents, and by amplifying the active site of the gyrA
gene by PCR methods. Two indirect methods were also investigated; the first involved
158
the amplification of the gyrA gene by PCR methods and the restriction of the reported
active site with Sstll, and the second involved probing for gyrA mutants with a plasmid
containing the sensitive E.coli wild type gyrA gene.
4.4.1 Determination of DNA Gyrase Activity.
This study, unlike previous studies on gyrase resistance in P.aeruginosa (Inoue et al
1987; Robillard and Scarpa 1988) studied gyrase mutations in a large number of clinical
isolates obtained from a wide variety of sources. The effect of three quinolones,
ciprofloxacin, ofloxacin and norfloxacin, and one courmarin, novobiocin, upon the
ability of the isolated gyrase to supercoil relaxed pBR322 was investigated. The
quinolones were chosen as they are available clinically, and demonstrated the presence
of gyrA mutations, and novobiocin was selected as it indicated the presence of gyrB
mutations.
The IC50 of ciprofloxacin, the most widely prescribed 4-quinolone, fell into three broad
categories. The majority of isolates belonged to a group with low IC50 values which
were at least 100-fold greater than the ciprofloxacin IC50S of the quinolone-sensitive
reference strain, PAOl. The remaining isolates were split equally between two groups,
those with moderate ciprofloxacin IC50S and those with very high ciprofloxacin IC50S.
The initial hypothesis of this study was that strains in these IC50 groups might exhibit
similar, or identical gyrase mutations. All of the clinical isolates investigated exhibited
gyrase mutations.
Further interpretation of the results demonstrated that the ofloxacin and norfloxacin
IC50S did not mirror the ciprofloxacin results, and that strains with low ciprofloxacin
IC50S could exhibit high ofloxacin and norfloxacin IC50S. This questioned the accuracy
of measuring IC50S. It is impossible to compare directly IC50 values between strains,
as the method employed does not quantify the amount of DNA gyrase present in each
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sample. Also, the DNA gyrases isolated have not been completely purified, and so the
amount of enzyme lost in each strain as a result of the purification process might be
unequal. Strains exhibiting high IC50 values might contain larger amounts of gyrase
than those exhibiting low IC50 values, or they might contain gyrase in a more active
state. The activity of DNA gyrase is hard to establish, as cells must be caught at the
correct growth phase to isolate large amounts of active gyrase. This study found, for
example, that three times as much cell weight was needed to isolate gyrase from strain
3, compared with strain C32, although both strains exhibited similar IC50 values.
Bazile and colleagues (1992) have evaluated gyrase activity by another parameter, the
minimal effective dose (MED) which is the minimum amount of drug required to cause
any inhibition of DNA gyrase activity. They reported that MED values are more
accurate than IC50 values and that they are easier to evaluate by gel electrophoresis.
Bazile and co-workers (1992) were also able to compare MED values between strains
after applying a correction factor for the bacterial accumulation of quinolones. This
study chose to investigate IC50 values, as these were the classical values expressed in
all previous reports.
Initial attempts to quantify the activities of DNA gyrase from 4131 and 4133 gave very
low IC50 results, which on re-isolating the DNA gyrase became 5- to 10-fold higher
(results not shown). These results suggested that the discrepancies between the IC50
groups was caused by differences in DNA gyrase-specific activities, rather than in the
actual gyrase mutations themselves.
The discrepancies in IC50 values between low and intermediate IC50 groups, and the
intermediate and high groups, can also be explained as not all IC50 assays were
performed immediately after the isolation of DNA gyrase. Some DNA gyrases were
stored for 4-5 weeks before IC50 assays were undertaken. This accounts for slightly
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lower IC50 values in some cases, as DNA gyrase activity has been shown to decline
with storage (Sato et al 1986). Reports by Gellert and colleagues (1976) and Inoue and
co-workers (1987), however, indicate that IC50 values do not decline noticeably during
one month's storage of gyrase, so any decline in IC50 value because of storage would
be unlikely to explain the 10-fold changes in IC50 values between the low and high
IC50 groups.
The validity of the IC50 results were investigated further by sequentially diluting the
DNA gyrases of two strains and determining the new ciprofloxacin IC50 values. Both
strains demonstrated that dilution of the DNA gyrase reduced the IC50 value by the
same factor; a 50% dilution of the DNA gyrase resulted in a 50% reduction of the IC50
value. This reduction in values, however, was insufficient to explain the ten-fold
differences in gyrase activities between DNA gyrases in the low and high IC50 groups,
indicating that these groups displayed different gyrase mutations.
The dilution of the DNA gyrase produced another interesting result as, unlike most
enzymatic assays where decreasing the enzyme concentration has little or no effect upon
the final result, decreasing the gyrase concentration in this assay had noticeable effects
on the IC50 results. This suggested that the quinolones were actually binding to a
DNA/DNA gyrase complex and not to the DNA or to the DNA gyrase themselves, and
confirms the findings of Shen and colleagues (1989) and Willmott and Maxwell
(1993). The sequential dilution of DNA gyrases demonstrated that the ratio of
supercoiled to relaxed pBR322 did not alter significantly (results not shown) until very
small amounts of gyrase were present. This again confirms that quinolones bind
preferentially to a DNA/DNA gyrase complex and not to the single constituents
themselves.
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The difference in ratio of IC50 values between quinolones was also investigated, as it
has been proposed that the differences in IC50 ratios between quinolones, and not the
differences in IC50 values of a single quinolone, indicate the presence of a specific
gyrase mutation (Dr K. Sato, personal communication). This study found that no
distinct groups could be determined on the basis of quinolone resistance ratios,
although several strains did exhibit the same basic trend. Dr Sato, however, based his
hypothesis on the IC50 ratios of at least eight quinolone antimicrobial agents, and by
only using three quinolones in this study it is likely that insufficient data were obtained
to group the clinical isolates in this way.
4.4.2 Relationship Between IC50 and MIC.
The comparison of IC50 and MIC values corroborated the findings of other
investigators, (Inoue et al 1987), that MIC values are generally lower than IC50 values.
This is because quinolones are thought to accumulate in the interior of the bacterial cell
(Yoshida et al 1990b), therefore subjecting the DNA gyrase to much higher quinolone
concentrations than those in the external medium. The relationship between MIC and
IC50 values has also been investigated. Jin and Piddock (1993) reported correlations
between MIC and IC50 values in ciprofloxacin-resistant laboratory mutants of
Streptococcus pneumoniae, and Piddock and Zhu (1991) reported correlations between
MIC and IC50 values for sparfloxacin and ciprofloxacin in several bacterial strains.
These reports contradict the findings of this study, where no correlation was observed
between MICs and IC50 values for any of the quinolones studied. Jin and Piddock
(1993), however, only considered the MIC and IC50 value relationship in five
laboratory mutants of S.pneumoniae, whilst Piddock and Zhu (1991) only investigated
one strain of P.aeruginosa. This study contained 23 strains, so the investigation here
into the relationship between IC50 and MIC is likely to be more accurate.
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Direct comparison between MIC and IC50 values assumes that bacterial cell growth is
inhibited by inhibiting the activity of DNA gyrase by 50%, but this assumption has not
been proven. Bazile and colleagues (1992) compared MICs in E.coli isolates with the
MED, and found that for most of the quinolones studied a positive correlation was
obtained. The MED is a more accurate parameter with which to compare MIC values,
but Bazile and colleagues (1992) observed that accurate results were only obtained
when a drug accumulation correction factor was applied to the MED. Bazile and co¬
workers (1992) also found that the MED was higher than the MIC, which mirrored the
observations for IC50 values in this study.
The relationships between the quinolone IC50S indicated that various quinolone
antimicrobial agents are affected to different extents by different gyrase mutations. This
has been linked to the binding affinity of the drug for the DNA/DNA gyrase complex.
Yoshida and co-workers (1993) have reported that enoxacin binds at two different
frequencies to the DNA/DNA gyrase complex, and that mutations in the gyrase enable
some drugs to bind more easily than others, thus affecting IC50 values. The model of
quinolone binding to the DNA/DNA gyrase complex proposed by Shen and colleagues,
(1989), also suggests that alterations in the DNA gyrase configuration may have
several effects upon different quinolone structures.
4.4.3 Determination of DNA Gyrase Activity in Laboratory Mutants.
Mutant isolates were selected from strains C32 and 4149 until they had MIC values of
32mg/l ciprofloxacin, and the OMP profiles and DNA gyrase activities of these mutant
strains were then investigated. Neither strain had demonstrated visible OMP alterations
previously, but on investigating the OMPs after the mutation experiments, 4149R
exhibited an extra 38kD protein. The production of an extra 38kD protein had been
previously observed in six of the clinical isolates, and was linked to an increase in
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quinolone resistance. No alteration in OMP profile of the ciprofloxacin-resistant mutant
of C32 was observed.
The mutant of 4149, 4149R, also exhibited a three-fold increase in quinolone IC50
compared to its parent strain, which suggested the presence of a low level resistance
gyrase mutation, and the novobiocin IC50 value was observed to decrease three-fold.
The results from the strain C32R were inconclusive, as the drug concentrations used in
the initial assay were too low to give a clear IC50 value. There was not, however, a
three-fold increase in IC50 values as seen in 4149R. The novobiocin IC50 value of
C32R, like that of 4149R, did fall two-fold. The reason for this fall in novobiocin IC50
is unclear, but alterations in the gyrA subunit might confer a conformational change in
that subunit which alters the relationship between the gyrA and gyrB subunits, and thus
facilitates novobiocin binding to the (3 subunit. This result confirms the theory of
Yoshida and colleagues (1993) that alterations in gyrA may affect the gyrB subunit.
GyrB mutations were also present in some unpaired clinical isolates in this study. It
was observed that two strains, C32 and 3, both in the high IC50 group, exhibited
novobiocin IC50 values which were seven-fold greater than those of the sensitive strain
PAOl, and five-fold greater than those of the other clinical isolates. This indicated that
these two strains contained gyrB mutations. Three strains 4149, 4374 and 4352
exhibited novobiocin IC50 values three-fold greater than PAOl, and might also harbour
gyrB mutations. These findings corroborate reports by other investigators (Yoshida et
al 1990b) that gyrB mutations are much less frequent than gyrA mutations, and thus
would be expected to have a lesser effect upon bacterial resistance. Strains exhibiting
suspected gyrB mutations were not investigated further as there was insufficient time.
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4.4.4 Relationship Between OMP Alterations and DNA Gyrase
Mutations.
Quinolone-resistant clinical isolates of P.aeruginosa which exhibited permeability
alterations might be expected to possess gyrase mutations conferring low level
resistance, that is low IC50 levels. This is because OMP alterations would reduce the
uptake of the quinolone antimicrobial agents into the cell, and in the case of norfloxacin
allow any efflux mechanisms to exert a greater effect on overall quinolone accumulation
in the cell. The gyrases of bacteria possessing OMP mutations would therefore be
subjected to lower levels of quinolones in the cell, and are more likely to develop
gyrase mutations conferring low-level quinolone resistance. Conversely, those resistant
bacteria with no visible membrane protein alterations should contain DNA gyrases with
high levels of quinolone resistance, as there is no restraint upon quinolone
accumulation in the cell.
The results contradict this assumption. High IC50 values were observed in three
strains, CI, C32 and C49, with no visible OMP mutations, however, the remaining
two strains with high ciprofloxacin IC50 values, 3 and 4374, did exhibit OMP
alterations; strain 3 lost a 51kD protein and gained a 28kD protein, whereas strain 4374
gained a 38kD protein and exhibited decreased expression of a 51kD protein. Strain 3
did however have an elevated MIC compared to the other strains in this group, and the
OMP alteration might have contributed to this four-fold increase in MIC, but did not
otherwise affect the gyrase mutation.
Three strains C2, 271 and 4149, exhibited low IC50 values with no visible OMP
changes, whilst still exhibiting ciprofloxacin MICs of 32, 8 and 8 mg/l; respectively.
These strains should have exhibited moderate to high IC50 levels as no other quinolone
resistance mechanisms were detected. The absence of paired strains, however, does not
allow us to assume that these strains exhibited no OMP alterations. Indeed, the EDTA
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results suggested that all of the clinical strains displayed OMP mutations, and so the
techniques employed in this study are obviously not adequate to detect minor changes
in protein expression. Uptake studies on these bacteria might have demonstrated the
presence of OMP alterations or efflux mechanisms, but again, without the original
parent strain as a reference the results would be inconclusive.
Eight strains exhibited low IC50 values in conjunction with visible OMP mutations, as
expected, and the remaining strains with moderate IC50 values all demonstrated OMP
alterations. The level of IC50 resistance, however, could not be linked to alterations in
specific OMPS, but again this may be because the strains were unpaired and so slight
alterations in OMPs might not have been detected.
4.4.5 Direct Sequencing of the P.aeruginosa GyrA gene.
GyrA gene mutations were investigated by amplifying a region of 300 base pairs,
incorporating the 'quinolone resistance-determining region' by PCR methods. This
study attempted to sequence the 300 base pair product of the PCR reaction directly
using a technique with DMSO (Winship 1989). This technique was found to produce
multiple bands at each nucleotide, producing an unreadable sequence. To combat this
the annealing times of the primers were lowered, as reproduction of bands is indicative
of primer mismatching and reannealing. Attempts to modify this technique were
unsuccessful, and it was hoped to use single-strand sequencing techniques using biotin
labelled probes instead, but there was insufficient time in this study.
It would be expected, from studying the P.aeruginosa amino acid sequence of the gyrA
gene, that mutations would occur from threonine 83 to isoleucine to cause high level
quinolone resistance. This alteration has been documented for C.jejuni (Wang et al
1993), which is the only other bacteria possessing a threonine residue at the active site.
As the gyrA sequence of amino acids in P.aeruginosa is almost identical to that of
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E.coli, mutations causing amino acid alterations in E.coli would also be expected to
occur in P.aeruginosa. This study was unable to sequence double-stranded DNA
directly by DMSO techniques, so it was impossible to confirm the gyrA sequence of
P.aeruginosa, donated by L.E. Bryan. The PCR reactions using specific primers from
this sequence were successful, however, which suggests that the sequence was correct.
4.4.6 Indirect Analysis of the GyrA gene.
The presence of threonine at the active site of P.aeruginosa was also verified using
indirect methods. PCR products were restricted with the enzyme Sstll which cleaves
the P.aeruginosa quinolone-sensitive gyrA gene between amino acids 83 and 84, and
recognises a sequence of six nucleotides within this region (refer to Fig 3.20 pi32).
Amino acid alterations from threonine to isoleucine will change the second . fc>wst in
this t^odc-rv from cytosine to thymine, and mutations of alanine 84 to valine will
again alter the second base. , cytosine, to thymine. Both these changes would then
prevent restriction by the Sstll enzyme and thus indicate gyrA mutations at this site.
The results demonstrated that half of the bacterial strains investigated carried alterations
at either amino acid 83 or amino acid 84. Without sequencing the PCR product this
study was unable to determine which amino acid had been altered. From previous
investigations on E.coli, S.aureus and K.pneumoniae it is likely that the majority of
alterations would occur from Thr83 to isoleucine, which causes high level resistance in
C.jejuni.
The analysis of the eight strains with gyrase mutations around amino acids 83 and 84
demonstrated that only one strain, CI, belonged to the high IC50 group. Of the
remaining strains two, 4124 and 4161, were in the intermediate IC50 group and five
strains demonstrated low IC50 levels of ciprofloxacin. Of the nine strains which were
uncleaved, and therefore did not carry mutations at amino acids 83 and 84, two strains,
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C32 and 4374, exhibited high IC50 values of ciprofloxacin. Again, of the remaining
strains two, 4133 and 4375, belonged to the intermediate group and five belonged to
the low IC50 group.
These results are unexpected, as it was thought that strains carrying amino acid
alterations at position 83 would exhibit high ciprofloxacin IC50 levels. There are several
explanations as to why these results have occurred. The first is that the IC50 results are
unreliable, as the levels of DNA gyrase in the assay were not quantified. The dilution of
DNA gyrase lowers IC50 values, and so strains in the low IC50 group harbouring
gyrase mutations might exhibit medium and high levels of quinolone resistance, but
these have remained undetected.
An alternative suggestion is that strains with high IC50 levels could harbour several
amino acid alterations, and that the threonine to isoleucine and the alanine 84 to proline
amino acid alterations only confer medium level resistance, which in concert with
another amino acid alteration cause high IC50 values. Strains C32 and 4374 which were
not cleaved by Sstll would be expected to carry amino acid alterations in other parts of
the quinolone-determining region. As the amino acid sequence of the gyrA gene is
highly conserved, possible mutations could occur in amino acid 87 from aspartic acid to
asparagine, as this has been documented to cause medium and high-level quinolone
resistance in E.coli (Yoshida et. al 1990a). This study was unable to obtain restriction
enzymes which recognised mutations in nucleotide sequences around this site, or at
other sites known to harbour base changes in E.coli, and so this possibility could not
be investigated further.
Strain C32 was also thought to harbour mutations in the gyrB gene, and this coupled
with low or medium resistance mutations in the gyrA gene might have led to a high
IC50 value. Strains 4374, 4375 and 4149 also demonstrated novobiocin IC50 levels
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which were three-fold greater than that of the reference strain PAOl, and these too
might harbour gyrB mutations which, coupled with low level gyrA resistance could
contribute to the medium and high levels of ciprofloxacin IC50S observed.
The Sstll cleaved strains with low IC50 levels would be expected to carry amino acid
mutations at threonine 83 which conferred low level quinolone resistance, although no
mutations in C.jejuni conferring low level quinolone resistance have been documented.
An alternative suggestion is that these strains carry alterations in amino acid 84 which
gives medium level resistance to quinolones in E.coli.
4.4.7 Analysis of the GyrA gene with pNJR3-2.
In order to determine whether the clinical isolates carried gyrA mutations an attempt
was made to introduce a plasmid carrying the wild-type E.coli gyrA gene into
P.aeruginosa. Previous work by Robillard (1990) and Piddock and colleagues (1992)
had demonstrated that the introduction of a sensitive gyrA gene into P.aeruginosa
resulted in the reduction of quinolone MIC, if the strain also carried OMP or efflux
mutations, or complete reversion to quinolone sensitivity, if the strain carried only
DNA gyrase mutations. Both groups have been successful in introducing the probe
pNJR3-2 into P.aeruginosa by conjugation and transformation methods.
Attempts to introduce the probe into P.aeruginosa were unsuccessful, as the clinical
isolates of P.aeruginosa in this study exhibited high intrinsic resistance to the selection
markers on the probe, tetracycline and kanamycin. Alternative conjugation experiments,
with different methods from those of Robillard (1990), were also unsuccessful, again
because of the selection techniques. Experiments with EDTA demonstrated that most of
the clinical strains retained their tetracycline resistance in the presence of EDTA,
suggesting that, in these isolates, tetracycline resistance was carried by plasmid
determinants.
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Attempts to introduce pNJR3-2 into PAOl, which demonstrated lower tetracycline
MICs than the majority of the clinical isolates in this study, were also unsuccessful.
Investigations into the mobility of the plasmid demonstrated that the plasmid could
mobilise in the same strain, which suggested that the transfer problem was likely to be
caused by strain differences between P.aeruginosa and E.coli. To overcome this it was
decided to introduce pNJR.3-2 into P.aeruginosa by electroporation methods previously
reported by Diver and colleagues (1990a).
Again, attempts to introduce pNJR3-2 into P.aeruginosa by electroporation methods
were unsuccessful, because of impurities in both the plasmid and bacterial preparations,
which lead to excessive arcing when the resistivity of the Electrocell Manipulator was
increased. Arcing is caused by the presence of excessive salts, and it is likely that the
plasmid extraction method of Takahashi and Nagano (1984) did not provide plasmid
DNA with sufficiently low salt concentrations to prevent arcing from occurring.
Reports by Heisig and Wiedemann (1991) have suggested that pNJR3-2 is too large to
successfully introduce into P.aeruginosa, as they obtained very low transfer
frequencies in their experiments. Heisig and Wiedemann (1991) have successfully
transformed the E.coli gyrA gene into P.aeruginosa with a smaller plasmid, pBP515,
and reported that transformation was stable and occurred at a greater frequency than that
of pNJR3-2.
Recent reports by Soussy and colleagues(1993), however, have questioned the overall
validity of performing these experiments. Soussy and co-workers (1993) reported that
introducing sensitive gyrA genes by transformation techniques produced many false
negative results, caused by plasmid instability. This suggested that pNJR3-2 was




To summarise, quinolone resistance in P.aeruginosa occurs by several mechanisms,
either by permeability changes, gyrase mutations, efflux mechanisms, or a combination
of the three. This study indicated that permeability and gyrase alterations are pleiotropic
in nature, and that all of the unpaired clinical isolates investigated contain both types of
mutations. This begs the question of which resistance develops first, the impermeability
mutation or the gyrase mutation? Work with other antimicrobial agents suggests that
permeability alterations occur first, which reduce the effect of the antimicrobial agent on
the bacteria, allowing it to develop other resistance mechanisms. The EDTA results
demonstrated that each strain investigated earned membrane mutations, which suggests
that OMP mutations occur before gyrase mutations. This study, however, could not
resolve the question completely, as no strains were isolated which exhibited a sole
quinolone resistance mechanism.
The OMP mutations observed were in a variety of proteins, but all of the ciprofloxacin-
resistant isolates exhibited an increased expression of a 36kD protein. Many isolates
also exhibited a decrease in the expression of a 51kD protein, which suggested that in
P.aeruginosa alterations in these two proteins were responsible for the majority of
quinolone resistance. Alterations in a 46kD protein, in the paired clinical isolates, were
also shown to be important in quinolone resistance. The DNA gyrases of the paired
strains were not investigated because these strains exhibited low level quinolone
resistance and were still classified as quinolone sensitive by the BSAC guide-lines
(1991). It would be interesting to determine whether these isolates contained only
permeability mutations, or whether gyrase mutations had also developed.
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This study also demonstrated that the measurement of IC50 values might not be an
accurate method for determining the extent ofDNA gyrase mutations, and that PCR and
direct sequencing methods, as employed in E.coli and other bacteria are superior
techniques. This study, like Soussy and colleagues (1993) also questions the validity of
employing conjugation, transformation and electroporation techniques in the
determination of DNA gyrase mutations.
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APPENDIX.
Appendix i: Pyocin types of mutant isolates
Appendix ii : Integral values from the densitometer readings used to calculate the




U423 76 / ut (s - 7, a, d, e )
U423A ut / ut (s - 7)
U423B ut / ut (s - 7)
U423C 9 / ut (s - 7)
U423D 9 / ut (s - 7)
U423E ut / ut (s - 7, a )
U423F ut / ut (s - 7)




91-32-4 3 / x
91-32-5 1/d
91-32-6 3/k
8252 10 / ut (s - 5, a, d, e )
3221 10 / ut (s - a, d, e )
ut - untypable strains, s - sensitivity shown to reagents named.
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APPENDIX ii.
STRAIN DRUG INTEGRAL AT DRUG CONCENTRATION (mg/1) OF
0 0.25 0.5 1 2 4
IC50
(mg/1)
PA01 CPX 1251 - 904 584 - - 0.94
OFX 1688 - - 1122 1024 894 4
NFX 1204 1187 1145 1027 551 - 1.89
NOV 1053 1267 1103 931 157 - 1.52
0 0.25 0.5 1
PAOl CPX 4239 2660 1628 104 0.38
Colindale OFX 4254 4298 3523 1505 0.85
NFX 4896 3603 2944 1153 0.64
NOV 3040 1767 1679 222 0.55
0 0.25 0.5 64 128 256
CI CPX 2097 - - 2041 1297 661 178.0
OFX 2087 - - 1439 468 - 90.1
NFX 1690 - - 1264 1089 761 223.3
NOV 2081 1471 1037 - - - 0.49
0 0.25 16 32 64 128
C48 CPX 2772 - 1707 743 - 18.7
OFX 10630 - 6212 4837 - 27.3
NFX 4189 - - 3202 2065 63.2
NOV 6702 3279 - - - 0.24
191
STRAIN DRUG INTEGRAL AT DRUG CONCENTRATION (mg/1) OF IC50
(mg/1)
0 0.25 0.5 8 16 32
271 CPX 2551 - 2227 1354 807 16.9
OFX 3183 - 2657 1478 1057 15.2
NFX 2275 - 2275 1789 539 24.3
NOV 2617 1991 1186 " " " 0.46
0 0.5 1 8 16 32
273 CPX 3251 - 1705 1493 - 11.0
OFX 2336 - 1869 1358 0 17.1
NFX 1507 - 1746 942 603 24.9
NOV 1582 1392 467 - " - 0.82
0 0.25 4 8 16 32
274 CPX 2014 1738 963 - - 7.7
OFX 2922 - 1758 927 - 10.9
NFX 2812 - 2531 1546 985 20.0
NOV 1664 802 " " 0.25
0 0.25 16 32 64 128
4124 CPX 2649 1390 1394 879 - 36.32
OFX 2864 3055 1640 1111 - 44.6
NFX 2173 - - 2173 611 108.5
NOV 2270 1135 - - - 0.25
0 0.25 0.5 16 32 64
4133 CPX 4336 - 4226 2572 1521 44.3
OFX 4293 - 2377 1916 - 24.0
NFX 4901 - 3910 2781 1839 43.23
NOV 5577 3495 2919 - - - 0.47
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STRAIN DRUG INTEGRAL AT DRUG CONCENTRATION (mg/1) OF
IC50
(mg/1)
0 0.25 8 16 32 64
4269 CPX 1015 808 659 353 - 23.9
OFX 1403 1329 1153 414 - 25.8
NFX 1875 1522 1351 1287 526 46.7
NOV 1206 119 " - - 0.71
0 1 2 16 32 64
4352 CPX 1146 - 1146 326 263 27.2
OFX 1988 - 1288 989 - 31.7
NFX 2402 - 1587 1225 1189 53.3
NOV 1935 1092 72 " - - 1.12
0 1 2 64 128 256
4375 CPX 514 - 414 183 - 88.3
OFX 611 - - 464 0 171.7
NFX 984 - - 688 253 185.7
NOV 634 317 - - - 2.0
0 0.25 0.5 8 16 32
4495 CPX 5763 - 2891 1133 844 16.1
OFX 4627 - 1878 1582 966 6.7
NFX 4924 - 4269 2454 755 15.9
NOV 2316 1553 585 - - - 0.35
0 1 2 32 64 128
90-62 CPX 2124 - 1384 954 - 55.96
OFX 2376 - 2033 1530 701 90.40
NFX 1989 - 1763 1248 494 85.52
NOV 5333 4375 0 - - - 1.35
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STRAIN DRUG INTEGRAL AT DRUG CONCENTRATION (mg/1) OF:- IC50
(mg/1)
0 2 4 64 128 256 512
3 CPX 994 - - 700 716 183 - 180.6
OFX 1385 - - 1376 751 578 - 171.3
NFX 910 - - - 910 637 224 368.8
NOV 410 309 155 - ~ - - 3.50
0 0.5 1 32 64 128 256
4158 CPX 1648 - - 1596 970 296 - 77.9
OFX 2218 - - 1542 984 - - 56.8
NFX 1986 - - - 1572 1124 746 172.4
NOV 1987 1475 861 - - - - 0.89
0 1 2 64 128 256 512
4374 CPX 3477 - - 3475 3000 1233 - 219.4
OFX 6364 - - 3726 2510 - - 87.4
NFX 6212 - - 4253 3342 3177 2946 334.7
NOV 5646 3098 2086 - - " - 1.27
0 0.5 1 8 16 32 64
4532 CPX 2326 - - 1575 1274 439 - 18.1
OFX 2165 - - 1575 1337 342 - 20.1
NFX 2001 - - 1773 1803 1499 847 56.5
NOV 1606 1569 279 - " - - 0.8
0 1 2 64 128 256 512
C32R CPX 2606 - - 2092 1766 1528 1109 393.47
OFX 1592 - - 1397 1342 985 628 391.53
NFX 1673 - - 1629 1414 1218 796 392.49
NOV 2101 1887 717 - - - - 1.72
194
STRAIN DRUG INTEGRAL AT DRUG CONCENTRATION (mg/1) OF
0 0.25 0.5 1 16 32 64
IC50
(mg/1)
4149R CPX 2194 - 1907 981 - 30.0
OFX 11467 - 8559 6373 3691 39.63
NFX 7892 - 7606 6127 3847 62.61
NOV 10954 10069 5289 2093 - - - 0.49
STRAIN DRUG INTEGRAL AT DRUG CONCENTRATION (mg/1) OF IC50
(mg/1)
0 0.25 0.5 1 8 16 32 64
C2 CPX 3920 - - - 1830 1556 - - 10.7
OFX 3242 - - - 1836 1556 - - 14.1
NFX 3829 - - - - 2345 2067 1667 44.2
NOV 1823 1684 1555 567 - - - - 0.83
0 0.25 0.5 1 16 32 64 128
4125 CPX 8642 - - - 7542 3583 - - 29.02
OFX 7050 - - - 5874 5037 3637 3119 77.8
NFX 6977 - - - - 6837 3637 673 67.2
NOV 5095 4058 2599 0 - - - - 0.51
0 0.5 1 2 4 8 16 32
4149 CPX 1585 - - 1571 1386 951 167 258 9.9
OFX 1359 - - - 1032 802 320 - 10.0
NFX 1227 - - - 1023 960 767 418 23.0
NOV 949 942 649 62 " - - - 1.27
0 0.5 1 16 32 64 128 256
4161 CPX 1807 - - 1815 1577 512 - - 52.2
OFX 1739 - - 1907 495 - - - 27.8
NFX 1705 - - - - 1458 1221 572 200.7
NOV 2025 1656 87 - - - - - 0.71
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STRAIN DRUG INTEGRAL AT DRUG CONCENTRATION (mg/1) OF IC50 (mg/1)
0 2 4 256
C32 CPX 4740 - - 4260 >256
OFX 4795 - - 2449 >256
NFX 2998 - - 1513 >256
NOV 3560 2918 1492 " 3.59
0 128 256
C49 CPX 7974 4906 3933 248.9
OFX 2395 1727 983 219.1
NFX 2068 - 1924 >256
NOV - - - -
0 4 8 16
4131 CPX 334 201 119 - 5.7
OFX 610 605 263 - 10.6
NFX 659 - 412 295 13.6
NOV - - - - -
CPX - Ciprofloxacin, OFX - Ofloxacin, NFX - norfloxacin, Nov - Novobiocin.
- reading not taken.
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STRAIN DILUTION INTEGRAL AT CIPROFLOXACIN CONCENTRATION (mg/1)) OF
















0 2 4 8 16 32
90-62 0
50%
75%
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2139
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1944 1665
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1647
799
>32
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